American Society of Hematology (ASH) Annual Meeting  
Dec 1-4, 2018  
http://www.hematology.org/Annual-Meeting/Program/  

**Case CCC Members in BOLD; Presenter UNDERLINED**

**PRESENTATIONS/SESSION CHAIRS**

Matt Kalaycio, MD  
Case Comprehensive Cancer Center, Cleveland Clinic  
Chair and Speaker, Riding the Wave: Clinical Management of Myeloid Malignancies in an Era of Novel Therapies  
Friday, Nov 30, 2018, 7-11 am; Hyatt, Coronado Ballroom, A-C

Hetty E. Carraway, MD, MBA  
Case Comprehensive Cancer Center, Cleveland Clinic  
Chair, Hematology Oncology Training Program Directors Workshop  
Friday, Nov 30, 2018, 11 am-2 pm; Petco Park, The Auditorium  
Speaker, Blood Drops: Career 101: Early career planning topics; Knocking Your Fellowship Interview Out of the Park: Tips to Make Sure Your Interview Day Is a Homerun  
Friday, Nov 30, 2018, 3:30-3:45 pm; Western Metal Concourse (Petco Park)

Alok Khorana, MD  
Case Comprehensive Cancer Center, Cleveland Clinic  
Chair, What's New in VTE? Evaluating the Latest Evidence and Grades of Recommendation  
Friday, Nov 30, 2018, 12:30-4:30 pm; Hyatt, Coronado Ballroom, A-C

Mikkael A. Sekeres, MD, MS  
Case Comprehensive Cancer Center, Cleveland Clinic  
Co-Chair, Education Program  
Speaker, Blood Drops: Wellness: Topics to help your well-being; Telling It Like It Is: Essays About Medicine  
Friday, Nov 30, 2018, 1:30-1:45 pm; Western Metal Concourse (Petco Park)  
Co-Chair, Late-Breaking Abstracts Session  
Tuesday, Dec 4, 2018, 7:30-9:00 am; San Diego Convention Center, Hall AB

Anne T. Neff, MD  
Cleveland Clinic  
Speaker, Blood Drops: Hematology 201: A mid-level clinical topic: Identifying White Cell Disorder on the Peripheral Smear  
Friday, Nov 30, 2018, 1:30-4:45 pm; Western Metal Concourse (Petco Park)

Aziz Nazha, MD  
Case Comprehensive Cancer Center, Cleveland Clinic  
Speaker, Blood Buddies/Mentor Session 1; Adult Clinical Malignant Hem
Keith R. McCrae, MD
Case Comprehensive Cancer Center, Cleveland Clinic
Speaker, Blood Buddies/Mentor Session 1; Laboratory & Translational Hem and Adult Clinical Non-Malignant Hem
Friday, Nov 30, 2018, 2:30-3:00 pm; Section 124 – The Porch (Petco Park)
Speaker, Blood Buddies/Mentor Session 2; Laboratory & Translational Hem and Adult Clinical Non-Malignant Hem
Friday, Nov 30, 2018, 3:30-4:00 pm; Section 124 – The Porch (Petco Park)
Chair, Scientific Committee on Thrombosis and Vascular Biology: Microparticles and Exosomes: Ready for the Clinic?
Saturday, Dec 1, 2018, 9:30-11:00 am; San Diego Convention Center, Room 24B
Saturday, Dec 1, 2018, 4:00-5:30 pm; San Diego Convention Center, Room 11B
Co-Chair and Speaker, Special Symposium on the Basic Science of Hemostasis and Thrombosis; Best of ASH in Hemostasis and Thrombosis 2
Monday, Dec 3, 2018, 4:30-6:30 pm; San Diego Convention Center, Room 30D

Navneet Majhail, MD
Case Comprehensive Cancer Center, Cleveland Clinic
Speaker, Career-Development Lunch Session Ballroom AB: Adult Clinical Malignant Hematology/BMT
Saturday, Dec 1, 2018, 11:15 am-12:15 pm; Sapphire Ballroom AB (Hilton San Diego Bayfront)

Alvin H. Schmaier, MD
Case Comprehensive Cancer Center, Case Western Reserve University
Chair, Scientific Committee on Hemostasis: Vascular Biology Components of Hemostasis
Saturday, Dec 1, 2018, 2:00-3:30 pm; San Diego Convention Center, Room 31B
Sunday, Dec 2, 2018, 7:30-9:00 am; San Diego Convention Center, Room 31B
Co-Chair and Speaker, Special Symposium on the Basic Science of Hemostasis and Thrombosis; Best of ASH in Hemostasis and Thrombosis 1
Monday, Dec 3, 2018, 4:30-6:30 pm; San Diego Convention Center, Room 30D

Mukesh Jain, MD
Case Comprehensive Cancer Center, University Hospitals, Case Western Reserve University
Speaker, Scientific Committee on Hemostasis: Vascular Biology Components of Hemostasis; Krüppel-Like Factors in Thrombosis and Hemostasis
Saturday, Dec 1, 2018, 2:00-3:30 pm; San Diego Convention Center, Room 31B
Sunday, Dec 2, 2018, 7:30-9:00 am; San Diego Convention Center, Room 31B

Betty K. Hamilton, MD
Case Comprehensive Cancer Center, Cleveland Clinic
Speaker, Current Approaches to Prevent and Treat GVHD Following Allogeneic Stem Cell Transplantation: Reining in Graft-Versus-Host Disease (GVHD) After Allogeneic Hematopoietic Cell Transplantation
Sunday, Dec 2, 2018, 7:30-9:00 am; Manchester Grand Hyatt San Diego, Grand Hall D
Monday, Dec 3, 2018, 10:30 am-12:00 pm; Manchester Grand Hyatt San Diego, Grand Hall D

Aaron T. Gerds, MD, MS
Case Comprehensive Cancer Center, Cleveland Clinic
Chair, Social Media for the Hematologist: Today and in the Future
Sunday, Dec 2, 2018, 11:15-12:15 pm; San Diego Convention Center, Room 28D

Sudipto Mukherjee, MD, PhD, MPH
Case Comprehensive Cancer Center, Cleveland Clinic
Speaker, Population Risks of Developing Myeloid Malignancies: From Fat Man to Agent Orange and Beyond: When Myeloid Malignancies Strike
Sunday, Dec 2, 2018, 4:30-6:00 pm; San Diego Convention Center, Room 11B

Eric Kodish, MD
Case Comprehensive Cancer Center, Cleveland Clinic
Speaker, Ethical Conundrums in Pediatric Genomics; Using Genomics to Risk Stratify and Treat Kids
Sunday, Dec 2, 2018, 9:30-11:00 am; Marriott Marquis San Diego Marina, San Diego Ballroom B
Monday, Dec 3, 2018, 7:00-8:30 am; Marriott Marquis San Diego Marina, San Diego Ballroom 21

ORAL ABSTRACTS – CASE CCC PRESENTER (with CASE CCC CO-AUTHORS)

33 Results of SWOG 1318: A Phase 2 Trial of Blinatumomab Followed By Pomp (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) Maintenance in Elderly Patients with Newly Diagnosed Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia
Program: Oral and Poster Abstracts
Type: Oral
Session: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Improving Frontline Therapy in ALL
Hematology Disease Topics & Pathways: antibodies, Biological, ALL, Leukemia, Diseases, Therapies, Lymphoid Malignancies
Saturday, December 1, 2018: 8:00 AM; Pacific Ballroom 20 (Marriott Marquis San Diego Marina)

Anjali S. Advani, MD1, Anna Moseley, M.S.2*, Kristen Marie O'Dwyer, MD3, Brent Wood, MD PhD4*, Min Fang, MD, PhD5, Matthew J. Wieduwilt, MD, PhD6, Ibrahim Aldoss, MD7, Jae H. Park, MD8, Rebecca Klisovic, MD9, Maria R. Baer, MD10, Wendy Stock, MD11, Rupali Bhave, M.D.12*, Megan Othus, PhD13, Mark R. Litzow, MD14, Richard M. Stone, MD14 and Harry P. Erba, MD, PhD15

1Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH
2SWOG Statistics and Data Management Center, Seattle, WA
3University of Rochester Medical Center, Rochester, NY
4Department of Laboratory Medicine and Division of Hematopathology, University of Washington, Seattle, WA
5Fred Hutchinson Cancer Research Center, Seattle, WA
6University of California, San Diego, La Jolla, CA
7University of Southern California, Duarte, CA
8Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
9Ohio State University, Columbus, OH (past during conduct of trial)/ Emory University, Atlanta, GA
10University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD
11Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL
12Comprehensive Cancer Center of Wake Forest Baptist Health, Winston-Salem, NC
13Division of Hematology, Mayo Clinic, Rochester, MN
14Dana-Farber Cancer Institute, Boston, MA
15University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL
206 A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Stem Cell Transplant in Patients with Myelodysplastic Syndromes: On Behalf of the CIBMTR Chronic Leukemia Committee
Program: Oral and Poster Abstracts
Type: Oral
Session: 732. Clinical Allogeneic Transplantation: Results: To Transplant or Not to Transplant? That Is the Question
Hematology Disease Topics & Pathways: Diseases, MDS, Myeloid Malignancies
Saturday, December 1, 2018: 2:15 PM; Seaport Ballroom A (Manchester Grand Hyatt San Diego)
Aziz Nazha, MD1, Zhen-Huan Hu, MPH2*, Tao Wang, PhD3-5, Betty K. Hamilton, MD4, Navneet S. Majhail, MD, MS5, R. Coleman Lindsay, M.D., Ph.D.6, Ronald Sobecks, MD6, Uday Popat, MD7, Bart L Scott, MD8 and Wael Saber, MD, MS9
1Cleveland Clinic, Cleveland, OH
2CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
3Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WV
4Taussig Cancer Institute, Blood and Marrow Transplant Program, Cleveland Clinic Foundation, Cleveland, OH
5Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH
6Dana-Farber Cancer Institute, Boston, MA
7Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
8Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

397 Safety and Efficacy of Venetoclax Combined with Rituximab, Ifosfamide, Carboplatin and Etoposide Chemoimmunotherapy (VICER) for Treatment of Relapsed Diffuse Large B Cell Lymphoma: Results from the Phase 1 Study
Program: Oral and Poster Abstracts
Type: Oral
Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: New Agents
Hematology Disease Topics & Pathways: Diseases, Biological, apoptosis, Adult, Therapies, Non-Biological, Non-Hodgkin Lymphoma, chemotherapy, B-Cell Lymphoma, Study Population, Lymphoid Malignancies, Clinically relevant
Sunday, December 2, 2018: 12:00 PM; Pacific Ballroom 20 (Marriott Marquis San Diego Marina)
Paolo Caimi, MD1, Deepa Jagadeesh, MD, MPH2, Kirsten Marie Boughan, DO1, Robert M. Dean, MD2, Brenda Cooper, MD1, Brad Pohlman, MD3, Molly M Gallogly, MD, PhD1, Sarah L. Ondrejka, DO4, Erika Moore, MD5, Kwadwo Asare Oduro, MD, PhD5, Eric D. Hsi, MD3, Marcos de Lima, MD1 and Brian T. Hill, MD, PhD6,7
1Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH
2Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH
3Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
4Robert J. Tomish Pathology & Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH
5Department of Hematopathology, University Hospitals Cleveland Medical Center, Cleveland, OH
6Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH
7Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

466 PD-L1 Blockade with Atezolizumab in Higher-Risk Myelodysplastic Syndrome: An Initial Safety and Efficacy Analysis
Program: Oral and Poster Abstracts
Type: Oral
Session: 637. Myelodysplastic Syndromes—Clinical Studies: Novel Therapeutics II
Hematology Disease Topics & Pathways: Diseases, antibodies, Biological, Therapies, MDS, checkpoint inhibitors, Myeloid Malignancies
Sunday, December 2, 2018: 5:15 PM; Grand Hall A (Manchester Grand Hyatt San Diego)
793 A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes
Program: Oral and Poster Abstracts
Type: Oral
Session: 637. Myelodysplastic Syndromes—Clinical Studies: Prognosis and Prediction
Hematology Disease Topics & Pathways: AML, Diseases, MDS, Technology and Procedures, Clinically relevant, Myeloid Malignancies, molecular testing, NGS
Monday, December 3, 2018: 2:45 PM; G-158.452

Aziz Nazha, MD1, Rami S. Komrokji, MD2, Manja Meegendorfer, PhD3, Sudipto Mukherjee, MD, PhD, MPH5, Najia Al Ali, M.Sc5, Wencke Walter, PhD5, Stephan Hutter, PhD3, Eric Padron, MD5, Yazan F. Madanat, MD6, David A Sallman, MD7, Teodora Kuzmanovic8, Cassandra M. Hirsch9, Vera Adema, PhD9, David P. Steensma, MD10, Amy E. DeZern, MD11, Gail J. Roboz, MD12, Guillermo Garcia-Manero, MD13, Alan F. List, MD14, Claudia Haferlach, MD15, Jaroslaw P. Maciejewski2, Torsten Haferlach, MD15 and Mikkael A. Sekeres, MD, MS16

1Cleveland Clinic, Cleveland, OH 2Department of Malignant Hematology, H Lee Moffitt Cancer Center, Tampa, FL 3MLL Munich Leukemia Laboratory, Munich, Germany 4Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 5H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 6Taugus Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH 7Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL 8Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 9Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH 10Dana-Farber Cancer Institute, Boston, MA 11Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 12Weill Cornell Medicine and The Weill Medical College of Cornell University, New York, NY 13Department of Leukemia, MD Anderson Cancer Center, Houston, TX 14H. Lee Moffitt Cancer Center, Tampa, FL 15MLL Munchner Leukamie Labor Gmbh, Munchen, Germany 16Department of Translational Hematology and Oncology Research, Taussig Cancer Institute Taussig Cancer Institute, Cleveland, OH

ORAL ABSTRACTS – NON-CASE CCC PRESENTER (with CASE CCC/CLEVELAND CO-AUTHORS)

1 The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions
Program: General Sessions
Session: Plenary Scientific Session
Hematology Disease Topics & Pathways:
Biological, Diseases, MDS, Myeloid Malignancies
Sunday, December 2, 2018, 2:00 PM-4:00 PM; Hall AB (San Diego Convention Center)

Pierre Fenaux, MD, PhD1, Uwe Platzbecker, MD2, Ghulam J. Mufeed3, Guillermo Garcia-Manero, MD4, Rena Buckstein, MD, FRCP5, Valeria Santin5, Maria Diez-Campe10, Carlo Finelli, MD8, Mario Cazzola9,
Osman Ilhan, MD1, Mikkael A. Sekeres, MD, MS11, José F. Falantes12, Beatriz Arrizabalaga, MD. PhD13, Flavia Salvi14, Valentina Giai14, Paresh Vyas, MRCP FRCP FRCPPath15, David Bowen, MD16, Dominik Selleslag, MD17, Amy E. DeZern, MD18, Joseph G. Jurcic, MD19, Ulrich Germing, MD20, Katharina S. Götzte, MD21, Bruno Quesnel22, Odile Beyne-Raunzy23, Thomas Cluzeau, MD, PhD24*, Maria Teresa Vosa25, Dominiek Maze26, Edo Vellenga27, Peter L Greenberg, M.D.28, Eva Hellstrom Lindberg, MD, PhD29, Amer M. Zeidan, MBBS, MHS30*, Abderrahmane Laadem, MD31, Aziz Benzoher32, Jennie Zhang31*, Anita Rampersad31, Peter G. Linde33, Matthew L. Sherman33, Rami S. Komrokji, MD34 and Alan F. List, MD34

1Service d’Hématologie Sénior, Hôpital Saint-Louis, Université Paris 7, Paris, France
2University Hospital Dresden, Dresden, Germany
3Department of Haemat-Oncology, King’s College London, London, United Kingdom
4Department of Leukemia, MD Anderson Cancer Center, Houston, TX
5Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
6MDS Unit, AOI Careggi, University of Florence, Florence, Italy
7Institute of Biomedical Research of Salamanca, University Hospital of Salamanca, Salamanca, Spain
8Department of Oncology and Hematology, S.Orsolo-Malpighi University Hospital, Bologna, Italy
9University of Pavia, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy
10Department of Hematology Science, School of Medicine, Ankara University, Ankara, Turkey
11Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
12Unidad de Hematología, Hospital Universitario Virgen del Rocio, Seville, Spain
13Department of Hematology, Hospital Universitario Cruces, Vizcaya, Spain
14Hematology Unit, Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy
15Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
16Department of Haematology, Leeds Teaching Hospitals, Leeds, United Kingdom
17Department of Haematology, AZ Sint-Jan, Bruges, Belgium
18The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
19Division of Hematology/Oncology, Columbia University Medical Center, New York, NY
20Klinik für Hämatologie, Onkologie und Klinische Immunologie, Universitätsklinik Düsseldorf, Düsseldorf, Germany
21Department of Medicine III, Technical University of Munich, Munich, Germany
22Service des Maladies du Sang, Hôpital Huriez, Centre Hospitalier Universitaire de Lille, Lille, France
23Hematologie clinique, Centre Hospitalier Universitaire de Nice, Nice, France
24Dipartimento di Biopatologia e Diagnostica per Immagini, University of Rome Tor Vergata, Rome, Italy
25Universitair Ziekenhuis Gent, Ghent, Belgium
26Department of Hematology, University Medical Center Groningen, Groningen, Netherlands
27Stanford University Cancer Center, Stanford, CA
28University Hospital Dijon, Dijon, France
29Department of Mediterranean and Molecular Pathology, University of Florence, Florence, Italy
30Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT
31Celgene Corporation, Summit, NJ
32Cellgene International, Boudry, Switzerland
33Acceleron Pharma, Cambridge, MA
34Moffitt Cancer Center, Tampa, FL

75 Neutrophil KLF2 Regulates Arterial and Venous Thrombosis

Program: Oral and Poster Abstracts
Type: Oral
Session: 301. Vascular Wall Biology, Endothelial Progenitor Cells, and Platelet Adhesion, Activation, and Biochemistry: Vascular Physiology and Thrombosis
Hematology Disease Topics & Pathways: Biological Processes, inflammation
Saturday, December 1, 2018: 10:00 AM; Room 28D (San Diego Convention Center)

Lalitha V. Nayak, MD1, Stephanie Lapping, MS2*, Andrei Maiseyeu3, Alvin H. Schmaier, MD4 and Mukesh Jain, MD2,5

1University Hospitals Cleveland Medical Center, Cleveland, OH
2Case Cardiovascular Research Institute, CWRU, Cleveland
3Case Cardiovascular Research Institute, Case Western Reserve University, Cleveland
4Case Western Reserve University, Cleveland, OH
5Case Western Reserve University / University Hospitals Health System, Cleveland, OH

91 Axicabtagene Ciloleucel (Axi-cell) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience
Invariant Patterns of Clonal Succession Determines Specific Phenotypic and Clinical Features of Myelodysplastic Syndromes (MDS)

Program: Oral and Poster Abstracts
Type: Oral
Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Outcomes With CD19 CAR T Therapy and Checkpoint Blockade in the Real World Setting

Hematology Disease Topics & Pathways: Biological, Therapies, CAR-Ts
Saturday, December 1, 2018: 9:30 AM; Pacific Ballroom 20 (Marriott Marquis San Diego Marina)

Loretta J. Nastoupil, MD1, Michael D. Jain, MD, PhD2, Jay Y. Spiegel, MD, FRCP3, Armin Ghobadi, MD4*, Yi Lin, MD, PhD5, Saurabh Dahiya, MD6, Matthew A. Lunning, DO7, Lazaros J. Lekakis, MD8*, Patrick M. Reagan, MD9, Olalekan O. Oluwole, MBBS, MPH10, Joseph P. McGuirk, DO11, Abhinav Deol, MD12, Alison R. Sehgol, MD13, Andre Goy, MD14, Brian T. Hill, MD, PhD15,16, Charalambos Andreadis, MD17,18, Javier Munoz, MD19, Jason R. Westin, MD20, Julio C. Chavez, MD21, Amanda F Cashen, MD22, Nora N Bennani, MD23, Aaron R. Rapoport, MD23, Julie M. Vose, MD, MBA24, David B. Miklos, MD, PhD24, Sattva S. Neelapu, MD25 and Frederick L. Locke, MD26

1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
2Moffitt Cancer Center, Tampa, FL
3Stanford University Medical Center, Stanford, CA
4Washington University School of Medicine and Siteman Cancer Center, St. Louis, MO
5Division of Hematology, Mayo Clinic, Rochester, MN
6University of Maryland School of Medicine, Baltimore, MD
7University of Nebraska Medical Center, Omaha, NE
8Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL
9Wilmer Cancer Institute Division of Hematology/Oncology, University of Rochester Medical Center, Rochester, NY
10Vanderbilt-Ingram Cancer Center, Nashville, TN
11Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS
12Department of Oncology, Blood and Marrow Stem Cell Transplant Program, Karmanos Cancer Institute/Wayne State University, Detroit, MI
13UPMC Hillman Cancer Center, Pittsburgh, PA
14John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, NJ
15Tauussig Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH
16Tauussig Institute, Cleveland Clinic, Cleveland, OH
17Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA
18Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA
19Banner MD Anderson Cancer Center, Gilbert, AZ
20Department of Lymphoma and Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston
21H. Lee Moffitt Cancer Center and Research Institute, Lutz, FL
22Department of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO
23University of Maryland Medical Center Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD
24Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University, Stanford, CA
25Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX
26H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

104 Invariant Patterns of Clonal Succession Determines Specific Phenotypic and Clinical Features of Myelodysplastic Syndromes (MDS)

Program: Oral and Poster Abstracts
Type: Oral
Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Somatic Mutations and Germline Predisposition

Hematology Disease Topics & Pathways: Adult, Diseases, MDS, Biological Processes, Myeloid Malignancies, molecular interactions
Saturday, December 1, 2018: 9:45 AM; Seaport Ballroom A (Manchester Grand Hyatt San Diego)

Yasunobu Nagata1, Hideki Makishima, MD, PhD2, Tetsuichi Yoshizato, MD, PhD3, Hiromichi Suzuki, M.D.4, Ph.D.5, Cassandra M. Hirsch6, Abhinav Goyal7, Hassan Awada, MD8, Mohammad Fahad B. Asad9, Teodora Kuzmanovic, BA10, Bartlomej P. Przychoden11, Kenichi Yoshida, MD, PhD12, Kenichi Chiba, PhD13, Hiroko Tanaka, BA14, Yuichi Shiraishi, PhD15, Satoru Miyano, PhD16, Sudipto Mukherjee, MD, PhD, MPH17, Tomas Radivoyevitch, PhD18, Thomas Lafraamboise, PhD19, Aziz Nazha, MD20, Mikkael A. Sekeres, MD, MS21, Torsten Haferlach, MD22, Seishi Ogawa, MD, PhD23 and Jaroslav P. Maciejewski24

ASH 2018 Annual Meeting
107 SNP-Array Genome Wide Association Study Meta-Analysis Identifies Innate Immune Susceptibility Loci Associated with Non-Del(5q) Myelodysplastic Syndromes Predisposition

Program: Oral and Poster Abstracts
Type: Oral
Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Somatic Mutations and Germline Predisposition

Hematology Disease Topics & Pathways: Diseases, Biological Processes, MDS, Technology and Procedures, Study Population, Myeloid Malignancies, inflammation

Saturday, December 1, 2018: 10:30 AM; Seaport Ballroom A (Manchester Grand Hyatt San Diego)

Kathy L McGraw, PhD1, Chia-Ho Cheng, Ph.D.2,*, Y. Ann Chen, Ph.D.3,*, Hsin-An Hou, MD, PhD4,*, Giulio Genovese, Ph.D.5,*, Thomas Cluzeau, MD, PhD6,*, Andrea Pellagatti, PhD7,*, Bartlomiej Przychoden8,*, Mar Mallo, Ph.D.9,*, Arenillas Leonor, MD, PhD10,*, Azim M. Mohamedali, Ph.D.11,*, Pierre Fenaux, MD12, David A Sallman, MD13, Eric Padron, MD14, Lubomir Sokol, MD, PhD15, Chimene Moreihlon16,*, Sophie Raynaud, MD, PhD17,*, Bjorn Nilsson, Ph.D.18,*, Hwei-Fang Tien, M.D., Ph.D.19, Jacqueline Boulwood, PhD7, Benjamin L. Ebert, MD, PhD20, Francesc Sole, PhD21, Pierre Fenaux, MD, PhD22, Gulam Mufti23,*, Jaroslaw P. Maciejewski24, Peter Kanetsky, Ph.D.2*, and Alan F. List, MD2

1Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL
2H. Lee Moffitt Cancer Center, Tampa, FL
3H. Lee Moffitt Cancer Center, Tampa
4Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan
5Broad Institute of the Massachusetts Institute of Technology, Cambridge, MA
6Département de Hématologie Clinique, Centre Hospitalier Universitaire de Nice, Nice, France
7Bloodwise Molecular Haematology Unit, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
8Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
9Institut de Recerca Contra la Leucèmia Josep Carreras, Institut Català d'Oncologia, Barcelona, Spain
10Laboratori de Citologia Hematològica i Citogenètica, servei de Patologia, Hospital del Mar. GRETNHE - Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain
11Kings College London, London, GBR
12INSERM UMR-S1131, Institut Universitaire d'Hématologie, Hôpital St Louis/ Paris 7 University, PARIS, France
13Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL
14H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
15Moffitt Cancer Center, Tampa, FL
16CHU of Nice, Nice, France
17CHU of Nice, Onc-hematology Laboratory, Cote D’Azur University, Nice Sophia Antipolis University, Nice, France
18Lund University, Lund, Sweden
19Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
20Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
21MDS Research Group, Instituto de Recerca Contra la Leucèmia Josep Carreras, Institut Català d’Oncologia-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
22INSERM UMR-S1131, Institut Universitaire d’Hématologie, Université Paris-Diderot, Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, Paris, France
23Department of Haematological Medicine, King’s College Hospital NHS Foundation Trust, London, United Kingdom
24Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

108 Novel and Significant Impact of Germline Variants Predisposed to Pathogenic Somatic Mutations and Loss of Heterozygosity (LOH) in Myelodysplastic Syndromes (MDS) and Clonal Hematopoiesis of Indeterminate Potential (CHIP)

Program: Oral and Poster Abstracts
Type: Oral
Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Somatic Mutations and
Germline Predisposition
Hematology Disease Topics & Pathways: Diseases, Adult, MDS, Biological Processes, Technology and Procedures, Study Population, Clinically relevant, genomics, Myeloid Malignancies, Quality Improvement, NGS
Saturday, December 1, 2018: 10:45 AM; Seaport Ballroom A (Manchester Grand Hyatt San Diego)
Hideki Makishima, MD, PhD\(^1\), Tetsuichi Yoshizato, MD, PhD\(^2\), Yasuhide Momozawa, PhD\(^3\), Yoshiho Atsuta, MD, PhD\(^4\), Yuke Shiozawa, M.D., Ph.D.\(^2\), Yuka Iijima-Yamashita\(^6\), Kenichi Yoshida, MD, PhD\(^7\), Yuchi Shiraiishi, PhD\(^7\), Hiromichi Suzuki, M.D., Ph.D.\(^2\), June Takeda, MD\(^8\), Yasunobu Nagata\(^9\), Yusuke Sato\(^10\), Nobuyuki Kakiuchi, M.D.\(^2\), Keisuke Kataoka, MD, PhD\(^2\), Kenichi Chiba, PhD\(^7\), Hiroko Tanaka, BA\(^1\), Hiroo Ueno, MD\(^2\), Masahiro Marshall Nakagawa, MD, PhD\(^12\), Hidehiro Itonaga, M.D., Ph.D.\(^13\), Yoshinobu Kanda, MD, PhD\(^14\), Yasushi Miyazaki, MD, PhD\(^15\), Keizo Horibe, MD, PhD\(^16\), Masashi Sanada, MD, PhD\(^16\), Yoichiro Kamatani, MD, Ph.D\(^17\), Michiaki Kubo, MD, Ph.D\(^17\), Satoru Miyano, PhD\(^18\) and Seishi Ogawa, MD, PhD\(^19\)
\(^1\)Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Japan, Kyoto, Japan
\(^2\)Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
\(^3\)Tokyo University, Tokyo, Japan
\(^4\)Center for Integrative Medical Sciences (IMS), RIKEN, Laboratory for Genotyping Development, Tsurumi, Japan
\(^5\)Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan
\(^6\)Department of Advanced Diagnosis, Clinical Research Center, Nagoya Medical Center, Nagoya, Japan
\(^7\)Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
\(^8\)Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, KYO, Japan
\(^9\)Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
\(^10\)Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan
\(^11\)Department of Hematology/Oncology, Tokai University School of Medicine, Isehara, Japan
\(^12\)Graduate School of Medicine, Kyoto University, Kyoto, Japan
\(^13\)Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
\(^14\)Saitama Medical Ctr. Jichi Medical Univ., Saitama, Japan
\(^15\)Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan
\(^16\)Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan
\(^17\)RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
\(^18\)Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
\(^19\)Department of Pathology and Tumor Biology, Kyoto University, Sakyoku, Japan

157 Outcomes and Healthcare Utilization of Children with Mucopolysaccharidosis with and without Hematopoietic Stem Cell Transplantation
Program: Oral and Poster Abstracts
Type: Oral
Session: 903. Outcomes Research—Non-Malignant Hematology: Health Outcomes in Sickle Cell Disease and Mucopolysaccharidosis
Hematology Disease Topics & Pathways: Pediatric, Technology and Procedures, Study Population, Clinically relevant, newborn screening
Saturday, December 1, 2018: 12:00 PM; Room 24B (San Diego Convention Center)
Cara E Carr, MD\(^1\)*, Nikita Goel, MD\(^1\)*, Nori Minich, BS\(^2\)*, Steven L Shein, MD\(^1\)* and Jignesh Dalal, MD\(^1\)
\(^1\)Rainbow Babies & Children’s Hospital, Cleveland, OH
\(^2\)Case Western Reserve University, Cleveland, OH

158 Iron Overload Is Under-Recognized and Under-Treated in SCD: A Report from the GRNDaD Registry
Program: Oral and Poster Abstracts
Type: Oral
Session: 903. Outcomes Research—Non-Malignant Hematology: Health Outcomes in Sickle Cell Disease and Mucopolysaccharidosis
Hematology Disease Topics & Pathways: Diseases, sickle cell disease, Hemoglobinopathies
Saturday, December 1, 2018: 12:15 PM; Room 24B (San Diego Convention Center)
Matthew Sears, PhD1, Sophie Lanzkron, MD, MHS2, Carolyn Hoppe, MD3, Joshua J. Field, MD4, Payal C Desai, MD5, Elizabeth Williams6* and Jane Little, MD7,8
1Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA
2Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD
3UCSF Benioff Children's Hospital, Oakland, CA
4Blood Center of Wisconsin, Medical College of Wisconsin, Milwaukee, WI
5Department of Hematology, The Ohio State University, Columbus, OH
6Johns Hopkins School of Medicine, Baltimore, MD
7CWRU School of Medicine, Cwru/University Hospitals, Cleveland, OH
8Division of Hematology/Oncology, Case Western Reserve University/University Hospitals Seidman Cancer Center, Cleveland, OH

**207 Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: A Large Real-Time Multi-Center Prospective Longitudinal Observational Study**

Program: Oral and Poster Abstracts
Type: Oral
Session: 732. Clinical Allogeneic Transplantation: Results: To Transplant or Not to Transplant? That Is the Question
Hematology Disease Topics & Pathways: Adult, Biological, AML, Diseases, bone marrow, Therapies, Elderly, Study Population, Clinically relevant, Myeloid Malignancies, transplantation
Saturday, December 1, 2018: 2:30 PM; Seaport Ballroom A (Manchester Grand Hyatt San Diego)

Mohamed L. Sorror, MD, MSc1,2, Barry E. Storer, PhD3,4*, Aaron T. Gerds, MD, MS5, Bruno C. Medeiros, MD6, Paul J Shami, MD7, John P. Galvin, MD, MS, MPH8, Kehinde U. Adekola, MBBS, MS9, Selina Luger, MD10, Maria R. Baer, MD11, David A. Rizziere, MD12, Tanya M. Wildes, MD, MS13, Eunice S. Wang, MD14, Stefan Faderl, MD15, Jamie L. Koprinikar, MD15, Mikkael A. Sekeres, MD, MS16, Sudipto Mukherjee, MD, PhD, MPH17, Julie Smith, MD16*, Mitchell Garrison, MD16*, Kiara Kajouri, MD17*, Jennifer E. Nyland, PhD17*, Rachelle R. Moore, BS14*, Sophie L. Fleuret, BS17*, Ylinne Lynch, MD14,18, Pamela S. Becker, MD14,19, Mary-Elizabeth M. Percival, MD, MS15,19, Brenda M. Sandmaier, MD15,19, Frederick R. Appelbaum, MD10,12 and Elihu H. Estey, MD1,19
1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
2Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA
3Department of Biostatistics, University of Washington School of Public Health, Seattle, WA
4Clinical Statistics Program, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
5Leukemia & Myeloid Disorders Program, Cleveland Clinic, Cleveland, OH
6Department of Medicine, Division of Hematology, Stanford University, Palo Alto, CA
7Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
8Feinberg School of Medicine, Northwestern University, Chicago, IL
9Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL
10Abramson Cancer Center at the University of Pennsylvania School of Medicine, Philadelphia, PA
11University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD
12Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC
13Division of Oncology, Washington University School of Medicine, St Louis, MO
14Leukemia Service, Roswell Park Comprehensive Cancer Center, Buffalo, NY
15John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ
16Confluence Health/Wenatchee Valley Hospital, Wenatchee, WA
17Skagit Valley Hospital Regional Cancer Care Center, Mount Vernon, WA
18Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA
19Division of Hematology, Department of Medicine, University of Washington, Seattle, WA

**211 Development of a Novel Class of Agents Targeting the RNA-Splicing Machinery in Myeloid Malignancies**

Program: Oral and Poster Abstracts
Type: Oral
Session: 802. Chemical Biology and Experimental Therapeutics: New Targeted Therapies and Drug Development
Hematology Disease Topics & Pathways: Diseases, Therapies, Non-Biological, chemical interactions,
MDS, Biological Processes, Technology and Procedures, Clinically relevant, Myeloid Malignancies, genomics, RNA sequencing

Saturday, December 1, 2018: 2:00 PM; Room 7B (San Diego Convention Center)

Valeria Visconte, PhD1, Bartłomiej P. Przychodzen1*, Vera Adema, PhD1*, Cassandra M. Hirsch2*, Allison Noe2*, Rachel Toth2*, Christina Snider, BA2, Hassan Awada, MD1, Amy C Graham, BS, MS3*, Yvonne Parker4*, Drew Adams5*, Hetty E. Carraway, MD, MBA6,7, Anjali S. Advani, MD9, Tomas Radivoyevitch3*, Heesun J. Rogers, MD, PhD9, Kevin R Kelly, MD, PhD10*, Steffan T. Nawrocki, PhD11, Jennifer S. Carew, PhD12, Daniel Lindner, MD, PhD12*, Richard A Padgett13*, Mikkael A. Sekeres, MD, MS14, James G Phillips, PhD15* and Jaroslaw P. Maciejewski1

1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
3Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
4Department of Genetics and Genome Sciences, Small-Molecule Drug Development Core, Case Western Reserve University School of Medicine, Cleveland, OH
5Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
6Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH
7Leukemia Program, Department of Hematology & Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
8Department of Hematopathology, Cleveland Clinic, Cleveland, OH
9Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, University of Southern California Keck School of Medicine, Los Angeles, CA
10Division of Translational and Regenerative Medicine, Department of Medicine, University of Arizona Cancer Center, Tucson, AZ
11The University of Arizona Cancer Center, Tucson, AZ
12Cellular and Molecular Medicine, Cleveland Clinic Foundation, Cleveland, OH
13Cleveland Clinic Lerner College of Medicine of CWRU, Cleveland, OH

216 A First-in-Class Inhibitor of ISWI-Mediated (ATP-Dependent) Transcription Repression Releases Terminal-Differentiation in AML Cells While Sparing Normal Hematopoiesis

Program: Oral and Poster Abstracts
Type: Oral
Session: 802. Chemical Biology and Experimental Therapeutics: New Targeted Therapies and Drug Development
Hematology Disease Topics & Pathways: Non-Biological, Therapies, chemical interactions, Biological Processes, epigenetics

Saturday, December 1, 2018: 3:15 PM; Room 7B (San Diego Convention Center)

Ashwin Kishtagari, MBBS, Kwok Peng Ng, PhD*, Charlotte Jarman*, Anand D. Tiwari, PhD*, James G Phillips, PhD1, Caroline Schuerger*, Babal K. Jha* and Yogenthiran Saunthararajah, MD

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

217 Hepatocyte-Derived Tissue Plasminogen Activator Regulates Systemic Fibrinolysis

Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways: Diseases, Hemostasis, Bleeding and clotting, Biological Processes, thrombosis

Saturday, December 1, 2018: 4:00 PM; Room 28D (San Diego Convention Center)

Ze Zheng, MD, PhD1, Lalitha V. Nayak, MD2, Mukesh Jain, MD3* and Ira Tabas, MD, PhD4*

1Department of Medicine, Columbia University, New York, NY
2University Hospitals Cleveland Medical Center, Cleveland, OH
3Case Western Reserve University / University Hospitals Health System, Cleveland, OH
4Department of Medicine, Columbia University, New York City, NY

268 High Molecular Weight Kininogen Contributes to End-Organ Damage and Mortality in a Mouse Model of Sickle Cell Disease

ASH 2018 Annual Meeting
Program: Oral and Poster Abstracts
Type: Oral
Session: 113. Hemoglobinopathies, Excluding Thalassemia—Basic and Translational Science: Sickle Cell Disease—Role of Coagulation and Inflammation in Pathophysiology
Hematology Disease Topics & Pathways: Sickle cell disease, Diseases, Animal models, Biological Processes, Hemoglobinopathies, Study Population, Clinically relevant, inflammation, pathogenesis
Sunday, December 2, 2018: 8:15 AM; Room 33B (San Diego Convention Center)

Erica Sparkenbaugh, PhD, BS*, Kathryn Wilson, BS**, Malgorzata Kasztan, PhD†, David M. Pollock, PhD‡, Keith R. McCrae, MD§ and Rafal Pawlinski, PhD∥
1UNC Chapel Hill McAllister Heart Institute, Chapel Hill, NC
2McAllister Heart Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC
3Department of Medicine Division of Nephrology, The University of Alabama at Birmingham, Birmingham, AL
4Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
5Division of Hematology/Oncology, University of North Carolina, Chapel Hill, NC

308 Related and Unrelated Donor Transplantation for β Thalassemia Major: Results of an International Survey
Program: Oral and Poster Abstracts
Type: Oral
Session: 732. Clinical Allogeneic Transplantation: Results: Optimizing Outcomes After Allogeneic Transplantation
Hematology Disease Topics & Pathways: Biological, Diseases, Therapies, thalassemia, Pediatric, Hemoglobinopathies, Young Adult, Study Population, Clinically relevant, transplantation
Sunday, December 2, 2018: 7:45 AM; Grand Hall A (Manchester Grand Hyatt San Diego)
1Nanfang-Chunfu Children's Institute of Hematology & Oncology, Taixin Hospital, Dongguan, China
2Nanfang Hosp. Southern Medical University, Guangzhou, China
3Department of Haematology, Christian Medical College, Vellore, India
4Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
5CIBMTR and Medical College of Wisconsin, Milwaukee, WI
6Guangzhou Women and Children's Medical Center, Guangzhou, China
7Shenzhen Children’s Hospital, Shenzhen, China
8West China Second University Hospital, Sichuan University, Chengdu, China
9Medical College of Wisconsin, Milwaukee, WI
10Division of Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University Medical Center, Stanford, CA
11Pediatric Blood and Marrow Transplantation Program, Pediatric Blood and Marrow Transplantation Program University Hospital Utrecht, Utrecht, Netherlands
12Department of Pediatrics, University of California – San Francisco, San Francisco, CA
13Nationwide Children's Hospital, Columbus, OH
14Children’s Mercy Hospital, Kansas City, MO
15School of Medicine, University of Missouri, Kansas City, Kansas City, KS
16Department of Pediatric Hematology Oncology and Bone Marrow Transplant, Cleveland Clinic, Cleveland, OH
17University of North Carolina, Chapel Hill
18Washington University Medical Center, Saint Louis, MO
19UCSF Benioff Children's Hospital, Oakland, CA

314 Patient Satisfaction of Care in the Treatment of Vaso-Occlusive Crises: A Comparison of Emergency Department and Infusion Centers in the Escaped Study
Program: Oral and Poster Abstracts
Type: Oral
Session: 901. Health Services Research—Non-Malignant Conditions: Sickle Cell Disease
Hematology Disease Topics & Pathways: Diseases, sickle cell disease, Adult, Hemoglobinopathies, Study Population, Quality Improvement

Sunday, December 2, 2018: 7:45 AM; Room 28D (San Diego Convention Center)

Nebras Abu Al Hamayel, MBBS, MPH1,2, Jasmine Brooks, BA2, Hang Wang, PhD3, Rebecca Seufert, BS1,2, Carlton Haywood Jr., PhD, MA1,2, Ravi Varadhan, PhD3,4, Mustapha Saheed, MD5,6, Jodi Segal, MD2,7, Chiung-Yu Huang, PhD2,3, Joshua J. Field, MD6, Steven Frymark2,10, Jane Little, MD1,7,11,12, Brandi Griffin, BSN, RN13, Nicole Arnold14,5, Joseph Ryan Shows, MD15, Allie Piehet, BS16, Marc Proudford17, Derek Robertson, MBA, JD18, Marcus Wallace, MD19, Adrienne Kincaid20, Charles Green21, Lorri Burgess, BS22 and Sophie Lanzkron, MD23,24

1Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
2Johns Hopkins University, School of Medicine, Baltimore, MD
3School of Medicine, Johns Hopkins University, Baltimore, MD
4The Johns Hopkins University, Baltimore, MD
5Oncology Biostatistics and Bioinformatics, Johns Hopkins University, Baltimore, MD
6Johns Hopkins University, School of Medicine, Baltimore, MD
7School of Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD
8Department of Epidemiology & Biostatistics, University of California San Francisco, San Francisco, CA
9Blood Center of Wisconsin, Medical College of Wisconsin, Milwaukee, WI
10Froedtert Adult Sickle Cell Clinic, Blood Center of Wisconsin, Inc, Milwaukee
11CWRU School of Medicine, Cwru/University Hospitals, Cleveland, OH
12Division of Hematology/Oncology, Case Western Reserve University/ University Hospitals Seidman Cancer Center, Cleveland, OH
13Case Western Reserve University Hospital, Cleveland
14Case Western Reserve University Hospital, OH
15Our Lady of the Lake Hospital, Baton Rouge
16Our Lady of the Lake Regional Medical Center, Baton Rouge, LA
17Johns Hopkins Community Based Organization Partner, Baltimore
18Community Based Organization Partner, Maryland Sickle Cell Disease Association, Columbia
19Louisiana Health Care Connection, Baton Rouge, LA
20Community Based Organization Partner, Kincaid’s Kindred Spirits, Euclid
21Community Based Organization Partner, Blood Center of Wisconsin, Milwaukee
22Community Based Organization Partner, Lady of the Lake Regional Medical Center, Baton Rouge, LA
23Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
24Department of Medicine, Division of Hematology, Johns Hopkins Medicine, Baltimore, MD

331 Uproleselan (GMI-1271), an E-Selectin Antagonist, Improves the Efficacy and Safety of Chemotherapy in Relapsed/Refractory (R/R) and Newly Diagnosed Older Patients with Acute Myeloid Leukemia: Final, Correlative and Subgroup Analyses

Program: Oral and Poster Abstracts

Type: Oral

Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Combination Therapy

Hematology Disease Topics & Pathways: Diseases, AML, Adult, Therapies, Non-Biological, Study Population, Myeloid Malignancies

Sunday, December 2, 2018: 9:30 AM; Grand Hall B (Manchester Grand Hyatt San Diego)

Daniel J. DeAngelo, MD1, Brian A. Jonas, MD, PhD2, Jane L. Liesveld, MD3, Dale L. Bixby, MD, PhD4*, Anjali S. Advani, MD5, Paula Marlton6, Michael E O’Dwyer, MD7, William E Fogler, PhD8, Curt D Wolfgang, PhD9, John L Magnani, PhD9, Helen M Thackray, MD9 and Pamela S. Becker, MD9,10

1Dana-Farber Cancer Inst., Boston, MA
2University of California, Davis, Sacramento, CA
3Division of Hematology/Oncology, University of Rochester Medical Center, Rochester, NY
4Internal Medicine, University of Michigan, Ann Arbor, MI
5Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH
6Faculty of Medicine, University of Queensland, Brisbane, Australia
7National University of Ireland Galway, Galway City, Ireland
8GlycoMimetics, Inc., Rockville, MD
9Division of Hematology, University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA
10Division of Hematology, Department of Medicine, University of Washington, Seattle, WA

353 A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis

ASH 2018 Annual Meeting
366 Economic Burden of Venous Thromboembolism in Cancer Patients - a Comparative Analysis between Matched Patients with Cancer with and without a Diagnosis of Venous Thromboembolism

Program: Oral and Poster Abstracts
Type: Oral
Session: 901. Health Services Research—Non-Malignant Conditions: Thrombosis and Anticoagulation
Hematology Disease Topics & Pathways: Diseases, Bleeding and clotting, Thromboembolism, Clinically relevant, Quality Improvement
Sunday, December 2, 2018: 10:45 AM; Room 8 (San Diego Convention Center)

Surbhi Shah¹, Nathan Rubin, MS²* and Alok A. Khorana³,4,5,6,7,8,9

¹University of Minnesota, Minneapolis, MN
²UNIVERSITY OF MINNESOTA, Minneapolis, MN
³Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH
⁴Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
⁵Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH
⁶Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
⁷Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
⁸Taussig Cancer Institute, Cleveland
⁹Taussig Cancer Institute/Cleveland Clinic, Cleveland, OH

371 Survival Outcomes of Patients with Therapy-Related Myelodysplastic Syndromes in the United States

Program: Oral and Poster Abstracts
Type: Oral
Session: 904. Outcomes Research—Malignant Conditions: Outcomes in Myeloid Malignancies and Allogeneic Stem Cell Transplant
Hematology Disease Topics & Pathways: Adult, Diseases, MDS, Study Population, Clinically relevant, Myeloid Malignancies
Sunday, December 2, 2018: 10:30 AM; Room 25B (San Diego Convention Center)

Raffi Tchekmedyian, BS¹, Tomas Radivojevitch, PhD²*, Aaron T. Gerds, MD, MS³, Aziz Nazha, MD⁴, Hetty E. Carraway, MD, MBA⁵,6, Anjali S. Advani, MD⁶, Jaroslaw P. Maciejewski², Matt Kalaycio, MD⁷, Navneet S. Majhail, MD, MS⁷, Mikkael A. Sekeres, MD, MS⁸ and Sudipto Mukherjee, MD, PhD, MPH⁹

¹Cleveland Clinic Foundation, Cleveland, OH
²Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
³Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
⁴Cleveland Clinic, Cleveland, OH
⁵Taussig Cancer Institute, Cleveland Clinic, Department of Hematology and Medical Oncology, Cleveland, OH
398 Interim Results from the First-in-Human Clinical Trial of Adct-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Program: Oral and Poster Abstracts
Type: Oral
Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: New Agents
Hematology Disease Topics & Pathways:
Adult, Diseases, Biological, Therapies, B-Cell Lymphoma, Study Population, Lymphoid Malignancies
Sunday, December 2, 2018: 12:15 PM; Pacific Ballroom 20 (Marriott Marquis San Diego Marina)
John Radford, MD, FRCP, Brad S. Kahl, MD, Mehdi Hamadani, MD, Carmelo Carlo-Stella, MD, Paolo Caimi, MD, Kiril M. Ardesha, MMBChir, Jay Feingold, MD, PhD, Shui He, PhD, Erin Reid, MD, Melhem Solh, MD, Ki-Young Chung, MD, Leonard Heffner, MD, David Ungar, MD and Owen A. O’Connor, M.D., Ph.D.

416 The Platelet Factor-4 (PF4)-Dependent p-Selectin Expression Assay (PEA) Is Highly Accurate for the Detection of Pathogenic HIT Antibodies: Results of a 440-Sample Prospective Blinded Study

Program: Oral and Poster Abstracts
Type: Oral
Session: 331. Pathophysiology of Thrombosis: Risk Factors and Thromboembolism
Hematology Disease Topics & Pathways: Diseases, Bleeding and clotting, HIT
Sunday, December 2, 2018: 4:45 PM; Room 30D (San Diego Convention Center)
Deepti M. Warad, MD, Bethany T Samuelson Bannow, MD, Curtis Jones, BS, Shannon Pechauer*, Brian R. Curtis, PhD, Daniel W. Bougie, PhD, Parisa R Khalighi, BS, Diane E. Grill, MS, Rachel Leger, BAE®, Ruchika Sharma, MD, Dong Chen, MD, PhD, Richard H. Aster, MD, David A. Garcia and Anand Padmanabhan, MD, PhD
417 Risk of Venous Thrombosis in Patients with Sickle Cell Trait after Orthopedic Surgery
Program: Oral and Poster Abstracts
Type: Oral
Session: 331. Pathophysiology of Thrombosis: Risk Factors and Thromboembolism
Hematology Disease Topics & Pathways: Diseases, Biological Processes, Hemoglobinopathies, Clinically relevant, immune mechanism, inflammation
Sunday, December 2, 2018: 5:00 PM; Room 30D (San Diego Convention Center)
Jahnavi Gollamudi, MD1, Sadeer Al-Kindi, M.D.2, Petra Martin2, Jane Little, MD4,5 and Lalitha V. Nayak, MD3
1Department of Medicine / Division of Hematology and Oncology, University Hospitals Cleveland Medical Center, Cleveland, OH
2University hospitals case medical center, Cleveland
3University Hospitals Cleveland Medical Center, Cleveland, OH
4CWRU School of Medicine, CwrU/University Hospitals, Cleveland, OH
5Division of Hematology/ Oncology, Case Western Reserve University/ University Hospitals Seidman Cancer Center, Cleveland, OH

425 Heparin Vs Direct Thrombin Inhibitors in Patients with Previous HIT Undergoing Cardiothoracic Surgery: The Cleveland Clinic Experience
Program: Oral and Poster Abstracts
Type: Oral
Session: 332. Antithrombotic Therapy: Management of Challenging Patients and Scenarios
Hematology Disease Topics & Pathways: Adult, anticoagulant drugs, Diseases, Non-Biological, Therapies, Bleeding and clotting, HIT, Study Population, serologic tests
Sunday, December 2, 2018: 5:30 PM; Room 33B (San Diego Convention Center)
Daniel S Carlson, DO1, Keith R. McCrae, MD2 and Shruti Chaturvedi, MBBS, MS3
1Cleveland Clinic Foundation, Cleveland, OH
2Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
3Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

437 Minimal Residual Disease (MRD) at Time of Complete Remission Is Commonly Detected in Acute Myeloid Leukemia (AML) Patients Age ≥60 Years and Significantly Impacts Outcome Based on Post-Remission Treatment Strategies: Prospective Analysis of ECOG-ACRIN (E-A) E2906 Phase III Trial
Program: Oral and Poster Abstracts
Type: Oral
Session: 613. Acute Myeloid Leukemia: Clinical Studies: Minimal Residual Disease and Genetic Characterization
Hematology Disease Topics & Pathways: AML, Diseases, Therapies, Non-Biological, Elderly, chemotherapy, Technology and Procedures, Study Population, Clinically relevant, Myeloid Malignancies, flow cytometry
Sunday, December 2, 2018: 5:30 PM; Seaport Ballroom F (Manchester Grand Hyatt San Diego)
James M. Foran, MD1, Zhourxin Sun, PhD2, Elisabeth Paietta, PhD3, Janis Racevskis, PhD3, David F. Claxton, MD4, Hillard M Lazarus, MD5, Daniel A. Arber, MD6, Jacob M. Rowe, MD7, Jessica K. Altman, MD8, Aref Al-Kali, MD9, Hong Zheng, MD, PhD10, Keith W. Pratz, MD11, Edward R. Broun, MD12, Bayard L. Powell, MD13, Kristen Marie O'Dwyer, MD14, John Godwin, MD15, Yanming Zhang, MD16, Martin S. Tallman, MD17, Selina Luger, MD18 and Mark R. Litzow, MD19
1Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic Florida, Jacksonville, FL
2ECOG-ACRIN statistical center, Boston
3ECOG-ACRIN statistical center, Bronx, NY
4Penn State Cancer Institute, Penn State M.S. Hershey Medical Center, Hershey, PA
5Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH
6University of Chicago, Chicago, IL
7The Ruth and Bruce Rappaport Faculty of Medicine, Shaare Zedek Medical Center, Jerusalem, Israel
8Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL
9Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Rochester, MN
451 Outcomes of Patients with Limited-Stage Aggressive Large B-Cell Lymphoma with MYC Rearrangement with and without BCL2 and/or BCL6 Rearrangements: A Retrospective Analysis from 15 US Academic Centers

Program: Oral and Poster Abstracts
Type: Oral
Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Population Based Outcomes in Aggressive Lymphoma

B. Cohen, MD, MS1, L. Jeffrey Medeiros, MD2, Emily C. Ayers, MD3, Daniel J. Landsburg, MD4, David A. Bond, MD5, Kami J. Maddocks, MD6, Anshu Giri, MD7,*, Brian T. Hess, MD5, Luu Q. Pham8,*, Ranjana H. Advani, MD9, Yang Liu, MD10,*, Stefan Klaus Barta, MD, MRCP, MS11, Julie M. Vose, MD, MBA12, Michael C. Churnetksi, BS13,*, Jonathon B. Cohen, MD, MS14, Madelyn Burkart, MD15,*, Reem Karmali, MD16, Joanna Zurko, MD17,*, Amitkumar Mehta, MD17,*, Adam J Olszewski, MD18, Sarah S Lee, MD19, Brian T. Hill, MD, PhD20,21, Timothy F. Burns, MD22, Frederick Lansigan, MD22, Emma Rabinovich, MD23,*, David Peace, MD24, Adrienne Groman, MS25,*, Kris Attwood, PhD, MS25,*, Francisco J. Hernandez-Izilturri, MD26 and Pallawi Torka, MD25

1Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY
2Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
3University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA
4Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
5Division of Hematology and Medical Oncology, The Ohio State University College of Medicine, Columbus, OH
6Division of Hematology, Ohio State University Hospital, Columbus, OH
7Medical University of South Carolina, Charleston, SC
8Division of Hematology/Oncology, Johns Hopkins Medical Institutions, Baltimore, MD
9Stanford University, Stanford, CA
10Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA
11Fox Chase Cancer Center, Philadelphia, PA
12University of Nebraska Medical Center, Omaha, NE
13Winship Cancer Institute—Department of Hematology and Medical Oncology, Emory University, Atlanta, GA
14Winship Cancer Institute, Emory University, Atlanta, GA
15Northwestern University, Chicago, IL
16Division of Hematology, Northwestern University, Chicago, IL
17University of Alabama at Birmingham, Birmingham, AL
18Department of Medicine, Alpert Medical School of Brown University, Providence, RI
19Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
20Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH
21Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
22Dartmouth-Hitchcock Medical Center, Lebanon, NH
23University of Illinois at Chicago, Chicago, IL
24Division of Hematology/Oncology, University of Illinois College of Medicine, Chicago
25Roswell Park Comprehensive Cancer Center, Buffalo, NY
26Departments of Medicine and Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY

453 Outcome of Patients with Aggressive B Cell Lymphomas Who Receive Second-Line Salvage Immunochemotherapy Following Treatment Failure of Intensive First-Line Immunochemotherapy
455 Outcomes of Patients with Relapsed/Refractory Double Expressor B Cell Lymphoma As Defined By Multicenter Pathology Review Treated with Ibrutinib Monotherapy
Program: Oral and Poster Abstracts
Type: Oral
Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Population Based Outcomes in Aggressive Lymphoma
Hematology Disease Topics & Pathways: Diseases, Adult, Biological, Therapies, Biological Processes, Non-Hodgkin Lymphoma, B-Cell Lymphoma, enzyme inhibitors, Study Population, Lymphoid Malignancies, Clinically relevant, signal transduction
Sunday, December 2, 2018: 5:30 PM; Ballroom 20D (San Diego Convention Center)
Daniel J. Landsburg, MD1, Mitchell E. Hughes, PharmD1*, Alexa Koike1*, David A. Bond, MD2, Kami J. Maddocks, MD2, Ling Guo, MD3*, Allison M. Winter, MD4, Brian T. Hill, MD, PhD4,5, Sarah L. Ondrejka, DO6, Eric D. Hsi, MD6, Sunita Dwivedy Nasta, MD1, Jakub Svoboda, MD1, Stephen J. Schuster, MD1 and Agata M. Bogusz, MD, PhD1*
1University of Pennsylvania, Philadelphia, PA
2Ohio State University, Columbus, OH
3Department of Pathology, Ohio State University, Columbus, OH
4Cleveland Clinic, Cleveland, OH
5FauSSID Cancer Institute, Cleveland Clinic, Cleveland, OH

495 Leukocyte Subtypes As Predictors for Venous Thromboembolism in Diffuse Large B-Cell Lymphoma
Program: Oral and Poster Abstracts
Type: Oral
Session: 903. Outcomes Research—Non-Malignant Hematology: Health Outcomes in Hemophilia, Thrombosis, ITP, and Hereditary Transthyreitin Amyloidosis
Hematology Disease Topics & Pathways: Diseases, Adult, Non-Hodgkin Lymphoma, Biological Processes, B-Cell Lymphoma, Study Population, Lymphoid Malignancies, Clinically relevant, inflammation
Sunday, December 2, 2018: 5:00 PM; Room 24B (San Diego Convention Center)
Jahnavi Gollamudi, MD1*, Gouri Dharmavaram2*, Petra Martin3*, Kirsten Marie Boughan, DO4, Brenda Cooper, MD4, Molly M Gallogly, MD, PhD4, Ehsan Malek, MD4, Leland Metheny, MD4, Folashade Otegbeye, MBBChir, MPH4, Benjamin K. Tomlinson, MD5, Marcos de Lima, MD5, Lalitha V. Nayak, MD5 and Paolo Caimi, MD4
1Department of Medicine / Division of Hematology and Oncology, University Hospitals Cleveland Medical Center, Cleveland, OH
2School of Medicine, Case Western Reserve University, Cleveland
3University Hospitals Cleveland Medical Center, Cleveland, OH
4Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH
5University Hospitals Seidman Cancer Center, Cleveland, OH

509 Efficacy and Safety of 1500mg Voxelotor in a Phase 2a Study (GBT440-007) in Adolescents with Sickle Cell Disease
Program: Oral and Poster Abstracts
Type: Oral
Session: 114. Hemoglobinopathies, Excluding Thalassemia—Clinical: Novel or Improved Approaches To Treating Sickle Cell Disease
Hematology Disease Topics & Pathways: Diseases, sickle cell disease, Hemoglobinopathies, Young Adult, Study Population
Monday, December 3, 2018: 8:00 AM; Room 28D (San Diego Convention Center)
11University Hospitals Seidman Cancer Center, Cleveland, OH
516 Polyclonal Immune Response in T-LGL Leads to Clonal Expansions Preceding Occurrence of STAT3 Mutations Further Solidifying Clonal Dominance

Program: Oral and Poster Abstracts
Type: Oral
Session: 203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: B and T Cell Biology
Hematology Disease Topics & Pathways: Leukemia, Diseases, LGLL, Lymphoid Malignancies
Monday, December 3, 2018: 8:15 AM; Room 8 (San Diego Convention Center)

Cassandra M. Hirsch1*, Michael Clemente, MS2*, Peter Chomczynski3*, Bartlomiej P. Przychodzen3*, Yasunobu Nagata4*, Vera Adema, PhD5*, Louis Williams, MD, MBA1, Valeria Visconte, PhD2, Alan Lichtin, MD2, Satu Mustjoki, MD, PhD2, Mikkael A. Sekeres, MD, MS6 and Jaroslaw P. Maciejewski1,9

1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2Taussig Cancer Institute, Cleveland Clinic, Department of Translational Hematology and Oncology Research, Cleveland
3Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
4Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
5Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland
6Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH
7Hematology Research Unit Helsinki, Department of Hematology, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
8Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
9Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

537 Next-Generation Sequencing Reveals a T Cell Receptor Signature Characteristic of Patients with Aplastic Anemia

Program: Oral and Poster Abstracts
Type: Oral
Session: 508. Bone Marrow Failure: Acquired Bone Marrow Failure and Somatic Genetics
Hematology Disease Topics & Pathways: Diseases, Anemias, Adult, aplastic anemia, Bone Marrow Failure, Elderly, Biological Processes, Technology and Procedures, Study Population, immune mechanism, NGS, pathogenesis
Monday, December 3, 2018: 7:30 AM; Grand Ballroom 2 (Marriott Marquis San Diego Marina)

Sofie Lundgren, BMed1*, Jani Huuhtanen, BMed1,2*, Mikko A Keränen, MD, PhD1,2, Cassandra M. Hirsch3, Emmi Jokinen, MSc2, Markus Heinonen, PhD2,4, Paula Savola, MD1,2, Tiina Kelkka, PhD1, Freja Ebeling, MD, PhD5, Jaroslaw P. Maciejewski3, Eva Hellstrom Lindberg, MD, PhD6, Harri Lähdesmäki, PhD2,4 and Satu Mustjoki, MD, PhD1,7

1Hematology Research Unit Helsinki, Department of Hematology, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
2Department of Computer Science, Aalto University School of Science, Espoo, Finland
3Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
4Helsinki Institute for Information Technology, Helsinki, Finland
5Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
6Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
7Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland

ASH 2018 Annual Meeting 20
564 Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML)

Program: Oral and Poster Abstracts
Type: Oral
Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Targeted Therapy
Hematology Disease Topics & Pathways: Adult, Diseases, AML, Therapies, Non-Biological, Study Population, Myeloid Malignancies, pharmacology
Monday, December 3, 2018: 8:15 AM; Seaport Ballroom F (Manchester Grand Hyatt San Diego)

Keith W. Pratz, MD1, Mohamad Cherry, MD, MS2, Jessica K. Altman, MD3, Brenda Cooper, MD4, Jose Carlos Cruz, MD5, Joseph G. Jurcic, MD6, Mark J. Levis, MD7, Tara Lin, MD8,9, Alexander E. Perl, MD10, Nikolai A. Podoltev, MD, PhD11, Gary J. Schiller, MD12, Chaofeng Liu, PhD, MBA13* and Erkut Bahceci, MD13

1John Hopkins University, Baltimore, MD
2Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK
3Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL
4Adult Hematologic Malignancies and Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH
5Methodist Physician Practices, San Antonio, TX
6Columbia University Medical Center, New York, NY
7Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
8University of Kansas Medical Center, Kansas City, KS
9Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas, Kansas City, KS
10Abramson Comprehensive Cancer Center, University of Pennsylvania, Philadelphia, PA
11Yale School of Medicine, New Haven, CT
12David Geffen School of Medicine at UCLA, Los Angeles, CA
13Astellas Pharma Global Development, Northbrook, IL

575 Patterns of Care of Diffuse Large B Cell Lymphoma Patients 80 Years and Older: Worse Outcomes after Treatment without Increased Relapse

Program: Oral and Poster Abstracts
Type: Oral
Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Outcomes Of Lymphoma In The Elderly
Hematology Disease Topics & Pathways: Diseases, Adult, Lymphoma (any), Elderly, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Study Population, Lymphoid Malignancies, Clinically relevant
Monday, December 3, 2018: 8:00 AM; Pacific Ballroom 18 (Marriott Marquis San Diego Marina)

Madison Keenan1*, Kirsten Marie Boughan, DO2, Brenda Cooper, MD2, Molly M Gallogly, MD, PhD2, Stanton L. Gerson, MD3, Hillard M Lazarus, MD3, Ehsan Malek, MD4, Leland Metheny, MD5, Folashade Otegbeye, MB BChir, MPH6, Benjamin K. Tomlinson, MD2, Erika Moore, MD5, Kwadwo Asare Oduro, MD, PhD5, Rose Beck, MD, PhD5, Howard Meyerson, MD5, Marcos de Lima, MD6 and Paolo F Caimi, MD6

1Case Western Reserve University, Cleveland, OH
2Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH
3Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH
4Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Shaker Hts, OH
5Department of Hematopathology, University Hospitals Cleveland Medical Center, Cleveland, OH
6Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals of Cleveland, Cleveland, OH

697 Low Levels of Neurologic Toxicity with Retained Anti-Lymphoma Activity in a Phase I Clinical Trial of T Cells Expressing a Novel Anti-CD19 CAR

Program: Oral and Poster Abstracts
Type: Oral
Session: 703. Adoptive Immunotherapy: In Vitro, Correlative, and Early Phase Studies to Improve Safety and Efficacy of CAR-T Cells
Hematology Disease Topics & Pathways: Biological, Diseases, bioengineering, Therapies, CAR-Ts, Non-
Hodgkin Lymphoma, Technology and Procedures, B-Cell Lymphoma, gene therapy, immunotherapy, Clinically relevant, Lymphoma Malignancies

Monday, December 3, 2018: 10:30 AM; San Diego Ballroom B (Marriott Marquis San Diego Marina)
Jennifer Brudno, MD1, Steven Hartman2, Noris Lam, BS3, David F. Stroncek4, John M. Rossi, MS5, Yueh-wei Shen*, Allen Xue, PhD*, Adrian Bot, MD, PhD*, Jennifer A Kanakry, MD*, Steven Z. Pavletic, MD*, Lekha Mikkilineni, MD7,*, Mark Roschewski, MD8, Robert M. Dean, MD9, Jeremy J. Rose, MS3, Rashmi Patel*, Brenna Hansen2, Steve A. Rosenberg10, Ronald E. Gress, MD11 and James N. Kochenderfer, MD12

1 Experimental Transplantation and Immunology Branch, NIH, NCI, Bethesda, MD
2 NIH, NCI, Bethesda
3 Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
4 National Institutes of Health, Clinical Center, Transfusion Medicine Department, Bethesda, MD
5 Kite, a Gilead Company, Santa Monica, CA
6 Experimental Transplantation and Immunology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD
7 National Institutes of Health Clinical Center, Bethesda, MD
8 Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD
9 Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH
10 Surgery Branch, National Institutes of Health Clinical Center, Bethesda, MD
11 Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
12 Experimental Transplantation and Immunology Branch, National Cancer Institute, Bethesda, MD

**704 Tyrosine Kinase Inhibitors with or without Donor Lymphocyte Infusion Continue to Provide Long-Term Survival after Relapse of Chronic Myeloid Leukemia Following Hematopoietic Cell Transplantation**

Program: Oral and Poster Abstracts

Type: Oral

Session: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Therapy of Post-Transplantation Relapse

Hematology Disease Topics & Pathways: Diseases, Biological, CML, Therapies, Clinically relevant, Myeloid Malignancies, transplantation, TKI

Monday, December 3, 2018: 10:45 AM; Grand Hall B (Manchester Grand Hyatt San Diego)
Sarah Ann Schmidt, PharmD1, Jennifer Holter Chakrabarty, MD2,*, Ying Liu, PhD1,4,*, Zhen-Huan Hu, MPH2,*, Kirsten M. Williams, MD3, Edwin P. Alyea II, MD6, Uday Popat, MD2, Ronald Sobecks, MD8, Bart L Scott, MD9 and Wael Saber, MD, MS3

1 University of Oklahoma, Oklahoma City, OK
2 Department of Hematology/Oncology, University of Oklahoma, Oklahoma City, OK
3 CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
4 Division of Biostatistics, Institution for Health and Society, Medical College of Wisconsin, Milwaukee
5 CETI, Children’s National Medical Center, Washington, DC
6 Center of Hematologic Oncology, Dana-Farber Cancer Institute, Boston, MA
7 Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
8 Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH
9 Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

**712 Pharmacist Interventions on Outpatient Leukemia Patients Improve Safety**

Program: Oral and Poster Abstracts

Type: Oral

Session: 902. Health Services Research—Malignant Diseases: Big Data And Outcomes Research

Hematology Disease Topics & Pathways: Quality Improvement

Monday, December 3, 2018: 11:15 AM; Room 24B (San Diego Convention Center)
Madeline Waldron, PharmD1,*, Caitlin Siebenaller, PharmD2,*, Marc Earl, PharmD2,*, Hetty E. Carraway, MD, MBA1,4, Anjali S. Advani, MD5, Aziz Nazha, MD5, Aaron T. Gerds, MD, MS3, Betty K. Hamilton, MD3, Ronald Sobecks, MD2, Matt Kalaycio, MD3, Barb Tripp, CNS5,*, Brian P. Hobbs, PhD5,*, Sudipto Mukherjee, MD, PhD, MPH10 and Mikaela A. Sekeres, MD, MS11
714 Area-Based Socioeconomic Status and Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Outcomes: A CIBMTR Analysis

Program: Oral and Poster Abstracts
Type: Oral
Session: 902. Health Services Research—Malignant Diseases: Big Data And Outcomes Research
Hematology Disease Topics & Pathways: Pediatric, Study Population, Quality Improvement
Monday, December 3, 2018: 11:45 AM; Room 24B (San Diego Convention Center)

Kira O Bona, MD, MPH1,2, Ruta Brazauskas, PhD3,4,5, Naya He6,7, Leslie E. Lehmann, MD4, Joanne Wolfe, MD, MPH8, Jignesh Dalal, MD9, Shahrulk K. Hashmi, MD, MPH, Theresa E. Hahn, PhD2,3, Nandita Khera, MD10, William A. Wood, MD, MPH11, Christine Duncan, MD12 and Wael Saber, MD, MS13

1Department of Pediatric Hematology, Dana-Farber Cancer Institute, Boston, MA
2Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI
3CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
4Dana-Farber/Boston Children’s Cancer & Blood Disorders Center, Boston, MA
5Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA
6Rainbow Babies & Children’s Hospital, Cleveland, OH
7Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
8Department of Internal Medicine, Mayo Clinic, Rochester, MN
9Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY
10Department of Hematology/Oncology, Mayo Clinic, Phoenix, AZ
11Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC
12Dana-Farber Cancer Institute, Boston, MA

853 A Five Fold Decrease in Admissions for Uncomplicated Vaso-Occlusive Crisis and Other Benefits from Care in Infusion Clinics: Results from the Escaped Trial

Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways: Diseases, sickle cell disease, Hemoglobinopathies, Clinically relevant
Monday, December 3, 2018: 4:30 PM; Room 25B (San Diego Convention Center)

Sophie Lanzkron, MD1, Jane Little, MD2,3, Joshua J. Field, MD4, Carlton Haywood Jr., PhD, MA5, Ravi Varadhan, PhD6, Mustapha Saheed, MD7, Marc Proudford8,9, Derek Robertson, MBA, JD10, Adrienne Kincaid11, Lorri Burgess, BS12, Charles Green13, Hang Wang, PhD13, Rebecca Seufert, BS14,15, Jasmine Brooks, BA16, Allie Piehet, BS16, Brandi Griffin, BSN, RN17, Nicole Arnold18, Steven Frymark19, Chiung-Yu Huang, PhD20, Marcus Wallace, MD21, Nebras Abu Al Hamayel, MBBS, MPH22 and Jodi Segal, MD23

1Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
2Department of Hematology/Oncology, Case Western Reserve University/University Hospitals Seidman Cancer Center, Cleveland, OH
3Blood Center of Wisconsin, Medical College of Wisconsin, Milwaukee, WI
4The Johns Hopkins University, Baltimore, MD
5Oncology Biostatistics and Bioinformatics, Johns Hopkins University, Baltimore, MD
6JHU School of Education, Baltimore, MD
7Johns Hopkins Community Based Organization Partner, Baltimore
8Community Based Organization Partner, Maryland Sickle Cell Disease Association, Columbia
900 Is There an Increased Risk of ALL in Patients with First Cancers Treated with Radiotherapy and/or Chemotherapy?

Program: Oral and Poster Abstracts

Type: Oral

Session: 612. Acute Lymphoblastic Leukemia: Clinical Studies: Improving Outcomes with Cellular Therapy

Hematology Disease Topics & Pathways: Adult, ALL, Leukemia, Diseases, Non-Biological, Therapies, Elderly, chemotherapy, Pediatric, Young Adult, Study Population, Clinically relevant, Lymphoid Malignancies

Monday, December 3, 2018: 5:45 PM; Room 6A (San Diego Convention Center)

Remco J Molenaar, MD PhD1,2*, Tomas Radivojevitch3*, Aaron T. Gerds, MD, MS4, Aziz Nazha, MD5, Hetty E. Carraway, MD, MBA6,7, Anjali S. Advani, MD6, Matt Kalaycio, MD6, Navneet S. Majhail, MD, MS6, Jaroslav P. Maciejewski4, Mikkael A. Sekeres, MD, MS10 and Sudipto Mukherjee, MD, PhD, MPH11

1Academic Medical Center, Amsterdam, Netherlands
2Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
3Departments of Quantitative Health Sciences and Translational Hematology and Oncology Research, Quantitative Health Sciences, Cleveland, OH
4Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
5Cleveland Clinic, Cleveland, OH
6Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH
7Department of Hematology/Oncology, Cleveland Clinic, Cleveland, OH
8Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH
9Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
10Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
11Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

928 Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma

Program: Oral and Poster Abstracts

Type: Oral

Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Hodgkin Lymphoma: Chemotherapy and Response Adapted Approaches

Hematology Disease Topics & Pathways: Diseases, Adult, Biological, Therapies, Study Population, Lymphoid Malignancies

Monday, December 3, 2018: 5:15 PM; Room 6F (San Diego Convention Center)

Mehdi Hamadani, MD1, Graham P. Collins, MB BS DPhil2, Felipe Samaniego, MD3, Alexander I Spira, MD4, Andrew Davies, MD5, John Radford, MD, FRCP6, Paolo Caimi, MD7, Tobias Menne, MD, PhD8, Joseph Boni, PhD9, Hans Cruz, PhD10, Jay Feingold, MD, PhD11*, Shui He, PhD9*, Jens Wuerthner10* and Steven M. Horwitz, MD12

1Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
2Oxford University Hospitals, NHS Trust, Oxford, United Kingdom
3Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
4Virginia Cancer Specialists Research Institute, Fairfax, VA
5Cancer Research UK Centre, University of Southampton, Southampton, United Kingdom
6Manchester Academic Health Centre, The University of Manchester and The Christie NHS Foundation Trust, Manchester, United Kingdom
7Case Western Reserve University (CWRU) - University Hospitals Cleveland Medical Center, Cleveland, OH
929 Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach

Program: Oral and Poster Abstracts
Type: Oral
Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Hodgkin Lymphoma: Chemotherapy and Response Adapted Approaches
Hematology Disease Topics & Pathways: Adult, Diseases, Non-Biological, Therapies, Hodgkin Lymphoma, chemotherapy, Study Population, Clinically relevant, Lymphoid Malignancies
Monday, December 3, 2018: 5:30 PM; Room 6F (San Diego Convention Center)
Deborah M. Stephens1, Hongli Li, MS2*, Heiko Schoder, MD3*, David J. Straus, MD4, Craig H. Moskowitz, MD5, Michael L. Leblanc, PhD6, Lisa M. Rimsza, MD7, Nancy L. Bartlett, MD8, Andrew M. Evens, DO, MSc9, Ann S. LaCasce, MD, MSc9, Paul Barr, MD9, Michael V. Knopp10*, Eric D. Hsi, MD11, John P. Leonard, MD12, Brad S Kohl, MD13, Sonali M. Smith, MD14 and Jonathan W. Friedman, MD15
1 Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
2 SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA
3 Memorial Sloan Kettering Cancer Center, New York, NY
4 Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
5 Department of Research, Mayo Clinic - Scottsdale, Scottsdale, AZ
6 Siteman Cancer Center, Washington University School of Medicine, Saint Louis, MO
7 Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
8 Dana-Farber Cancer Institute, Partners CancerCare, Boston, MA
9 University of Rochester, Rochester, NY
10 The Ohio State University, Columbus, OH
11 Department of Laboratory Medicine, Cleveland Clinic Foundation, Cleveland, OH
12 Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY
13 Department of Medicine, Washington University School of Medicine, Saint Louis, MO
14 University of Chicago, Chicago, IL
15 Wilmot Cancer Institute, University of Rochester, Rochester, NY

971 Maintenance with 5-Azacytidine for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Program: Oral and Poster Abstracts
Type: Oral
Session: 732. Clinical Allogeneic Transplantation: Results I
Hematology Disease Topics & Pathways: Biological, AML, Diseases, Therapies, MDS, Myeloid Malignancies, transplantation
Monday, December 3, 2018: 5:30 PM; Seaport Ballroom A (Manchester Grand Hyatt San Diego)
Betul Oran, MD, MS1, Marcos de Lima, MD2, Guillermo Garcia-Manero, MD3, Peter F Thall4*, Ruitao Lin4*, Amin M. Alousi, MD5, Chitra Hosing, MD6, Partow Kebriaei, MD7, Uday Popat, MD7, Sergio Giralt, MD7, Sairah Ahmed, MD5, Elizabeth J. Shpall, MD5, Borje S Andersson, MD, PhD8, Qaiser Bashir, MBBS8, Stefan O. Ciurea9, Katy Rezvani, MD, PhD9, Glenda Woodworth, BSN, OCN, RN10* and Richard E Champlin, MD1
1 Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
2 Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH
3 Department of Leukemia, MD Anderson Cancer Center, Houston, TX
4 Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
5 Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX
6 The University of Texas MD Anderson Cancer Center, Houston, TX
7 Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

988 Monitoring the Effects of Direct Oral Anticoagulants with a Novel Point-of-Care Sensor: Results of a Pilot Clinical Study
Program: Oral and Poster Abstracts
Type: Oral
Session: 332. Antithrombotic Therapy: New Drugs and Technology
Hematology Disease Topics & Pathways: Adult, Diseases, bioengineering, Hemostasis, Bleeding and clotting, Technology and Procedures, Study Population, Clinically relevant
Monday, December 3, 2018: 7:00 PM; Room 29C (San Diego Convention Center)

**Aman Opneja, MBBS**1,2, **Debnath Maji, M.Tech**3*, **Pedram Mohseni, PhD**3*, **Michael A Suster, PhD**3* and **Evi X Stavrou, MD**4,5

1Division of Hematology Oncology, Case Western Reserve University/University Hospitals Seidman Cancer Center, BALTIMORE, MD
2Division of Hematology Oncology, Louis Stokes Veterans Administration Hospital, Cleveland, OH
3Case Western Reserve University, Cleveland, OH
4Division of Hematology-Oncology, Louis Stokes Veterans Administration Hospital, Cleveland, OH
5Case Western Reserve University, Cleveland, OH

**1015 T-Replete Haploidentical Cell Transplantation Using Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes**

Program: Oral and Poster Abstracts
Type: Oral
Session: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Conditioning Intensity and Novel Approaches with Targeted therapy
Hematology Disease Topics & Pathways: Diseases, Leukemia, ALL, AML, Biological, Adult, Therapies, MDS, Study Population, Lymphoid Malignancies, Myeloid Malignancies, transplantation
Monday, December 3, 2018: 6:15 PM; Seaport Ballroom A (Manchester Grand Hyatt San Diego)

**Scott R Solomon, MD**1, **Andrew St. Martin, MS**2*, **Nirav N Shah, MD**2, **Giancarlo Fatobene, MD**4*, **Monzr Al Malki, MD**1, **Karen K. Ballen, MD**10*, **Asad Bashey, MD, PhD**4, **Nelli Bejanyan, MD**8, **Javier Bolaños-Meade, MD**9, **Claudio G Brunstein, MD, PhD**10, **Zachariah Defilipp, MD**11, **Richard E Champlin, MD**12, **Ephraim J. Fuchs, MD, MBA**9, **Mehdi Hamadani, MD**13, **Peiman Hematti, MD**14, **Christopher G. Kanakry, MD**15*, **Joseph P. McGuirk, DO**16, **Ian K. McNiece, PhD**17*, **Stefan O. Ciurea**18, **Marcelo C. Pasquini, MD**19, **Vanderson Rocha, MD, PhD**20, **Rizwan Romee, MD**21, **Sagar S. Patel, MD**22, **Sumithira Vasu, MD, MBBS**23, **Edmund K. Waller, MD**24, **John R. Wingard, MD**25, **Mei-Jie Zhang, PhD**26* and **Mary Eapen, MBBS, MS**2

1Blood and Marrow Transplant Program, BMT Group of Georgia, Atlanta, GA
2Medical College of Wisconsin, Milwaukee, WI
3Department of Medicine, Medical College of Wisconsin, Brookfield, WI
4Médico do Centro de Oncologia do Hospital Sirio-Libanês, Sao Paulo, Brazil
5Department of Hematology/HCT, City of Hope, Duarte, CA
6Division of hematology/oncology, University of Virginia Health System, Charlottesville, VA
7Blood and Marrow Transplant Group of Georgia, BMT Group of Georgia, Atlanta, GA
8H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
9Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
10Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN
11Department of Hematology and Medical Oncology, Winship Cancer Institute, Massachusetts General Hospital, Boston, MA
12The University of Texas MD Anderson Cancer Center, Houston, TX
13Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
14Division of Hematology/Oncology/Bone Marrow Transplantation, Department of Medicine, University of Wisconsin Hospital and Clinics, Madison, WI
15Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
16Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS
17CellMED Consulting, Miami, FL
18Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
19CIBMTR and Medical College of Wisconsin, Milwaukee, WI
20Department of Hematology, Clinics Hospital, University of São Paulo Medical School, São Paulo, Brazil
21Department of Medicine, Division of Oncology, Dana Farber Cancer Institute, Boston, MA
22Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
23Hematology, The Ohio State University, Columbus, OH
24Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA
25University of Florida Department of Medicine/Division of Hematology Oncology, Gainesville, FL
26CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
**1017 Targeted Conditioning of Iomab-B (131I-anti-CD45) Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Relapsed or Refractory Acute Myeloid Leukemia (AML): Preliminary Feasibility and Safety Results from the Prospective, Randomized Phase 3 Sierra Trial**

Program: Oral and Poster Abstracts  
Type: Oral  
Session: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Conditioning Intensity and Novel Approaches with Targeted therapy  
Hematology Disease Topics & Pathways: Diseases, AML, Biological, antibodies, Adult, Therapies, bone marrow, Elderly, Biological Processes, Technology and Procedures, immunotherapy, Study Population, Clinically relevant, Myeloid Malignancies, transplantation, stem cells  
Monday, December 3, 2018: 6:45 PM; Seaport Ballroom A (Manchester Grand Hyatt San Diego)

*Edward Aqura, MD*, **1**  
*Boglarka Gyurkocza, MD*, **2**  
*Rajneesh Nath, MD*, **3**  
*Mark R. Litzow, MD*, **4**  
*Benjamin K. Tomlinson, MD*, **5**  
*Sunil Abhyankar, MD*, **6**  
*Stuart Seropian, MD*, **7**  
*Patrick J. Stiff, MD*, **8**  
*Hannah K. Choe, MD*, **9**  
*Partow Kebriaei, MD*, **10**  
*Edward Agura, MD* **1**  
*Stuart Seropian, MD* **7**  
*Nathan Arora, MD* **11**  
*George Chen, MD* **12**  
*Moshe Yair Levy, MD* **13**  
*Hillard M Lazarus, MD* **14**  
*Sergio Giralt, MD* **2**  
*Mark S. Berger, MD* **14**  
*Vijay Reddy, MD, PhD* **14**  
*John M. Pagel, MD, PhD* **15**  

*1* Baylor University Medical Center at Dallas, Dallas, TX  
*2* Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY  
*3* Banner MD Anderson Cancer Center, Gilbert, AZ  
*4* Division of Hematology, Mayo Clinic, Rochester, MN  
*5* University Hospitals Seidman Cancer Center, Cleveland, OH  
*6* Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS  
*7* Yale University School of Medicine, New Haven, CT  
*8* Loyola Univ. Med. Ctr., Maywood, IL  
*9* The Ohio State University Comprehensive Cancer Center, Columbus  
*10* Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX  
*11* Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic Florida, Jacksonville, FL  
*12* Medicine, Roswell Park Cancer Institute, Buffalo, NY  
*13* Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH  
*14* Actinium Pharmaceuticals, New York, NY  
*15* Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA

---

**POSTER PRESENTATIONS**

**1038 Prognostic Value of Clone Size in Paroxysmal Nocturnal Hemoglobinuria (PNH) for Thrombotic Events in Untreated Patients in the International PNH Registry**

Program: Oral and Poster Abstracts  
Hematology Disease Topics & Pathways: Diseases, Anemias, Bleeding and clotting, Thrombosis, PNH  
Saturday, December 1, 2018, 6:15 PM-8:15 PM  
Hall GH (San Diego Convention Center)

*Regis Peffault De Latour* **1,2** *, Jaroslaw P. Maciejewski* **3** *, Austin G. Kulasekararaj, MBBS, MD, MRCP, FRCPATH* **4** *, Loree Larratt, MD, FRCP(C)* **5** *, Ronald S. Go, MD, MD* **6** *, David Dingli, MD, PhD* **6** *, Amanda Wilson, PhD* **7** *, Philippe Gustovic, MD* **8** *and Aleksandr Kulagin* **9** *

*1* Université Paris Diderot, Paris, France  
*2* French Reference Center for Aplastic Anemia and PNH Hematology-Bone Marrow Transplantation, Research Institute for Microbial Diseases, Hôpital Saint-Louis AP-HP, Paris, France  
*3* Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH  
*4* Department of Haematological Medicine, King’s College Hospital, NIHR/Wellcome King’s Clinical Research Facility, London, United Kingdom  
*5* Department of Medicine, University of Alberta, Edmonton, AB, Canada  
*6* Division of Hematology, Mayo Clinic, Rochester, MN  
*7* Alexion Pharmaceuticals, Inc., Lexington, MA  
*8* Alexion Pharma GmbH, Zürich, Switzerland  
*9* Pavlov First Saint Petersburg State Medical University, St. Petersburg, Russian Federation
1054 The LSD1 Inhibitor RN-1 Increases β-Globin Expression in Baboons By Targeting an Early Event Responsible for β-Globin Repression

Program: Oral and Poster Abstracts
Session: 112. Thalassemia and Globin Gene Regulation: Poster I

Hematology Disease Topics & Pathways:
Anemias, Diseases, Non-Biological, Therapies, Biological Processes, epigenetics, erythropoiesis, pharmacology

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)
Kestis Vaitkus1*, Vinzon Ibanez, B.S.2*, Maria Armila Ruiz, B.S.1*, Ramasamy Jagadeeswaran, PhD.2*, Yogenthiran Saunthararajah, MD3, James Douglas Engel, PhD4, Joseph DeSimone, PhD1*, Angela Rivers, MD2 and Donald Lavelle, PhD1

1Department of Medicine, University of Illinois at Chicago, Jesse Brown VA Medical Center, Chicago, IL
2Department of Pediatrics, University of Illinois at Chicago, Jesse Brown VA Medical Center, Chicago, IL
3Department of Translational Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic Case Western Reserve Univ., Cleveland, OH
4Department of Cell and Developmental Biology, University of Michigan, Ann Arbor, MI

1095 Clinical Testing of Hemechip in Nigeria for Point-of-Care Screening of Sickle Cell Disease

Program: Oral and Poster Abstracts
Session: 114. Hemoglobinopathies, Excluding Thalassemia—Clinical: Poster I

Hematology Disease Topics & Pathways:
Adult, Diseases, sickle cell disease, Pediatric, Technology and Procedures, Hemoglobinopathies, Young Adult, Study Population, Clinically relevant, newborn screening

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)
Muhammad Noman Hasan, MS1*, Arwa Fraiwan, PhD1*, Priyaleela Thota, MD2*, Tolulope Oginni, BS3*, Grace Mfon Olanipekun4*, Fatimah Hassan-Hanga, MD5*, Jane Little, MD1,6,7, Stephen K. Obaro, MD, PhD6,8* and Umut A. Gurkan, PhD1

1Case Western Reserve University, Cleveland, OH
2Hemex Health Inc., Portland, OR
3eHealth Africa, Kano, Nigeria
4International Foundation Against Infectious Disease in Nigeria, Abuja, Nigeria
5Aminu Kano Teaching Hospital, Bayero University, Kano, Nigeria
6Division of Hematology/Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH
7Division of Hematology/Oncology, Case Western Reserve University/University Hospitals Seidman Cancer Center, Cleveland, OH
8Division of Pediatric Infectious Diseases, University of Nebraska Medical Center, Omaha, NE

1116 Human Bone Marrow Derived Mesenchymal Stromal Cells Enhance the Number and Function of Umbilical Cord Blood Peripheral Tregs during IL-2 Driven Ex Vivo Expansion

Program: Oral and Poster Abstracts
Session: 203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Poster I

Hematology Disease Topics & Pathways:
Biological, Therapies, immunotherapy

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)
Jeong-Su Do, PhD1, Alex Y. Huang, MD, PhD2*, Daniel Zwick, PhD1*, Fei Zhong, MD1*, David Askew, PhD2*, Wouter van’t Hof, PhD2*, Marcie Finney, MS3* and Mary Laughlin, MD3

1Research & Development, Cleveland Cord Blood Center, Cleveland, OH
2Case Western Reserve University, Cleveland, OH
3Cleveland Cord Blood Center, Cleveland, OH

1226 Expression of Recombinant β2GPI and Site-Directed Mutants Provides Insight into the Pathogenesis of Antiphospholipid Syndrome

Program: Oral and Poster Abstracts
Session: 331. Pathophysiology of Thrombosis: Poster I
Hematology Disease Topics & Pathways:
cellular interactions, Biological Processes, Technology and Procedures, immune mechanism, inflammation, pathogenesis, signal transduction
Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

1237 Clinical Outcomes with Direct Oral Anticoagulants Compared to Low Molecular Weight Heparins in the Treatment of Cancer-Associated Venous Thromboembolism
Program: Oral and Poster Abstracts
Session: 332. Antithrombotic Therapy: Poster I
Hematology Disease Topics & Pathways:
anticoagulant drugs, Diseases, Non-Biological, Therapies, Bleeding and clotting, Clinically relevant, Thromboembolism
Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

1242 Outcomes Associated with Therapeutic Anticoagulation in Patients with Brain Metastasis
Program: Oral and Poster Abstracts
Session: 332. Antithrombotic Therapy: Poster I
Hematology Disease Topics & Pathways:
Adult, anticoagulant drugs, Diseases, Non-Biological, Therapies, Bleeding and clotting, Thrombosis, Study Population, Clinically relevant
Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

1302 Novel Small Molecule Stimulants of Hematopoietic Stem Cells and Their Mode of Action
Program: Oral and Poster Abstracts
Session: 508. Bone Marrow Failure: Poster I
Hematology Disease Topics & Pathways:
Diseases, Anemias, aplastic anemia, Therapies, Non-Biological, Bone Marrow Failure, chemical interactions, Biological Processes, hematopoiesis
Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

1303 Selective Pharmacologic Inhibition of Paroxysmal Nocturnal Hemoglobinuria Clones
Program: Oral and Poster Abstracts
Session: 508. Bone Marrow Failure: Poster I
Hematology Disease Topics & Pathways:
Anemias, Diseases, aplastic anemia, Bone Marrow Failure, Biological Processes, Technology and Procedures, PNH, Clinically relevant, Quality Improvement, flow cytometry, pathogenesis
Saturday, December 1, 2018, 8:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Amy C Graham, BS, MS1,2, Alexey EfANov, PhD3,4, Bartlomiej P. Przychoden5, Cassandra M. Hirsch4, Vera Adema, PhD5,6, Valeria Visconte, PhD7 and Jaroslaw P. Maciejewski1
1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
2Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH
3Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
4Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

1388 Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study
Program: Oral and Poster Abstracts
Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster I
Hematology Disease Topics & Pathways:
Adult, Biological, AML, Diseases, bone marrow, Therapies, Elderly, Study Population, Clinically relevant, Myeloid Malignancies, transplantation
Saturday, December 1, 2018, 8:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Mohamed L. Sorror, MD, MS1,2, Barry E. Storer, PhD3,4*, Aaron T. Gerds, MD, MS5, Bruno C. Medeiros, MD6, Paul J Shami, MD7, John P. Galvin, MD, MS, MPH8, Kehinde U. Adekola, MBBS, MS9, Selina Luger, MD10, Maria R. Baer, MD11, David A. Rizziere, MD12, Tanya M. Wildes, MD, MSCI13, Eunice S. Wang, MD14, Stefan Faderl, MD15, Jamie L. Koprivnikar, MD15, Mikkael A. Sekeres, MD, MS5, Sudipto Mukherjee, MD, PhD, MPH6, Julie Smith, MD16*, Mitchell Garrison, MD16*, Kiarash Kojouri, MD17*, Jennifer E. Nyland, PhD14*, Rachelle R. Moore, BS14*, Sophie L. Fleuret, BS14*, Ylinne Lynch, MD14*,18*, Pamela S. Becker, MD14*,19, Mary-Elizabeth M. Percival, MD1,2, Brenda M. Sandmaier, MD1,2, Frederick R. Appelbaum, MD1,2 and Elihu H. Estey, MD1,19
1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
2Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA
3Department of Biostatistics, University of Washington School of Public Health, Seattle, WA
4Clinical Statistics Program, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
5Leukemia & Myeloid Disorders Program, Cleveland Clinic, Cleveland, OH
6Department of Medicine, Division of Hematology, Stanford University, Palo Alto, CA
7Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
8Feinberg School of Medicine, Northwestern University, Chicago, IL
9Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL
10Abramson Cancer Center at the University of Pennsylvania School of Medicine, Philadelphia, PA
11University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD
12Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC
13Division of Oncology, Washington University School of Medicine, St Louis, MO
14Leukemia Service, Roswell Park Comprehensive Cancer Center, Buffalo, NY
15John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ
16Confluence Health/Wenatchee Valley Hospital, Wenatchee, WA
17Skagit Valley Hospital Regional Cancer Care Center, Mount Vernon, WA
18Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA
19Division of Hematology, Department of Medicine, University of Washington, Seattle, WA

1389 Clinical Outcomes for Patients with Myeloid Malignancies Harboring IDH1/2mutations after Intensive Chemotherapy
Program: Oral and Poster Abstracts
Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster I
Hematology Disease Topics & Pathways:
Adult, Diseases, Non-Biological, Therapies, chemotherapy, Study Population, Clinically relevant, Myeloid Malignancies
Saturday, December 1, 2018, 8:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

ASH 2018 Annual Meeting 30
1404 Comparison of Pegfilgrastim and Filgrastim to Prevent Neutropenic Fever during Consolidation with High Dose Cytarabine for Acute Myeloid Leukemia

Program: Oral and Poster Abstracts
Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster I
Hematology Disease Topics & Pathways:
AML, Adult, Diseases, Study Population, Myeloid Malignancies
Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Evan Field1, Paolo F Caimi, MD2, Brenda Cooper, MD3, Jane Little, MD4,5, Ehsan Malek, MD6, Leland Metheny, MD3, Marcos de Lima, MD1,7, Pingfu Fu8 and Ben Tomlinson, MD3

1Case Western Reserve University School of Medicine, Cleveland, OH
2Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals of Cleveland, Cleveland, OH
3Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH
4Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH
5Division of Hematology/Oncology, Case Western Reserve University/University Hospitals Seidman Cancer Center, Cleveland, OH
6Division of Hematology/Oncology, Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH
7Cleveland Clinic, Cleveland, OH
8Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

1428 Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An Analysis from a Large International Patient Cohort

Program: Oral and Poster Abstracts
Session: 615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Poster I
Hematology Disease Topics & Pathways:
AML, Diseases, Clinically relevant, Myeloid Malignancies
Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Maximilian Stahl, MD1, Wei Wei, MD, PhD2,3, Pau Fernandez4, Etienne Lengline, MD4,5, Rory M Shallis, MD4, Judith Neukirchen, MD5, Vijaya R. Bhatt, MD5, Mikkael A. Sekeres, MD, MS6, Amir T. Fathi, MD5, Heiko Konig, MD, PhD5, Selina Lugher, MD10, Irum Khan, MBBS11, Gail J. Roboz, MD12, Thomas Cluzeau, MD, PhD13, David Martinez-Cuadron, MD17, Emmanuel Raffoux, MD14, Ulrich Germing, MD15, Jayadev Manikkam Umakanthan, MBBS5, Sudipto Mukherjee, MD, PhD, MPH16, Andrew M. Brunner, Adam M. Miller, BS, MD17, Christine M. McMahon, MD10, Ellen K. Ritchie, MD12, Rebeca Rodriguez-Veiga, MD17, Raphael Itzykson, MD, PhD4, Blanca Boluda, MD3, Florence Rabian, MD4,3, Mar Tormo, MD15,5, Evelyn Gloria Acuna Cruz, MD13, Emma Rabinovich, MD11,4, Brenda Yoo10, Nikolai A. Podoltsev, MD, PhD1, Steven D. Gore, MD1 and Amer M. Zeidan, MBBS, MHS14
1491 Clinical, Immunophenotypic and Genomic Findings of Acute Undifferentiated Leukemia and Comparison to AML with Minimal Differentiation: A Study from the Bone Marrow Pathology Group

Program: Oral and Poster Abstracts
Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I

Hematology Disease Topics & Pathways:
Biological, AML, Adult, Diseases, Elderly, Study Population, Clinically relevant, Myeloid Malignancies

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Olga K Weinberg, MD, Robert P. Hasserjian, MD, Ezra Baraban, MD, Chi Young Ok, MD, Julia T Geyer, MD, John KSS Philip, MD, Jason H. Kurzer, MD, PhD, Heesun J. Rogers, MD, PhD, Valentina Nardi, MD, Richard M. Stone, MD, Jacqueline S. Garcia, Eric D. Hsi, MD, Adam Bagg, MD, Sa A. Wang, MD, Attilio Orazi, MD and Daniel A. Arber, MD

1 Harvard Medical school, Boston Children's Hospital, Newton, MA
2 Department of Pathology, Massachusetts General Hospital, Boston, MA
3 University of Pennsylvania, Philadelphia, PA
4 Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Pearland, TX
5 Pathology, Weill Cornell, New York, NY
6 Pathology, University of Chicago, Chicago, NY
7 Stanford University Medical School, Stanford, CA
8 Department of Hematopathology, Cleveland Clinic, Cleveland
9 Dana-Farber Cancer Institute, Boston, MA
10 Harvard Medical School, Boston, MA
11 Department of Laboratory Medicine, Cleveland Clinic Foundation, Cleveland, OH
12 Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA
13 Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
14 Weill Cornell Medical College, New York, NY
15 University of Chicago, Chicago, IL

1527 Differences in Genomic Patterns between African Americans and Whites with Acute Myeloid Leukemia

Program: Oral and Poster Abstracts
Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I

Hematology Disease Topics & Pathways:
Diseases, AML, Biological Processes, Myeloid Malignancies, genomics

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Rachel Hu, MD, Aziz Nazha, MD, Xuefei Jia, MS, Brian P. Hobbs, PhD, Hetty E. Carraway, MD, MBA, Sudipto Mukherjee, MD, PhD, MPH, Aaron T. Gerds, MD, MS, Anjali S. Advani, MD, Yasunobu Nagata, Cassandra M. Hirsch, Bartlomiej P. Przychodzen, Babal K. Jha, Jaroslaw P. Maciejewski and Mikkael A. Sekeres, MD, MS

1 Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH
2 Cleveland Clinic, Cleveland, OH

ASH 2018 Annual Meeting
1591 The Role of High Molecular Weight Kininogen in Lymphoma Microvascular Density and Growth

Program: Oral and Poster Abstracts
Session: 622. Lymphoma Biology—Non-Genetic Studies: Poster I

Hematology Disease Topics & Pathways:
Diseases, Non-Hodgkin Lymphoma, Lymphoid Malignancies

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)
Huseyin Halil Erdemir, MD1, Meenal Shukla, PhD2* and Keith R. McCrae, MD2,3

1Department of Pediatric Hematology/Oncology and BMT, Cleveland Clinic Children's Hospital, Cleveland, OH
2Department of Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, OH
3Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

1648 Chronic Lymphocytic Leukemia (CLL) Transformed into Hodgkin Lymphoma (HL): Clinical Characteristics and Outcomes from a Large Multi-Center Collaboration

Program: Oral and Poster Abstracts
Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster I

Hematology Disease Topics & Pathways:
Diseases, Adult, CLL, Hodgkin Lymphoma, B-Cell Lymphoma, Study Population, Lymphoid Malignancies, Clinically relevant

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)
Deborah M. Stephens1, Ken Boucher, PhD2, Elizabeth Kander, MD3, Sameer A. Parikh, MD4, Erin Parry, MD, PhD5, Mazyar Shadman, MD, MPH6, John M. Pagel, MD, PhD7, Jennifer Cooperstider, BA8, Joanna Rhodes, MD9, Anthony R. Mato, MD MSCE10, Allison M. Winter, MD11, Brian T. Hill, MD, PhD12,13, Sameh Gaballa, MD14*, Alexey V Danilov, MD, PhD15, Tycel J. Phillips, MD16, Danielle M. Brander, MD17, Sonali M. Smith, MD18, Matthew S Davids18*, Kerry A. Rogers, MD19, Martha Glenn, MD1 and John C. Byrd, MD1,2,20

1Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT
2Department of Population Health Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
3Division of Hematology, The Ohio State University, Columbus, OH
4Mayo Clinic, Rochester, MN
5Dana-Farber Cancer Institute, Boston, MA
6Fred Hutchinson Cancer Research Center, Seattle, WA
7Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA
8University of Chicago, Chicago, IL
9Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA
10CCL Program, Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY
11Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH
12Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH
13Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
14Thomas Jefferson University, Philadelphia, PA
15Knight Cancer Institute, Oregon Health and Science University, Portland, OR
16University of Michigan Cancer Center, Dexter, MI
17Duke Cancer Institute, Duke University Health System, Durham, NC
18Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
19Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH
20Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH

1675 Automated Generation and Phenotypic Characterization of Clinical Grade CD19 CAR-T Cells

Program: Oral and Poster Abstracts
Session: 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Poster I
1677 Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The Phase 2b Sadal Study

Program: Oral and Poster Abstracts
Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster I

Hematology Disease Topics & Pathways:
Adult, Diseases, Therapies, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Study Population, Clinically relevant, Lymphoid Malignancies

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Maria Maerevoet, MD1*, Joost Vermaat, MD, PhD2, Miguel A. Canales3, René-Olivier Casasnovas, MD4*, Eric Van Den Neste5, Andre Goy, MD6*, Brian T. Hill, MD, PhD7,8, Catherine Thieblemont, MD, PhD9*, Maria De Fatima De La Cruz10*, Federica Cavallo, MD, PhD11*, George Follows, MD12*, Sylvain Choquet, MD13*, Ronit Gurion, MD14*, Reda Bouabdallah, MD15*, Ulrich Jaeger, MD16, Agnes Nagy, MD17*, John Kuruvilla, MD18, Krzysztof Warzocha, MD19*, Nagesh Kalakonda, MD20*, Paolo Caimi, MD21, Sameer Bakhshi, MD22*, Matthew Ku, MBBS, FRACP, FRCPA23*, Nada Hamad, MD24*, Hendrik Veelken, MD, PhD2, Ewa Matczak, MD25*, Xiwen Ma26*, Jean-Richard Saint-Martin27*, Jatin J. Shah, MD28*, Michael G. Kauffman, MD, PhD29, Sharon Shacham, PhD, MBA25* and Josée M Zijlstra, MD26*

1Institute Jules Bordet, Brussels, Belgium
2Department of Hematology, Leiden University Medical Center, Leiden, Netherlands
3Hospital Universitaria La Paz, Madrid, Spain
4CHU Dijon, Dijon, FRA
5Cliniques universitaires Saint-Luc, Brussels, BEL
6John Theurer Cancer Center at Hackensack-UMC, Hackensack, NJ
7Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH
8Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
9Hospital St Louis, Paris, France
10Hospital University Virgen del Rocio, Seville, Spain
11University of Turin, Department of Molecular Biotechnologies and Health Sciences, Turin, Italy
12Cambridge University Teaching Hospitals NHS Foundation Trust, Cambridge, United Kingdom
13Hospital Pitie Salpetriere, Paris, France
14Rabin Medical Center, Petah Tikva, ISR
15Institut Paoli Calmettes, Department of Hematology, Marseille, France
16Department of Medicine I, Division of Hematology and Hemostaseology, and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
17University of Pécs, Pécs, Hungary
18Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
19Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
20Department of Haematology, Royal Liverpool University Hospital, Liverpool, United Kingdom
21Case Western Reserve University (CWRU) - University Hospitals Cleveland Medical Center, Cleveland, OH
22Dr. B. R. A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
23Department of Haematology, St. Vincent’s Hospital, Melbourne, Australia
24St. Vincent’s Hospital, Sydney, Australia
25Karyopharm Therapeutics, Newton, MA
26Department of Hematology, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands

1692 Phase I Trial of Carfilzomib + R-CHOP (CarR-CHOP) for Frontline Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
Program: Oral and Poster Abstracts
Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster I
Hematology Disease Topics & Pathways:
Diseases, Therapies, Non-Biological, chemotherapy, Biological Processes, B-Cell Lymphoma, Lymphoid Malignancies, Clinically relevant, signal transduction
Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

1737 Cardiovascular Mortality Among CML Patients in the Pre-TKI and TKI Eras: A SEER Analysis 1992-2004
Program: Oral and Poster Abstracts
Session: 632. Chronic Myeloid Leukemia: Therapy: Poster I
Hematology Disease Topics & Pathways:
Biological, Adult, Diseases, Therapies, CML, Study Population, Clinically relevant, Myeloid Malignancies, TKI
Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

1797 Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q)
Myelodysplastic Syndromes
Program: Oral and Poster Abstracts
Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster I
Hematology Disease Topics & Pathways:
Diseases, MDS, Technology and Procedures, Clinically relevant, Myeloid Malignancies, molecular testing, NGS
Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)
**1801 Pan-Myeloid Leukemia Analysis: Machine Learning-Based Approach to Predict Phenotype and Clinical Outcomes Using Mutation Data**

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster I

Hematology Disease Topics & Pathways:

Diseases, AML, CMML, MDS, Biological Processes, MPN, Technology and Procedures, Myeloid Malignancies, genomics, NGS

Saturday, December 1, 2018, 6:15 PM; Hall GH (San Diego Convention Center)

Kiyomi Morita, MD, PhD1,2, Feng Wang, PhD3*, Hideki Makishima, MD, PhD4, Yuqing Yan, PhD5*, Tetsuichi Yoshizato, MD, PhD6, Kenichi Yoshida, MD, PhD6*, Bartlomiej P. Przychodzen7*, Keyur Patel, MD, PhD8*, Carlos E. Bueso-Ramos, MD, PhD9, Curtis Gumbs9, Latasha Little9*, Samantha Tippen9*, Jianhua Zhang, PhD9, Xingzhi Song, PhD9, Tapan M. Kadia, MD9, Naval G. Daver, MD10, Naveen Pemmaraju, MD10, Courtney D. DiNardo, MD, MSc11, Farhad Ravandi, MBBS11, Srdan Verstovsek, MD, PhD10, Elias J. Jabbour, MD10, Jorge E. Cortes, MD11, Hagop M. Kantarjian, MD9, Guillermo Garcia-Manero, MD1, Jaroslaw P. Maciejewski12, Seishi Ogawa, MD, PhD13, P Andrew Futreal, PhD13 and Koichi Takahashi, MD13,14

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Hematology and Oncology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan
3Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
4Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan
5Department of Neurosurgery, The University of Texas Health Science Center at Houston, Houston, TX
6Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
7Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
8Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
9Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX
10Department of Pathology and Tumor Biology, Kyoto University, Sakyoku, Japan
11Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
12Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
13Department of Pathology and Tumor Biology, SA Pathology, Adelaide, Australia
14Department of Conventional Hematology, Central Adelaide Local Health Network, Adelaide, Australia
15Department of Haematology, Central Adelaide Local Health Network, Adelaide, Australia
16MD, FRACP, FRCPath, PhD1,17,18,19
1School of Medicine, University of Adelaide, Adelaide, Australia
2Royal Adelaide Hospital, Adelaide, SA, Australia
3Department of Genetics and Molecular Pathology, SA Pathology, Adelaide, Australia
4Centre for Cancer Biology, University of South Australia, Adelaide, Australia
5Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
6Department of Haematology, Central Adelaide Local Health Network, Adelaide, Australia
7Central Adelaide Local Health Network, Adelaide, AUS
8ACRF Cancer Genomics Facility, SA Pathology, Adelaide, Australia
9School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia

**1802 Genetic Predisposition to Therapy-Related Myeloid Neoplasm By Rare, Deleterious Germline Variants in DNA Repair Pathway and Myeloid Driver Genes**

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster I

Hematology Disease Topics & Pathways:

Adult, AML, Diseases, Biological Processes, Technology and Procedures, Myeloid Malignancies, genomics, NGS

Saturday, December 1, 2018, 6:15 PM; Hall GH (San Diego Convention Center)

Deepak Singhal, MBBS, MD, FRACP, FRCPA1,2, Christopher N. Hahn, PhD3,4,5, Cassandra M. Hirsch5*, Amilia Wee, BSc (Hons)6*, Monika M Kutyna, MSc*, Milena Babic, BMPharBio (Hons)7*, Rakshita Chhetri, MBBS8, Smita Hiwase, PhD7**, Wendy Parker, PhD1,8,9, Jinghua Feng, PhD10*, Andreas Schreiber, PhD8,10*, Joel Goehgehan, MSc8*, Peer Arts, PhD9*, Nimit Singhal, MBBS MD DM FRACP11,12,13, Karin Kassahn, PhD, FFSc (RCPA)12,13*, Susan Branford, PhD12,14, Anna L. Brown, PhD, BSc15,16, Ian D Lewis, MBBS, PhD16, Richard D’Andrea, PhD16, Hamish S. Scott, PhD17,18, Jaroslaw P. Maciejewski12 and Devendra K Hiwase, MBBS, MD, FRACP, FRCPath, PhD11,18,19

1School of Medicine, University of Adelaide, Adelaide, Australia
2Royal Adelaide Hospital, Adelaide, SA, Australia
3Department of Genetics and Molecular Pathology, SA Pathology, Adelaide, Australia
4Centre for Cancer Biology, University of South Australia, Adelaide, Australia
5Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
6Department of Haematology, Central Adelaide Local Health Network, Adelaide, Australia
7Central Adelaide Local Health Network, Adelaide, AUS
8ACRF Cancer Genomics Facility, SA Pathology, Adelaide, Australia
9School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia
1805 Biallelic TET2 Inactivation in Myeloid Neoplasia: From Clonal Hierarchy to Clinical Phenotypes

Program: Oral and Poster Abstracts
Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster I
Hematology Disease Topics & Pathways:
Diseases, Biological Processes, genomics, Myeloid Malignancies
Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Hassan Awada, MD1, Yasunobu Nagata1,2*, Abhinav Goyal1,2*, Mohammad Fahad B. Asad1, Bhumika J. Patel1,2, Cassandra M. Hirsch1,2, Teodora Kuzmanovic1,2, Vera Adema, PhD1,2, Mai Aly1,2, Bartlomiej P. Przychodzen1,2, Yihong Guan1,2, Wenyi Shen, MD 3, Louis Williams, MD, MBA1, Aziz Nazha, MD2,
Mohamed Abazeed1,2*, Mikkael A. Sekeres, MD, MS3, Tomas Radivoyevitch4*, Torsten Haferlach, MD5,
Babal K. Jha1,2, Valeria Visconte, PhD1 and Jaroslaw P. Maciejewski1,2

1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
3The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
4Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
5M.1. Municher Krankenhaus Labor GmbH, Munchen, Germany

1813 Geno-Clinical Model to Aid in the Diagnosis of Myelodysplastic Syndrome (MDS) Versus Chronic Myelomonocytic Leukemia (CMML)

Program: Oral and Poster Abstracts
Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster I
Hematology Disease Topics & Pathways:
Diseases, CMML, Biological Processes, MDS, Technology and Procedures, Clinically relevant, genetic profiling, genomics, Myeloid Malignancies
Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

C. Beau Hilton, BA1,2, Mikkael A. Sekeres, MD, MS3, Manjo Meggendorfer, PhD1, Wencce Walter, PhD3, Stephan Hutter, PhD3, Eric Padron, MD4, Michael R. Savona, MD5, Aaron T. Gerds, MD, MS6, Yihong Guan7*, David A Sallman, MD8, Sudipto Mukherjee, MD, PhD, MPh9, Mrinal M. Patnaik, MD, MBBS9, Brianna Smith, MD10, Yasunobu Nagata7, Vera Adema, PhD11, Metis Hasipek, PhD7, Cassandra M. Hirsch7, Bartlomiej P. Przychodzen1,2, Rami S. Komrokji, MD12, Babal K. Jha1,2, Claudia Haferlach, MD3, Jaroslaw P. Maciejewski1, Torsten Haferlach, MD3 and Aziz Nazha, MD2

1Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
2Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
3M.1. Municher Krankenhaus Labor GmbH, Munich, Germany
4H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
5Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
6Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
7Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
8Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL
9Division of Hematology, Mayo Clinic Rochester, MN
10Vanderbilt University Medical Center, Nashville, TN
11Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
12Department of Malignant Hematology, H Lee Moffitt Cancer Center, Tampa, FL

1824 Genotype-Resultant Morphology of Myelodysplastic Syndromes (MDS)
Program: Oral and Poster Abstracts
Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster I
Hematology Disease Topics & Pathways:
Diseases, MDS, Clinically relevant, Myeloid Malignancies
Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)
Abhinav Goyal1*, Inom Mirzaev1*, Mohammad Fahad B. Asad1, Hassan Awada, MD1, Cassandra M. Hirschi2*, Hideki Makishima, MD, PhD2, Kenichi Yoshida, MD, PhD2*, Bartlomiej P. Przychodzen3*, Aziz Nazha, MD3, Sudipto Mukherjee, MD, PhD, MPH1, Mikkael A. Sekeres, MD, MS4, Seishi Ogawa, MD, PhD4, Tomas Radivojevitch, PhD5*, Jacob Scott, MD1*, Jaroslav P. Maciejewski6 and Yasunobu Nagata5*
1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
3Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
4Department of Pathology and Tumor Biology, Kyoto University, Graduate School of Medicine, Kyoto, Japan
5Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

1825 Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a Large Web-Based Survey
Program: Oral and Poster Abstracts
Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster I
Hematology Disease Topics & Pathways:
Diseases, MDS, Clinically relevant, Myeloid Malignancies
Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)
Alexander B Pine, MD, PhD1. Nora B Chokr, MD2*, Maximilian Stahl, MD3, David P. Steensma, MD4, Mikkael A. Sekeres, MD, MS5, Mark R. Litzow, MD6, Selina Luger, MD7, Richard M. Stone, MD8, Peter L Greenberg, M.D.9, Rafael Bejar, MD, PhD9, Steven D. Gore, MD10 and Amer M. Zeidan, MBBS, MHS1
1Department of Medicine, Section of Hematology, Yale School of Medicine, Branford, CT
2Department of Medicine, Yale School of Medicine/Waterbury Hospital, Waterbury, CT
3Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT
4Dana-Farber Cancer Institute, Boston, MA
5Leukemia & Myeloid Disorders Program, Cleveland Clinic, Cleveland, OH
6Division of Hematology, Mayo Clinic, Rochester, MN
7Division of Hematology-Oncology/Department of Medicine, University of Pennsylvania, Philadelphia, PA
8Stanford University Cancer Center, Stanford, CA
9Moore's Cancer Center, University of California, San Diego, La Jolla, CA
10Yale Cancer Center, Yale University School of Medicine, New Haven, CT

1875 A Phase II Study of Curcumin and Vitamin D in Previously Untreated Patients with Early Stage Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Program: Oral and Poster Abstracts
Session: 642. CLL: Therapy, excluding Transplantation: Poster I
Hematology Disease Topics & Pathways:
Diseases, Leukemia, Adult, CLL, Therapies, Non-Biological, chemical interactions, Elderly, Biological Processes, cellular interactions, Technology and Procedures, Study Population, Lymphoid Malignancies, Clinically relevant, pharmacology, flow cytometry, inflammation
Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)
Basem M. Williams, MRCP, MD1, Kaylee Brillhart2*, Manuel A. Fable, MD3, Kristen Bakalarz, CNP4*, Brenda Cooper, MD5, Hillard M Lazarus, MD6, Stanton L. Gerson, MD7, Richard Creger, PharmD8*, Kalyanam Nagabhushanam, PhD9*, James Grote, MD10*, Pingfu Fu11*, Sandeep Kunati, PhD12*, Shuming Yang, PhD11*, Yan Xu, PhD11*1, Philip Woost, PhD13*, James Jacobberger, PhD13*, Marcos de Lima, MD5 and Paolo Caimi, MD14*
1Division of Hematology, The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH
2University Hospitals Cleveland Medical Center, Cleveland, OH
1899 Impact of Clinical Versus Biochemical Progression on Post-Progression Survival in Multiple Myeloma

Program: Oral and Poster Abstracts
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster I
Hematology Disease Topics & Pathways:
Diseases, multiple myeloma, Adult, Plasma Cell Disorders, Lymphoid Malignancies, Clinically relevant
Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Rajeshkhar Chakraborty, MBBS1, Hien D. Liu, MD2*, Lisa Rybicki, MS3*, Robert M. Dean, MD4, Beth M. Faiman, PhD, CNP5, Matt Kalaycio, MD6, Jack Khouri, MD6, Christy J. Samaras, DO6, Navneet S. Majhail, MD, MS6 and Jason Valent, MD7
1Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2Motfitt Cancer Center, Tampa, FL
3Cleveland Clinic Foundation, Cleveland, OH
4Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH
5Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
6Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH
7Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Eastlake, OH

1918 Vactosertib, a TGF-ß Receptor I Kinase/ALK5 Inhibitor, Diminishes Tumor Progression and Bone Disease in a Mouse Model of Multiple Myeloma and Overcomes Resistance to Proteasome Inhibitors

Program: Oral and Poster Abstracts
Session: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster I
Hematology Disease Topics & Pathways:
Diseases, multiple myeloma, Biological, Therapies, Plasma Cell Disorders, immunotherapy, Lymphoid Malignancies
Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Byung-Gyu Kim, PhD, DVM1,2*, Sung Hee Choi, PhD1,2*, George Luo1,2*, Olga Sergeeva, PhD3*, Zhenghong Lee, PhD3*, James Driscoll, MD, PhD4, Marcos de Lima, MD5,6, Rose Beck, MD, PhD7*, Seong-Jin Kim, PhD8,9*, John Letterio, MD1,2* and Ehsan Malek, MD6,10
1Department of Pediatrics, Case Western Reserve University, Cleveland, OH
2Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH
3Division of Hematology & Oncology, University of Cincinnati, Cincinnati, OH
4Hematologic Malignancies Program, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH
5Division of Hematology and Oncology, Case Western Reserve University, Cleveland, OH
6Department of Hematopathology, University Hospitals Cleveland Medical Center, Cleveland, OH
7Precision Medicine Research Center, Advanced Institute of Convergence Technology, Seoul National University, Suwon, Korea, Republic of (South)
8MedPacto Inc., Suwon, Korea, Republic of (South)
9Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH
10Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH

1948 Efficacy and Toxicity Profile of Ibrutinib Based Regimens for Refractory Multiple Myeloma: A Systematic Review

Program: Oral and Poster Abstracts
Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I
Hematology Disease Topics & Pathways:
Diseases, multiple myeloma, Non-Biological, Therapies, chemotherapy, Plasma Cell Disorders, Lymphoid Malignancies
Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)
Faiza Jamil, MD1*, Madeeha Shafqat1*, Ali Younas Khan, MD1*, Seren Durer, MD1*, Ceren Durer, MD1*, Zunairah Shah, MBBS1*, Anum Qureshi1*, Muhammad Abu Zar, MD1*, Ahmad Kamal, MD1*, Malik Qistas Ahmad, MD, MBBS1*, Chaudhry Saad Sohail, MD1*, Insija Ilyas Selene, MBBS1*, Mustafa Nadeem Malik, MD1*, Abdul Rafae, MD1* and Faiz Anwer, MD1,2
1Department of Medicine, Division of Hematology and Oncology, University of Arizona, Tucson, AZ
2Department of Hematology, Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

1949 Promising Clinical Efficacy and Toxicity Profile of Isatuximab Based Regimens for Treatment of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: A Systematic Review
Program: Oral and Poster Abstracts
Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I
Hematology Disease Topics & Pathways:
Biological, multiple myeloma, Diseases, antibodies, Therapies, Plasma Cell Disorders, Lymphoid Malignancies
Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)
Zunairah Shah, MBBS1*, Madeeha Shafqat1*, Faiza Jamil, MD1*, Mustafa Nadeem Malik, MD1*, Abdul Rafae, MD1*, Shehroz Aslam, MD1*, Anum Qureshi1*, Maryam Sadiq, MBBS1*, Muhammad Abu Zar, MD1*, Ahmad Kamal, MD1*, Insija Ilyas Selene, MBBS1*, Sharoorn Samuel, MBBS1*, Rida Riaz, MBBS1*, Midhat Lakhani, MD1* and Faiz Anwer, MD1,2,3
1Department of Medicine, Division of Hematology and Oncology, University of Arizona, Tucson, AZ
2University of Arizona, Tucson, AZ
3Department of Hematology, Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

1950 Clinical Efficacy of Intracellular Molecular Inhibitors for Relapsed, Refractory Multiple Myeloma: A Systematic Review of Early Clinical Data
Program: Oral and Poster Abstracts
Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I
Hematology Disease Topics & Pathways:
Diseases, multiple myeloma, apoptosis, Therapies, Biological Processes, Plasma Cell Disorders, Lymphoid Malignancies
Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)
Shehroz Aslam, MD1*, Mustafa Nadeem Malik, MD1*, Abdul Rafae, MD1*, Rida Riaz, MBBS1*, Muhammad Jahanzeb Khalil, MD1*, Faisal Mahfouz, MD2*, Madeeha Shafqat1*, Anum Qureshi1*, Insija Ilyas Selene, MBBS1*, Syed Shabee Hassan, MD1*, Muhammad Junaid Tariq, MD1*, Muhammad Yasir, MD1*, Sharoorn Samuel, MBBS1*, Maryam Sadiq, MBBS1* and Faiz Anwer, MD1,2,3
1Department of Medicine, Division of Hematology and Oncology, University of Arizona, Tucson, AZ
2Nawaz Sharif Medical College, University of Gujrat, Gujrat, Pakistan
3Department of Hematology, Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

1951 Presentation Patterns and Management Strategies for Central Nervous System Involvement in Multiple Myeloma: A Systematic Review of Literature
Program: Oral and Poster Abstracts
Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I
Hematology Disease Topics & Pathways:
Biological, multiple myeloma, Diseases, Non-Biological, Therapies, chemotherapy, Plasma Cell Disorders, immunotherapy, Lymphoid Malignancies, stem cells
Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)
1952 Evidence Based Recommendations for Supportive Care in Multiple Myeloma

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways:
- Diseases, multiple myeloma
- Therapies, Non-Biological, Plasma Cell Disorders, Lymphoid Malignancies

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Anum Qureshi, MD1*, Muhammad Junaid Tariq, MD1*, Zunairah Shah, MBBS1*, Muhammad Abu Zar, MD1*, Shehroz Aslam, MD1*, Abdul Rafae, MD1*, Mustafa Nadeem Malik, MD1*, Ahmad Kamal, MD1*, Jemin Aby Jose, MD1*, Insija Ilyas Selene, MBBS1*, Madeeha Shafqat, MD1*, Faiza Jamil, MD1*, Seren Durer, MD1*, Ceren Durer, MD1* and Faiz Anwer, MD1,2

1Department of Medicine, Division of Hematology and Oncology, University of Arizona, Tucson, AZ
2Department of Hematology, Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

1962 Preclinical Studies and a Phase I Trial of the TGF-β Receptor Inhibitor, Vactosertib (TEW-7197), in Combination with Pomalidomide in Patients with Multiple Myeloma Refractory to Bortezomib or Lenalidomide

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways:
- multiple myeloma, Diseases, Biological Processes, Plasma Cell Disorders, Lymphoid Malignancies, Clinically relevant, immune mechanism

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Ehsan Malek, MD1, Byung-Gyu Kim, PhD, DVM2*, Jason Valent, MD1, James Driscoll, MD, PhD4, Paolo Caimi, MD5, Seong-Jin Kim, PhD6,7*, Marcos de Lima, MD5 and John Letterio, MD9*

1Division of Hematology and Oncology, Case Western Reserve University, Cleveland, OH
2Department of Pediatrics, Case Western Reserve University, Solon, OH
3Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
4Division of Hematology & Oncology, University of Cincinnati, Cincinnati, OH
5University Hospitals of Cleveland, Cleveland, OH
6MedPacto Inc., Suwon, Korea, Republic of (South)
7Precision Medicine Research Center, Advanced Institute of Convergence Technology, Seoul National University, Suwon, Korea, Republic of (South)
8Hematologic Malignancies Program, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH
9Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

1992 Longer Term Follow up of the A Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT)

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways:
- Diseases, multiple myeloma, Biological, Adult, Therapies, Elderly, enzyme inhibitors, Plasma Cell Disorders, immunotherapy, Study Population, Lymphoid Malignancies, Clinically relevant, Quality Improvement
2009 Rapid Hematologic and Organ Responses with Daratumumab, Bortezomib and Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis
Program: Oral and Poster Abstracts
Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I
Hematology Disease Topics & Pathways:
- Diseases, Biological, Adult, antibodies, multiple myeloma, Therapies, chemotherapy, Study Population, Plasma Cell Disorders, Clinically relevant, Lymphoid Malignancies

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)
Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

2012 Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab
Program: Oral and Poster Abstracts
Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I
Hematology Disease Topics & Pathways:
- multiple myeloma, Adult, Diseases, Technology and Procedures, Study Population, Plasma Cell Disorders, Lymphoid Malignancies, flow cytometry

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)
William E. Pierceall, Nizar Bahlis, MD,  David S Siegel, MD, PhD, Gary J. Schiller, MD, Christy J. Samaras, DO, Michael Sebag, MD, PhD, Jesus G. Berdeja, MD, Siddhartha Ganguly, MD8, Jeffrey V Matous, MD, Kevin Song, MD, Christopher S. Seet, MD10, Giampaolo Talamo12*, Shanti Srinivas13,14*, Mirelis Acosta-Rivero15*, Michael Bar15*, Donald P. Quick, MD, Bertrand Anz18*, Gustavo Fonseca19*, Donna Reece20*, Weiyuan Chang1*, Natalya Serbina1*, Faiza Zafar, MPAS1*, Amit Agarwal, MD, PhD1 and Anjan Thakurta, PhD1*
1Celgene Corporation, Summit, NJ
2University of Calgary, Calgary, AB, Canada
3John Theurer Cancer Center, Myeloma and Lymphoma Divisions, Hackensack University Medical Center, Hackensack, NJ
4UCLA School of Medicine, Los Angeles, CA
5Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
6McGill University Health Centre, Montreal, QC, Canada
7Sarah Cannon Research Institute, Nashville, TN
8University of Kansas Medical Center, Westwood, KS
9Colorado Blood Cancer Institute, Denver, CO
10The Vancouver General Hospital, Vancouver, BC, CAN
11David Geffen School of Medicine at UCLA, Los Angeles, CA
12Penn State Hershey Cancer Institute, Hershey, PA
2022 Pomalidomide Based Regimens for Treatment of Relapsed Multiple Myeloma: A Systematic Review and Meta-Analysis of Clinical Trials

Program: Oral and Poster Abstracts
Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I
Hematology Disease Topics & Pathways:
multiple myeloma, Diseases, Therapies, Non-Biological, chemotherapy, Plasma Cell Disorders, Lymphoid Malignancies

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Adeela Mushtaq, MD1*, Ahmad Iftikhar, MD2*, Midhat Lakhani, MD3*, Fnu Sagar, MD3*, Ahmad Kamal, MD3*, Umar Zahid, MD, MPH13, Hamza Hassan, MD6*, Zeeshan Ali, MD7*, Faryal Razzaq, MBBS3*, Saad Ullah Malik, MD3*, Syeda Fatima Hassan, MBBS3*, Muhammad Abu Zar, MD3*, Mohammad Bilal Chaudhary, MD7*, Ahmad Safdar3*, Mohamed Mokhtar Bakr, MD8* and Faiz Anwer, MD3,9

1Department of Medicine, University of Pittsburgh Medical Center, McKeesport, PA
2Department of Medicine, University of Arizona, Tucson, AZ
3Department of Medicine, Division of Hematology and Oncology, University of Arizona, Tucson, AZ
4Johns Hopkins University, Baltimore, MD
5Jersey Shore Medical University, New Jersey
6Department of Medicine, Division of Hematology and Oncology, University of Arizona, Tucson, AZ
7Elmhurst Hospital Center, Queens, NY
8Jersey Shore University Medical Center, New Jersey
9Department of Hematology, Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

2025 Efficacy and Tolerability of Daratumumab in Heavily Pretreated AL Amyloidosis: A Systematic Review

Program: Oral and Poster Abstracts
Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I
Hematology Disease Topics & Pathways:
antibodies, Biological, Leukemia, Therapies, immunotherapy

Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Muhammad Aadil Rahman, MD4*, Ali Younas Khan, MD1*, Awais Ijaz, MD2*, Muhammad Junaid Tariq, MD4*, Muhammad Usman, MD4*, Muhammad Jahanzeb Khalil, MD1*, Muhammad Asad Fraz, MD3*, Faiza Jamil, MD1*, Abdul Rafae, MD1*, Mustafa Nadeem Malik, MD1*, Insija Ilyas Selene, MBBS1*, Jemin Aby Jose, MD1*, Ahmad Safdar, BS4*, Ali McBride, PharmD, MS2 and Faiz Anwer, MD1,6

1Department of Medicine, Division of Hematology and Oncology, University of Arizona, Tucson, AZ
2Department of Medicine, Division of Hematology and Oncology, University of Arizona, Tucson, AZ
3Department of Medicine, Division of Hematology and Oncology, University of Arizona, Tucson, AZ
4Department of Medicine, University of Arizona, Tucson
5Department of Medicine, Division of Hematology/Oncology, The University of Arizona Cancer Center, Tucson, AZ
6Department of Hematology, Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

2075 Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia

Program: Oral and Poster Abstracts
Hematology Disease Topics & Pathways:
AML, Adult, Diseases, Therapies, Non-Biological, Biological Processes, chemotherapy, Technology and
2123 Rapid and Robust CD4+ and CD8+ T-, NK-, B- and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation

Program: Oral and Poster Abstracts
Session: 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution:
Poster I

Hematology Disease Topics & Pathways:
AML, ALL, Leukemia, Biological, Diseases, CML, Therapies, Clinically relevant, Lymphoid Malignancies, Myeloid Malignancies, transplantation, stem cells

Saturday, December 1, 2018, 8:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Jaap Jan Boelens, MD, PhD1,2, Coco de Koning3, Mitchell E. Horwitz, MD4, Guillermo Sanz, MD, PhD5, Madan Jagasia, MD, MS6, John E. Wagner, MD7, Patrick J. Stiff, MD8, Rabi Hanna, MD9, Daniela Cillon3, MD, PhD10 and Stefan Nierkens, PhD11

1Pediatric Blood and Marrow Transplantation Program, University Medical Center Utrecht, Utrecht, Netherlands
2Princess Maxima Centre for Pediatric Oncology, Utrecht, Netherlands
3University Medical Center Utrecht, Utrecht, Netherlands
4Duke University School of Medicine, Durham, NC
5Hematology Department, Hospital Universitario La Fe, Valencia, Spain
6Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
7Division of Pediatric Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN
8Loyola Univ. Med. Ctr., Maywood, IL
9Department of Pediatric Hematology Oncology and Bone Marrow Transplant, Cleveland Clinic, Cleveland, OH
10University of Turin, Orbassano, Italy

2081 The Direction of KIR Ligand Incompatibility Is Associated with Graft Failure and May Predict the Dominant Donor Following Double Umbilical Cord Blood Transplantation

Program: Oral and Poster Abstracts

Hematology Disease Topics & Pathways:
Biological, Therapies, Biological Processes, Clinically relevant, NK cells, transplantation

Saturday, December 1, 2018, 8:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Lucy Li1, Merle Kolk2, Kirsten Marie Boughan, DO2, Paolo F Caimi, MD3, Molly M Gallogly, MD, PhD3, Jane Little, MD3, Ehsan Malek, MD4, Leland Metheny, MD5, Ben Tomlinson, MD6, Brenda Cooper, MD7, Marcos de Lima, MD2 and Folashade Otegbeye, MBBChir, MPH8

1Case Western Reserve University School of Medicine, Cleveland, OH
2Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH
3Division of Hematology/ Oncology, Case Western Reserve University/ University Hospitals Seidman Cancer Center, Cleveland, OH
2130 Impact of Maintenance Therapy on Nature of First Relapse in Multiple Myeloma Patients Underwent Autologous Stem Cell Transplant

Program: Oral and Poster Abstracts
Session: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Poster I
Hematology Disease Topics & Pathways:
Biological, Therapies, immunotherapy
Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)
Petra Martin1, Rebecca Ye, BA2, Merle Kolk3, Nicole Ferrari4, Paolo Caimi, MD5, Leland Metheny, MD6, James Driscoll, MD, PhD6, Marcos de Lima, MD7 and Ehsan Malek, MD7

1University Hospitals Cleveland Medical Center, Cleveland, OH
2New York University, New York, NY
3Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH
4University Hospitals Seidman Cancer Center, Cleveland, OH
5University Hospitals of Cleveland, Cleveland, OH
6Division of Hematology & Oncology, University of Cincinnati, Cincinnati, OH
7Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH

2170 Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG-ACRIN and CIBMTR Study

Program: Oral and Poster Abstracts
Session: 732. Clinical Allogeneic Transplantation: Results: Poster I
Hematology Disease Topics & Pathways:
Therapies, Clinically relevant
Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)
Celalettin Ustun, MD1, Jennifer Le-Rademacher, PhD2, Hai-Lin Wang, MPH3, Megan Othus4, Zhuoxin Sun, PhD5, Brittny Major6, Mei-Jie Zhang, PhD7, Elizabeth Storrick8, Jacqueline M Lafky9, Selina Chow9, Krzysztof Mrózek, MD, PhD10, Eyal C. Attar, MD11,12, Clara D. Bloomfield, MD13, Larry D Cripe, MD14*, Richard A. Larson, MD15, Guido Marcucci, MD16, Gail J. Roboz, MD17, Geoffrey L. Uy, MD18, Richard M. Stone, MD19, Aminah Jatoi20, Thomas C. Shea, MD20, Marcos de Lima, MD21, James M. Foran, MD22, Brenda M. Sandmaier, MD23,24,25, Mark R. Litzow, MD26, Harry P. Erba, MD, PhD27, Arti Hurria, MD28*, Daniel J. Weisdorf, MD29 and Andrew S. Artz, MD30,31

1Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN
2Dept of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN
3CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
4Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle
5Harvard T.H. Chan School of Public Health, Boston
6Department of Health Sciences Research, Mayo Clinic, Rochester
7Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN
8Mayo Clinic, Rochester
9University of Chicago Comprehensive Cancer Center, Chicago
10The Ohio State University Comprehensive Cancer Center, Columbus, OH
11Massachusetts General Hospital, Boston
12Agios Pharmaceuticals, Inc., Cambridge, MA
13Comprehensive Cancer Center, The Ohio State University, Columbus, OH
14Indiana University Simon Cancer Center, Indianapolis
15Department of Medicine and Comprehensive Cancer Center, University of Chicago, Chicago, IL
16Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematologic Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope Medical Center, Duarte, CA
17Weill Cornell Medicine and The Weill Medical College of Cornell University, New York, NY
18Washington University School of Medicine, Saint Louis, MO
19Dana-Farber Cancer Institute, Boston, MA
20Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
21Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH
22Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic Florida, Jacksonville, FL
2194 Gene Therapy for Thalassemia and Sickle Cell Anemia Poses Acceptable Toxicity and Efficacy: Clinical Outcomes in Forty-Seven Cases
Program: Oral and Poster Abstracts
Session: 801. Gene Therapy and Transfer: Poster I
Hematology Disease Topics & Pathways:
Biological, sickle cell disease, Diseases, Therapies, thalassemia, Hemoglobinopathies, gene therapy
Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)
Hafiz Muhammad Fazeel, MD1*, Muhammad Abu Zar, MD1*, Saad Ullah Malik, MD1*, Ahmad Kamal, MD1*, Mustafa Nadeem Malik, MD1*, Syeda Sabeeka Batool, MD2*, Ceren Durer, MD2*, Seren Durer, MD2*, Shehroz Aslam, MD2*, Madeeha Shafqat3, Faiza Ijaz, MBBS3, Faiz Anwer, MD1,3 and Shahrukh K. Hashmi, MD, MPH4
1Department of Medicine, Division of Hematology and Oncology, University of Arizona, Tucson, AZ
2Department of Internal Medicine, University of Alabama, Huntsville, AL
3Department of Hematology, Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH
4Division of Hematology, Mayo Clinic, Rochester, MN

2245 Access and Referral Barriers to Autologous and Allogeneic Hematopoietic Cell Transplantation in Adult Patients with Cancer: A Systematic Review with a Specific Focus on Geriatric Population
Program: Oral and Poster Abstracts
Session: 902. Health Services Research—Malignant Diseases: Poster I
Hematology Disease Topics & Pathways:
Adult, Elderly, Study Population, Clinically relevant
Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)
Kah Poh Loh, MBCHBAO1, Jian Liang Tan2, Colin M. McHugh, MD1*, Jane L. Liesveld, MD1, Kristen M. O’Dwyer, MD4*, Michael W. Becker, MD5, Jason H. Mendler, MD, PhD6, Omar S. Aljitawi, MD7, Heidi D. Klepin, MD3, Wendy Stock, MD4, Tanya Wildes, MD5, Andrew S. Artz, MD4,6, Areej El-Jawahri, MD7 and Navneet S. Majhail, MD, MS8
1Division of Hematology/Oncology, University of Rochester Medical Center, Rochester, NY
2Department of Medicine, Crozer-Chester Medical Center, Chester, PA
3Wake Forest University School of Medicine, Winston Salem, NC
4Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL
5Washington University, Saint Louis, MO
6Department of Medicine, Section of Hematology/Oncology, University of Chicago Hospital, Chicago, IL
7Massachusetts General Hospital, Allston, MA
8Tausigg Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

2246 Qualitative Study of Factors That Influence Treatment Decision-Making Among Community Oncologists and Older Patients with Acute Myeloid Leukemia
Program: Oral and Poster Abstracts
Session: 902. Health Services Research—Malignant Diseases: Poster I
Hematology Disease Topics & Pathways:
Elderly, Study Population, Clinically relevant
Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)
Kah Poh Loh, MBCHBAO1, Sindhuja Kadambi, MD2, Supriya G. Mohile, MD, MS1*, Jason H. Mendler, MD, PhD1, Jane L. Liesveld, MD1, Kristen M. O’Dwyer, MD1*, Michael W. Becker, MD1, Colin M. McHugh,
MD1*, Marsha Wittink, MD, MBE2*, Wendy Stock, MD3, Navneet S. Majhail, MD, MS4, Tanya Wildes, MD5, Paul Duberstein, PhD6 and Heidi D. Klepin, MD7
1Division of Hematology/Oncology, University of Rochester Medical Center, Rochester, NY
2Division of Geriatrics and Aging, University of Rochester Medical Center, Rochester, NY
3Department of Psychiatry, University of Rochester Medical Center, Rochester, NY
4Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL
5Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH
6Washington University, Saint Louis, MO
7Wake Forest University School of Medicine, Winston Salem, NC

**2259 Correlation between MPN-SAF TSS and EORTC QLQ-C30 Scores in Patients with PV: Data from the Reveal Study**

Program: Oral and Poster Abstracts
Session: 902. Health Services Research—Malignant Diseases: Poster I
Hematology Disease Topics & Pathways:
Diseases, Adult, MPN, Polycythemia vera, Study Population, Myeloid Malignancies, Quality Improvement
Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

**Ivy Altomare, MD1*, Aaron T. Gerds, MD, MS2, David Lessen, MD3, Philomena Colucci, DO, MS4*, Shreekant Parasuraman, BPharm, PhD5*, Dilan Chamikara Paranaganama, PhD4* and Ruben A. Mesa, MD, FACP6**
1Duke University Medical Center, Durham, NC
2Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
3Southeast Florida Hem-Onc Group, Fort Lauderdale, FL
4Incyte Corporation, Wilmington, DE
5University of Texas Health Science Center, San Antonio, TX

**2273 Patients with Immune Thrombocytopenia (ITP) Frequently Experience Severe Fatigue but Is It Under-Recognized By Physicians: Results from the ITP World Impact Survey (I-WiSh)**

Program: Oral and Poster Abstracts
Session: 903. Outcomes Research—Non-Malignant Hematology: Poster I
Hematology Disease Topics & Pathways:
Diseases, autoimmune disorders, Bleeding and clotting, ITP, Immune Disorders
Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

**Caroline Kruse1*, Alexandra Kruse1*, Shirley Watson2*, Mervyn Morgan2*, Nichola Cooper, MRCP3, Waleed Ghanima4, Andrew Provan5*, Donald M. Arnold, MD, MSc, FRCP6, Cristina Santoro7*, Ming Hou, MD8*, Yoshiaki Tomiyama, MD9, Serge Laborde10*, Barbara Lovrencic11*, John Waller, PhD, BSc12*, Gavin Taylor-Stokes12*, Tom Bailey12*, Miona Stankovic13* and James B. Bussel, MD14**
1Platelet Disorder Support Association, Cleveland
2ITP Support Association, Bohnhurst, United Kingdom
3Hammersmith Hospital, Imperial College London, London, United Kingdom
4Department of Medicine, Oslo University Hospital Trust, Kalnes, Norway
5Barts and The London School of Medicine and Dentistry, London, United Kingdom
6Department of Medicine, McMaster University, Hamilton, ON, Canada
7Department of Cellular Biotechnologies & Haematology, ‘Sapienza’ University of Rome, Rome, Italy
8Department of Hematology, Shandong University, Jinan, China
9Osaka University Hospital, Osaka, Japan
10O’Cyto, Saint Loubes, France
11Italian Association Immune Thrombocytopenic Purpura, Caprino Veronese, Italy
12Bespoke Team, Adelphi Real World, Macclesfield, United Kingdom
13Novartis Pharma AG, Basel, Switzerland
14Division of Hematology/Oncology, Weill Cornell Medical College, New York

**2298 Survival Outcomes of Patients with Therapy-Related Acute Myeloid Leukemia in the United States**

Program: Oral and Poster Abstracts
Session: 904. Outcomes Research—Malignant Conditions: Poster I
Hematology Disease Topics & Pathways:
Adult, AML, Diseases, Study Population, Clinically relevant, Myeloid Malignancies
Saturday, December 1, 2018, 6:15 PM-8:15 PM; Hall GH (San Diego Convention Center)

Robert A. Brodsky, MD1,2, Regis Peffault De Latour3,3, Scott T. Rottinghaus, MD4,5, Alexander Röth, MD5,6, Antonio M. Risitano, MD, PhD7, Ilene C. Weitz, MD7, 8, Peter Hillmen, MB ChB, PhD, FRCP, FRCPPath8,9,10, Jaroslaw P. Maciejewski11, Jeffrey Szer, MBBS12, Jong-Wook Lee, MD, PhD12, Austin G. Kulasekararaj, MBBS, MD, MRCP, FRCPPath12,13, Lori Volles, MD14, Andrew I. Damokosh, PhD14, Stephan Ortiz, RPh, PhD14, Lori Shafner, PhD14,15, Anita Hill, MD, PhD13 and Hubert Schrezenmeier, MD14,15
1Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
2Université Paris Diderot, Paris, France
3French Reference Center for Aplastic Anemia and PNH Hematopathy-Bone Marrow Transplantation, Research Institute for Microbial Diseases, Hôpital Saint-Louis AP-HP, Paris, France
4Alexion Pharmaceuticals, Inc., New Haven, CT
5Department of Hematology, University Hospital Essen, Essen, Germany
6Hematology, Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy
7Jane Anne Nohl Division of Hematology, Keck-USC School of Medicine, Los Angeles, CA
8Department of Haematology, St James’s University Hospital, Leeds, United Kingdom
9Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
10Clinical Haematology, Royal Melbourne Hospital, Melbourne, Australia
11Department of Haematology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South)
12Department of Haematological Medicine, King’s College Hospital, NIHR/Welcome King’s Clinical Research Facility, London, United Kingdom
13Department of Haematology, Leeds Teaching Hospitals, Leeds, United Kingdom
14Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen and University Hospital Ulm, Ulm, Germany
15Institute of Transfusion Medicine, University of Ulm, Ulm, Germany

2330 A Prospective Analysis of Breakthrough Hemolysis in 2 Phase 3 Randomized Studies of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria
Program: Oral and Poster Abstracts

Hematology Disease Topics & Pathways:
Diseases, Anemias, PNH
Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Robert A. Brodsky, MD1,2, Regis Peffault De Latour3,3, Scott T. Rottinghaus, MD4,5, Alexander Röth, MD5, Antonio M. Risitano, MD, PhD7, Ilene C. Weitz, MD7, 8, Peter Hillmen, MB ChB, PhD, FRCP, FRCPPath8, Jaroslaw P. Maciejewski11, Jeffrey Szer, MBBS12, Jong-Wook Lee, MD, PhD12, Austin G. Kulasekararaj, MBBS, MD, MRCP, FRCPPath12,13, Lori Volles, MD14, Andrew I. Damokosh, PhD14, Stephan Ortiz, RPh, PhD14, Lori Shafner, PhD14,15, Anita Hill, MD, PhD13 and Hubert Schrezenmeier, MD14,15
1Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
2Université Paris Diderot, Paris, France
3French Reference Center for Aplastic Anemia and PNH Hematopathy-Bone Marrow Transplantation, Research Institute for Microbial Diseases, Hôpital Saint-Louis AP-HP, Paris, France
4Alexion Pharmaceuticals, Inc., New Haven, CT
5Department of Hematology, University Hospital Essen, Essen, Germany
6Hematology, Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy
7Jane Anne Nohl Division of Hematology, Keck-USC School of Medicine, Los Angeles, CA
8Department of Haematology, St James’s University Hospital, Leeds, United Kingdom
9Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
10Clinical Haematology, Royal Melbourne Hospital, Melbourne, Australia
11Department of Haematology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South)
12Department of Haematological Medicine, King’s College Hospital, NIHR/Welcome King’s Clinical Research Facility, London, United Kingdom
13Department of Haematology, Leeds Teaching Hospitals, Leeds, United Kingdom
14Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen and University Hospital Ulm, Ulm, Germany
15Institute of Transfusion Medicine, University of Ulm, Ulm, Germany

2383 Mean Platelet Volume Predicts Mortality in Sickle Cell Disease
Program: Oral and Poster Abstracts
Session: 114. Hemoglobinopathies, Excluding Thalassemia—Clinical: Poster II

Hematology Disease Topics & Pathways:
Diseases, sickle cell disease, Hemoglobinopathies, Clinically relevant
Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Aravind Thavamani, MBBS, MD1,2, Regi Ramanathan, MBBS2,3 and Mammen Puliyel, MD, MBBS3,4
1Department of Pediatrics, Metrohealth Medical Center, Cleveland, OH
2Metrohealth Medical Center, Cleveland, OH
3Department of Pediatrics, Case Western Reserve University, Cleveland, OH
4Metro Health Medical Center, Cleveland, OH
2386 Red Blood Cell Adhesion in Adult Patients with Sickle Cell Disease, at Baseline and with Pain, Measured on SCD Biochip Microfluidic Assay

Program: Oral and Poster Abstracts
Session: 114. Hemoglobinopathies, Excluding Thalassemia—Clinical: Poster II
Hematology Disease Topics & Pathways:
Adult, Diseases, sickle cell disease, bioengineering, Technology and Procedures, Hemoglobinopathies, Study Population, Clinically relevant, flow cytometry, serologic tests
Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)
Alexandra Boye-Doe\(^1\) and Jane Little, MD\(^2\)
\(^1\)Case Western Reserve University School of Medicine, Cleveland
\(^2\)Division of Hematology/ Oncology, Case Western Reserve University/ University Hospitals Seidman Cancer Center, Cleveland, OH

2387 Red Blood Cell Adhesion Is Increased in the Young Adult Population with Sickle Cell Disease

Program: Oral and Poster Abstracts
Session: 114. Hemoglobinopathies, Excluding Thalassemia—Clinical: Poster II
Hematology Disease Topics & Pathways:
sickle cell disease, Diseases, Hemoglobinopathies
Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)
Erina Quinn\(^1\)^*, Charlotte Yuan, BA\(^2\), Sargam Kapoor, MD\(^3\), Karen Ireland, RN\(^4\)^*, Janine Keenan, RN\(^4\)^*, Deepa Manwani, MD\(^5\), Umut A. Gurkan, PhD\(^2\) and Jane Little, MD\(^3\)
\(^1\)Case Western Reserve University, Bradenton, FL
\(^2\)Case Western Reserve University, Cleveland, OH
\(^3\)Division of Hematology/ Oncology, Case Western Reserve University/ University Hospitals Seidman Cancer Center, Cleveland, OH
\(^4\)Division of Hematology/ Oncology, The Children's Hospital at Montefiore, Bronx, NY
\(^5\)Children's Hospital at Montefiore, Bronx, NY

2475 A Novel Point-of-Care Whole Blood Coagulation Assay to Monitor Emicizumab Therapy in Patients with Hemophilia

Program: Oral and Poster Abstracts
Session: 322. Disorders of Coagulation or Fibrinolysis: Poster II
Hematology Disease Topics & Pathways:
Diseases, Hemophilia, Bleeding and clotting, Technology and Procedures, Clinically relevant
Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)
Michael A Suster, PhD\(^1\)^*, Debnath Maji, M.Tech\(^1\)^*, Lalitha V. Nayak, MD\(^2\), Christina Jenkins, MSN-PNP, RN\(^3\)^*, Susan Hunter, BSN, RN-BC\(^3\)^*, Alvin H. Schmaier, MD\(^4\), Pedram Mohseni, PhD\(^1\)^* and Sanjay Ahuja\(^4\)
\(^1\)Case Western Reserve University, Cleveland, OH
\(^2\)University Hospitals Cleveland Medical Center, Cleveland, OH
\(^3\)University Hospitals Rainbow Babies & Children’s Hospital, Cleveland, OH
\(^4\)University Hospitals Rainbow Babies & Children’s Hospital, Cleveland, OH

2500 Real-World Data of Immune Tolerance Induction Using rFVIII Fc in Subjects With Severe Hemophilia A With Inhibitors at High Risk for ITI Failure

Program: Oral and Poster Abstracts
Session: 322. Disorders of Coagulation or Fibrinolysis: Poster II
Hematology Disease Topics & Pathways:
Adult, Biological, Diseases, Bleeding and clotting, Therapies, Pediatric, Study Population, Clinically relevant
Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)
Manuel Carcao\(^1\), Amy Shapiro\(^2\), Nina Hwang\(^3\)^*, Steven Pipe\(^4\), Sanjay Ahuja\(^5\), Kenneth Lieuw, MD, PhD\(^6\), Janice Staber\(^7\), Haowei Linda Sun\(^8\)^*, Hilda Ding\(^9\)^*, Michael Wang, MD\(^10\), Macgregor Steele\(^11\)^*, Elisa Tsao\(^12\)^*, Jing Feng\(^12\)^*, Zahra Al-Khateeb\(^13\)^*; Jennifer Dumont\(^12\) and Nisha Jain\(^12\)*
2510 **Venous Thromboembolism in Cancer Patients Receiving Immunotherapy**

Program: Oral and Poster Abstracts

**Session**: 331. Pathophysiology of Thrombosis: Poster II

**Hematology Disease Topics & Pathways:**

Diseases, Biological, Bleeding and clotting, Therapies, immunotherapy, Thromboembolism, Clinically relevant, Quality Improvement

**Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)**

*Joanna Roopkumar, MBBS, MPH*, **Ann S. Kim, BA**, **Thapa Bicky, MD**, **Brian P. Hobbs, PhD** and **Alok A. Khorana**

1. Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
2. Cleveland Clinic, Cleveland, OH
3. Department of Internal Medicine, Cleveland Clinic Fairview Hospital, Cleveland, OH
4. Cancer Biostatistics, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

**2523 Safety of Apixaban in Patients with CKD Stage V and ESRD with Venous Thromboembolism**

Program: Oral and Poster Abstracts

**Session**: 332. Antithrombotic Therapy: Poster II

**Hematology Disease Topics & Pathways:**

Therapies, Non-Biological

**Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)**

*Jahnavi Gollamudi, MD*, **Sadeer Al-Kindi, M.D.**, **Petra Martin** and **Lalitha V. Nayak, MD**

1. Department of Medicine / Division of Hematology and Oncology, University Hospitals Cleveland Medical Center, Cleveland, OH
2. Division of Cardiology, Case Western Reserve University, Cleveland
3. University Hospitals Cleveland Medical Center, Cleveland, OH

**2572 Distinct Features of Chip–Derived and De Novo MDS**

Program: Oral and Poster Abstracts

**Session**: 503. Clonal Hematopoiesis: Aging and Inflammation: Poster II

**Hematology Disease Topics & Pathways:**

Diseases, MDS, Biological Processes, Myeloid Malignancies, genomics

**Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)**

*Yasunobu Nagata*, **Hideki Makishima, MD, PhD**, **Cassandra M. Hirsch**, **Hassan Awada, MD**, **Abhinav Goyal**, **Teodora Kuzmanovic, BA**, **Bartlomiej P. Przychodzen**, **Tetsuichi Yoshizato, MD, PhD**, **Kenichi Yoshida, MD, PhD**, **Kenichi Chiba, PhD**, **Hiroko Tanaka, BA**, **Yuichi Shiraishi, PhD**, **Satoru Miyano, PhD**, **Sudipto Mukherjee, MD, PhD, MPH**, **Tomas Radiovoyevitch, PhD**, **Thomas Laframboise, PhD**, **Aziz Nazha, MD**, **Mikaela A. Sekeres, MD, MS**, **Torsten Haferlach, MD**, **Seishi Ogawa, MD, PhD** and **Jaroslaw P. Maciejewski**

1. Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2. Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
3. Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
4. Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
5. Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH
6. Cleveland Clinic, Cleveland, OH
2583 Pathogenic Germline Variants in Acquired Aplastic Anemia (AA) and Paroxysmal Nocturnal Hemoglobinuria (PNH)

Program: Oral and Poster Abstracts
Session: 508. Bone Marrow Failure: Poster II
Hematology Disease Topics & Pathways:
Diseases, Bone Marrow Failure, Biological Processes, Technology and Procedures, genomics, NGS

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Wenyi Shen, MD.1,2*, Cassandra M. Hirsch3*, Bartlomiej P. Przychodzen4*, Hideki Makishima, MD, PhD5,
Louis Williams, MD, MBA6, Sudipto Mukherjee, MD, PhD, MPH7, Hetty E. Carraway, MD, MBA8,9,
Mikkael A. Sekeres, MD, MS10 and Jaroslaw P. Maciejewski11,12
1The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
2Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China
3Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
4Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
5Department of Pathology and Tumor Biology,Graduate School of Medicine, Kyoto University,Japan, Kyoto, Japan
6NYU, New York, NY
7Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
8Cleveland Clinic, Cleveland, OH
9Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH
10Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
11Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

2590 Clinical and Molecular Heterogeneity of Moderate Aplastic Anemia

Program: Oral and Poster Abstracts
Session: 508. Bone Marrow Failure: Poster II
Hematology Disease Topics & Pathways:
Diseases, Bone Marrow Failure

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Bhumika J. Patel, MD1, Shimoli Vipul Barot, MD2, Teodora Kuzmanovic, BA3*, Bartlomiej P. Przychodzen3*,
Cassandra M. Hirsch3*, Hassan Awada, MD4, Metis Hasipek, PhD4, Swapna Thota, MD5,
Tomas Radivoyevitch, PhD4, Anjali S. Advani, MD7, Matt Kalaycio, MD8, Mikkael A. Sekeres, MD, MS9, Hetty E. Carraway, MD, MBA7,10 and Jaroslaw P. Maciejewski11
1Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2Internal Medicine, Cleveland Clinic, Cleveland, OH
3Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
4Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
5Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Fairview Park, OH
6Department of Medicine, RoswellPark, Buffalo, NY
7Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH
8Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
9Department of Translational Hematology and Oncology Research, Taussig Cancer Institute Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
10Taussig Cancer Institute, Cleveland Clinic, Department of Hematology and Medical Oncology, Cleveland, OH

2647 Synergistic Anti-Leukemic Activity of PARP Inhibition Combined with IMGN632, an Anti-CD123
Antibody-Drug Conjugate in Acute Myeloid Leukemia Models

Program: Oral and Poster Abstracts
Session: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster II
Hematology Disease Topics & Pathways:
apoptosis, antibodies, AML, Diseases, Non-Biological, Therapies, Biological Processes, DNA repair,
Myeloid Malignancies, pharmacology

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)
2699 Comparison of CD22 Expression between Baseline, End of Treatment, and Relapse Among Patients Treated with Inotuzumab Ozogamicin Who Responded and Subsequently Relapsed in Two Clinical Trials

Program: Oral and Poster Abstracts
Session: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Poster II

Hematology Disease Topics & Pathways:
antibodies, Biological, ALL, Leukemia, Diseases, Therapies, Lymphoid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Hagop M. Kantarjian, MD1, Wendy Stock, MD2, Ryan D. Cassaday, MD3, Daniel J. DeAngelo, MD4, Elias J. Jabbour, MD5, Susan M. O’Brien, MD6, Matthias Stelljes, MD7, Tao Wang8, Katherine F Liau9, Kevin Nguyen10, Barbara Sleight8, Erik Vandendries, MD, PhD11, Alexander Neuhof, MD12, A. Douglas Laird8 and Anjali S. Advani, MD13

1Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX
2Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL
3UW/FHCRC, Seattle, WA
4Dana-Farber Cancer Inst., Boston, MA
5Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
6UCI Cancer Center, Orange, CA
7Universitätsklinikum Münster, Münster, Germany
8Pfizer Inc, Groton, CT
9Pfizer Inc, San Diego, CA
10Navigate BioPharma Services (formerly Genoptix BioPharma Services), a Novartis subsidiary, Carlsbad, CA
11Pfizer Inc, Cambridge, MA
12Pfizer Pharma GmbH, Berlin, Germany
13Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

2732 Glasdegib in Addition to Intensive or Non-Intensive Chemotherapy in Patients with Acute Myeloid Leukemia: Safety Analysis of Glasdegib ‘On Target’ Adverse Events

Program: Oral and Poster Abstracts
Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II

Hematology Disease Topics & Pathways:
Diseases, AML, Biological, Therapies, enzyme inhibitors, Clinically relevant, Myeloid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Jorge E. Cortes, MD1, Cristina Papayannidis2, Catriona Jamieson, MD, PhD3,4, Gary J. Schiller, MD5, Anna Candoni, MD6, Brian Leber, MD7, Claudia D. Baldus, MD8, José A. Pérez-Simón, MD, PhD9, Weidong Wendy Ma10, Corrado Gallo Stampino10, Ashleigh O’Connell10, Mirjana Zeremski, MD11, Geoffrey Chan, MD12 and Mikkael A. Sekeres, MD, MS13

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology “L. e A. Seràgnoli”, University of Bologna, Bologna, Italy
3Sanford Stem Cell Clinical Center, University California, San Diego, La Jolla, CA
4Moores Cancer Center, University of California, San Diego, La Jolla, CA
5Ronald Reagan University of California Los Angeles Medical Center, Santa Monica, CA
6Division of Hematology and Bone Marrow Transplantation, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy
7Juravinski Hospital and Cancer Centre, Hamilton, ON, Canada
8Hämatoonkologie und Onkologie, Charité-Universitätsmedizin Berlin, Berlin, Germany
9Instituto de Biomedicina de Sevilla (IBIS), UGC-Hematologia, Hospital Universitaria Virgen del Rocío/ CSIC/ CIBERONC, Universidad de Sevilla, Sevilla, Spain
10Pfizer Inc, New York, NY
11Pfizer Canada Inc., Kirkland, QC, CAN
2735 Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Program: Oral and Poster Abstracts
Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II

Hematology Disease Topics & Pathways:
AML, Diseases, MDS, Myeloid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Rachel J. Cook, MD1, Tamara Mayo, MD, PhD2,3, Jane L. Liesveld, MD3, David A. Rizzieri, MD4, Eytan M. Stein, MD5, Stephane De Botton, MD, PhD6,7, Gail J. Roboz, MD7, Mikkael A. Sekeres, MD, MS8, Joseph G. Jurcic, MD9, Azra Raza, MD10, Robert L. Redner, MD11, Dale L. Bixby, MD, PhD12, Jorge E. Cortes, MD13, Kristin Stephens14, Angela Volkert14, Qing Kang, PhD14, Emmanuelle Di Tomaso, PhD14, David A. Roth, MD14 and Carlos E Vigil, MD15

1Knight Cancer Institute, Oregon Health and Science University, Portland, OR
2Vanderbilt University, Nashville, TN
3Division of Hematology/Oncology, University of Rochester Medical Center, Rochester, NY
4Dept. of Medicine, Div. of Hematological Malignancies & Cellular Therapy, Duke University Medical Center, Durham, NC
5Division of Hematologic Oncology, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY
6Department of Hematology, Gustave Roussy Cancer Center, Villejuif, France
7Weill Cornell Medicine and The Weill Medical College of Cornell University, New York, NY
8Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
9Columbia University Medical Center, New York, NY
10Myelodysplastic Syndrome Center, Columbia University Medical Center, New York, NY
11UPMC Hillman Cancer Center, Pittsburgh, PA
12Internal Medicine, University of Michigan, Ann Arbor, MI
13Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
14Syros Pharmaceuticals, Cambridge, MA
15Division of Hematology, Oncology, and Blood & Marrow Transplantation, The University of Iowa, Iowa City, IA

2809 Molecular Characterization of Acute Myeloid Leukemia Patients with Normal Karyotype

Program: Oral and Poster Abstracts
Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster II

Hematology Disease Topics & Pathways:
Diseases, AML, Technology and Procedures, Clinically relevant, Myeloid Malignancies, molecular testing, NGS

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Aziz Nazho, MD1, Manja Meggendorfer, PhD2, Sudipto Mukherjee, MD, PhD, MPH3, Wencke Walter, PhD4,5, Stephan Hutter, PhD5,6, Ahmed Makhoul, MD7, Cassandra M. Hirsch8, Bartlomiej P. Przychoden9, Hetty E. Carraway, MD, MBA4,7, Yasunobu Nagata4, Yihong Guan8, Teodora Kuzmanovic, BA9, Metis Hasipek, PhD4, Babai K. Jha5, Jaroslaw P. Maciejewski6, Claudia Haferlach, MD2, Mikkael A. Sekeres, MD, MS9 and Torsten Haferlach, MD2

1Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2MLL Munich Leukemia Laboratory, Munich, Germany
3Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH
4Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
5Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
6Taussig Cancer Institute, Cleveland Clinic, Department of Hematology and Medical Oncology, Cleveland, OH
7Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH
8Taussig Cancer Institute, Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH
9Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

2874 Safety and Efficacy of Adct-402 (Loncastuximab Tesirine), a Novel Antibody Drug Conjugate, in Relapsed/Refractory Follicular Lymphoma and Mantle Cell Lymphoma: Interim Results from the Phase 1 First-in-Human Study

ASH 2018 Annual Meeting
**Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster II**

**Hematology Disease Topics & Pathways:**
- Follicular Lymphoma, Diseases, Biological, Adult, Therapies, Mantle Cell Lymphoma, B-Cell Lymphoma, Study Population, Lymphoid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

**Paolo Caimi, MD**

- Brad S. Kahl, MD
- Mehdi Hamadani, MD
- Carmelo Carlo-Stella, MD
- Shui He, PhD
- David Ungar, MD
- Jay Feingold, MD
- Kirit M. Ardesna, MA MD FRCP FRCPPath
- John Radford, MD
- Melhem Solh, MD
- Leonard Heffner, MD
- and Owen A. O’Connor, M.D., Ph.D.

1. Case Western Reserve University (CWRU) - University Hospitals Cleveland Medical Center, Cleveland, OH
2. St Louis University, Louis, MO
3. Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
4. Hematology, Humanitas Cancer Center, Rozzano, Milano, Italy
5. ADC Therapeutics America, Inc, Murray Hill, NJ
6. ADC Therapeutics, Inc, Murray Hill, NJ
7. Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom
8. The University of Manchester and The Christie NHS Foundation Trust, Manchester, United Kingdom
9. Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA
10. Department of Hematology and Medical Oncology, Emory University School of Medicine, Emory
11. Center for Lymphoid Malignancies, Department of Medicine, Columbia University, New York, NY

**2878 Short Diagnosis to Treatment Interval (DTI) Is Associated with Inferior Outcome in Newly Diagnosed Patients with Mantle Cell Lymphoma, a MER/LEO and Alliance Collaboration**

Program: Oral and Poster Abstracts

**Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster II**

**Hematology Disease Topics & Pathways:**
- Diseases, Adult, Mantle Cell Lymphoma, Non-Hodgkin Lymphoma, Study Population, Clinically relevant, Lymphoid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

**Matthew J Maurer, MS**

- Amy S. Ruppert, MAS, PhD
- Brian K. Link, MD
- Lawrence D Kaplan, MD
- David J Inwards, MD
- Andrew L. Feldman, MD
- Eric D. Hsi, MD
- Adam Pettinger
- Jonathon B. Cohen, MD
- Peter Martin, FRCP
- Brad S Kahl, MD
- Nancy L. Bartlett, MD
- James R. Cerhan, MD, PhD
- John P. Leonard, MD
- and Thomas M. Habermann, MD

1. Department of Health Sciences Research, Mayo Clinic, Rochester, MN
2. Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN
3. Division of Hematology, The Ohio State University, Columbus, OH
4. Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA
5. Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA
6. Division of Hematology, Mayo Clinic, Rochester, MN
7. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
8. Department of Laboratory Medicine, Cleveland Clinic Foundation, Cleveland, OH
9. Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN
10. Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory University, Atlanta, GA
11. Division of Hematology and Oncology, Weill Cornell Medical College-New York Presbyterian Hospital, New York, NY
12. Division of Medical Oncology, Washington University School of Medicine, Saint Louis, MO
13. Mayo Clinic, Rochester, MN
14. Weill Medical College of Cornell University, New York, NY

**2893 Preliminary Safety and Efficacy Results with an Intermittent Schedule of the PI3kδ Inhibitor ME-401 Alone or in Combination with Rituximab for B-Cell Malignancies**

Program: Oral and Poster Abstracts

**Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster II**

**Hematology Disease Topics & Pathways:**
- Follicular Lymphoma, Leukemia, Diseases, Adult, Non-Biological, Therapies, CLL, Non-Hodgkin Lymphoma, Study Population, Lymphoid Malignancies, Clinically relevant
2914 The Predictive Value of PET/CT for Post-Transplant Outcomes in T Cell Lymphoma

Program: Oral and Poster Abstracts
Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster II
Hematology Disease Topics & Pathways:
Diseases, Adult, Non-Biological, Therapies, Biological Processes, chemotherapy, Technology and Procedures, T-Cell Lymphoma, Study Population, Clinically relevant, Lymphoid Malignancies, Quality Improvement, imaging

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)
Nancy Kaddis, MD, MPH1, Eric D Jacobsen, MD2, Ailbhe O’Neill, MD3*, Nikhil Ramaiya, MD4* and Robert A. Redd, MS5

1Dana Farber Cancer Institute, Harvard Medical School, Boston, MA
2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
3Department of Radiology, St Vincent’s University Hospital, Dublin 4, Ireland
4Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA
5Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA

2925 Pooled Safety Analysis and Efficacy of Tenalisib (RP6530), a PI3Kδ/γ Inhibitor, in Patients with Relapsed/Refractory Lymphoid Malignancies

Program: Oral and Poster Abstracts
Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster II
Hematology Disease Topics & Pathways:
Diseases, Biological, Therapies, Hodgkin Lymphoma, T-Cell Lymphoma, Lymphoid Malignancies, TKI

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)
Swami P. Iyer, MD1, Auris Huen, MD2*, Andres J M Ferreri, MD3, Brad M. Haverkos, MD, MPH, MS4, Jasmine M. Zain, MD5, Radhakrishnan Ramchandren, MD6, Mary Jo Lechowicz, MD7, Sumana Devata, MD8, Neil Korman, MD9, Lauren C. Pinter-Brown, MD10, Richard Delarue, MD11, Kasi Viswanath VRouthu, PhD12*, Prajak Barde, MD13*, Ajit M Nair, PhD13* and Carmelo Carlo-Stella, MD14

1The Methodist Cancer Center, Houston, TX
2The University of Texas MD Anderson Cancer Center, Houston, TX
3Unit of Lymphoid Malignancies, IRCCS San Raffaele Scientific Institute, Milano, Italy
4University of Colorado, Denver, CO
5Department of Hematology/Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
6Department of Oncology, Karmanos Cancer Institute, Detroit, MI
7Emory University, Atlanta, GA
8Internal Medicine/Hematology/Oncology, University of Michigan, Ann Arbor, MI
9Department of Dermatology at Case Western Reserve University and University Hospitals Cleveland Medical Center, Cleveland, OH
10University of California, Irvine, Beverly Hills, CA
11Hematology Department / Hemophilia Center, Necker University Hospital, AP-HP, Paris, France
12Rhizen Pharmaceuticals S.A., Hyderabad, Telangana, India

Program: Oral and Poster Abstracts
Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster II

Hematology Disease Topics & Pathways:
Clinically relevant

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Chul S. Ha, MD1, Hongli Li, MS2,*, Heiko Schoder, MD3, Chelsea C Pinnix, MD4,*, Elizabeth Brem, MD5, Nancy L. Bartlett, MD6, Andrew M. Evens, DO, MSc7, Eric D. Hsi, MD8, Lisa M. Rismsa, MD9, John P. Leonard, MD10, Brad S Kahl, MD11, Michael L. Leblanc, PhD12, Sonali M. Smith, MD12, Louis S. Constine, MD13 and Jonathan W. Friedberg, MD13

1University of Texas Health Science Center At San Antonio, San Antonio, TX
2SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA
3Memorial Sloan Kettering Cancer Center, New York, NY
4Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston
5Division of Hematology/Oncology, Dept. of Medicine, University of California at Irvine School of Medicine, Huntington Beach, CA
6Siteman Cancer Center, Washington University School of Medicine, Saint Louis, MO
7Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
8Department of Laboratory Medicine, Cleveland Clinic Foundation, Cleveland, OH
9Department of Research, Mayo Clinic - Scottsdale, Scottsdale, AZ
10Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY
11Department of Medicine, Washington University School of Medicine, Saint Louis, MO
12University of Chicago, Chicago, IL
13Wilmot Cancer Institute, University of Rochester, Rochester, NY

2967 2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cell) in Patients with Refractory Large B Cell Lymphoma

Program: Oral and Poster Abstracts
Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster II

Hematology Disease Topics & Pathways:
Diseases, Biological, Lymphoma (any), Therapies, CAR-Ts, Non-Hodgkin Lymphoma, B-Cell Lymphoma, immunotherapy, Lymphoid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Sattva S. Neelapu, MD1, Armin Ghobadi, MD2,*, Caron A. Jacobson, MD, MMSc3, David B. Miklos, MD, PhD4, Lazaros J. Lekakis, MD5, Olalekan O. Oluwole, MBBS, MPH6, Yi Lin, MD, PhD7, Ira Braunischweig, MD8,*, Brian T. Hill, MD, PhD9,10, John M. Timmerman, MD11, Abhinav Deol, MD12, Patrick M. Reagan, MD13, Patrick J. Stiff, MD14, Ian W. Flinn, MD, PhD15, Umar Farooq, MD16, Andre Goy, MD17, Peter A. McSweeney, MD18,*, Javier Munoz, MD19, Tanya Siddiqi, MD20, Julio C. Chavez, MD21, Alex F. Herrera, MD22, Allen Xue, PhD23,*, Yizhou Jiang, PhD23,*, Adrian Bot, MD, PhD23,*, John M. Rossi, MS23,*, Jenny J. Kim, MD, MS23,*, William Y. Go, MD, PhD23 and Frederick L. Locke, MD24

1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
2Washington University School of Medicine, St. Louis, MO
3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
4Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University, Stanford, CA
5University of Miami Health System, Sylvester Comprehensive Care Center, Miami, FL
6Vanderbilt-Ingram Cancer Center, Nashville, TN
7Division of Hematology, Mayo Clinic, Rochester, MN
8Department of Hematology and Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY
9Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH
10Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
11UCLA David Geffen School of Medicine, Los Angeles, CA
12Department of Oncology, Blood and Marrow Stem Cell Transplant Program, Karmanos Cancer Institute/Wayne State University, Detroit, MI
13Wilmot Cancer Institute Division of Hematology/Oncology, University of Rochester Medical Center, Rochester, NY

ASH 2018 Annual Meeting 56
3027 Efficacy of Combined Ruxolitinib and Decitabine in Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms: Results of a Phase II Study (MPN-RC 109 trial)

Program: Oral and Poster Abstracts
Session: 634. Myeloproliferative Syndromes: Clinical: Poster II
Hematology Disease Topics & Pathways:
Diseases, AML, Biological, Adult, Therapies, Non-Biological, Biological Processes, MPN, epigenetics, Study Population, Clinically relevant, Myeloid Malignancies, TKI, signal transduction
Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)
Raajit K. Rampal, MD, PhD1, John Mascarenhas, MD, MD2, Heidi E. Kosiorek, MS3*, Rupali Bhave, M.D.4*, Elizabeth O. Hixson, MD, MS5, Eunice S. Wang, MD6, Aaron T. Gerds, MD, MS7, Mark L Heaney, MD, PhD8, Camille N Abboud, MD9, Marina Kremyanskaya, MD, PhD10*, Dmitriy Berenzon, MD11*, Olatoyosi Odenike, MD12, Elizabeth Virtgaym13*, Lonette Sandy10*, Rona Singer Weinberg, PhD14, Vesna Najfeld, MD15. Mohamed E. Salama, MD16, Ross L. Levine, MD17, Ruben A. Mesa, MD, FACP18, Amylou C. Dueck, PhD19 and Ronald Hoffman, MD, MD10
1Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; Myeloproliferative Neoplasm Research Consortium (MPN-RC), New York, NY
2Icahn School of Medicine at Mount Sinai, New York, NY
3Department of Biostatistics, Mayo Clinic, Scottsdale, AZ
4Comprehensive Cancer Center of Wake Forest Baptist Health, Winston-Salem, NC
5Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA
6Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY
7Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
8Columbia University Medical Center, New York, NY
9Division of Oncology, Washington University School of Medicine, Saint Louis, MO
10Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
11Comprehensive Cancer Center, Wake Forest Baptist Health, Comprehensive Cancer Center, Wake Forest Baptist Health, Winston Salem, NC
12Section of Hematology/Oncology, University of Chicago, Chicago, IL
13Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York
14New York Blood Center, New York, NY
15Division of Hematology/Medical Oncology/Pathology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai; Myeloproliferative Neoplasm Research Consortium (MPN-RC), New York, NY
16Mayo Medical Laboratories, Rochester, MN
17Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY
18UT Health San Antonio Cancer Center, San Antonio, TX
19Department of Biostatistics, Mayo Clinic Arizona, Scottsdale, AZ

3073 LUC7L2 Is a Novel RNA-Splicing Regulatory Factor Mutated in Myelodysplastic Syndromes

Program: Oral and Poster Abstracts
Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster II
Hematology Disease Topics & Pathways:
Diseases, Bone Marrow Failure, Biological Processes, Technology and Procedures, genomics, NGS, RNA sequencing
Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)
Courtney Hershberger, BS1*, James Hiznay1*, Rosemary Dietrich1*, Xiaorong Gu, PhD2*, Cassandra M. Hirsch3*, Amy Graham, BS, MS3*, Bartlomiej P. Przychodzen3*, Valeria Visconte, PhD3, Vera Adema, PhD4*,

ASH 2018 Annual Meeting 57
Yvonne Parker3, Hetty E. Carraway, MD, MBA4,7, Tomas Radivojevitch, PhD3*, Mikkael A. Sekeres, MD, MS3, Yogenthiran Saanthararajah, MD9, Jaroslaw P. Maciejewski3 and Richard A Padgett1*

1Cellular and Molecular Medicine, Cleveland Clinic Foundation, Cleveland, OH
2Tassig Cancer Institute, Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH
3Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
4Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
5Cleveland Clinic, Cleveland, OH
6Cleveland Clinic, Cleveland, OH
7Tassig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH
8Leukemia & Myeloid Disorders Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
9Department of Translational Hematology and Oncology Research, Tassig Cancer Institute, Cleveland Clinic Case Western Reserve Univ., Cleveland, OH

3074 Analysis of Even a Limited Number of Genes Indicates a Strong Inherited Component in Otherwise Typical Sporadic MDS

Program: Oral and Poster Abstracts
Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster II
Hematology Disease Topics & Pathways:
Diseases, MDS, Myeloid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)
Cassandra M. Hirsch1*, Wenyi Shen, MD 2*, Bartlomiej P. Przychodzen1*, Yasunobu Nagata3, Vera Adema, PhD4*, Teodora Kuzmanovic, BA1*, Louis Williams, MD, MBA1, Aziz Nazha, MD5, Valeria Visconte, PhD6, Hetty E. Carraway, MD, MBA7, Mikkael A. Sekeres, MD, MS8 and Jaroslaw P. Maciejewski1,9

1Department of Translational Hematology and Oncology Research, Tassig Cancer Institute, Cleveland Clinic, Cleveland, OH
2Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH
3Department of Translational Hematology and Oncology Research, Tassig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
4Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
5Cleveland Clinic, Cleveland, OH
6Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
7Tassig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH
8Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH
9Department of Translational Hematology and Oncology Research, Cleveland Clinic Foundation, Cleveland, OH

3084 Somatic Mutations in Therapy-Related Myeloid Neoplasms Are Influenced By Therapeutic Modality and Clonal Hematopoiesis of Indeterminate Potential

Program: Oral and Poster Abstracts
Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster II
Hematology Disease Topics & Pathways:
Diseases, AML, CMML, MDS, Myeloid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)
Teodora Kuzmanovic4*, Bhumika J. Patel, MD5, Srinivasa Reddy Sanikommu, MD3, Yasunobu Nagata4*, Hassam Awada, MD5, Cassandra M. Hirsch4*, Bartlomiej P. Przychodzen1*, Remco J Molenaar, MD PhD6,7*, Babal K. Jha10, Sudipto Mukherjee, MD, PhD, MPH2, Anjali S. Advani, MD8, Aziz Nazha, MD2, Aaron T. Gerds, MD, MS2, Hetty E. Carraway, MD, MBA4,10, Mikkael A. Sekeres, MD, MS11, Jaroslaw P. Maciejewski11,12 and Tomas Radivojevitch, PhD4,13*

1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
3Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium health, Charlotte, NC
4Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
5Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Fairview Park, OH
6Academic Medical Center, Amsterdam, Netherlands
7Tassig Cancer Institute, Cleveland Clinic, Cleveland, OH
8Tassig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH
9Tassig Cancer Institute Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
10Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
11Leukemia Program, Tassig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
12Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

ASH 2018 Annual Meeting 58
3091 Phase 1b/2 Combination Study of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Program: Oral and Poster Abstracts
Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster II
Hematology Disease Topics & Pathways:
Diseases, apoptosis, Non-Biological, Therapies, MDS, Biological Processes, chemotherapy, Myeloid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

David A Sallman, MD\(^1\), Amy E. DeZern, MD\(^2\), David P. Steensma, MD\(^3\), Kendra L. Sweet, MD\(^4\), Thomas Cluzeau, MD, PhD\(^5\), Mikkael A. Sekeres, MD, MS\(^6\), Guillermo Garcia-Manero, MD\(^6\), Gail J. Roboz, MD\(^7\), Amy F McLemore, M.S.\(^8\)*, Kathy L McGraw, PhD\(^9\), John Puskas, PhD\(^10\), Ling Zhang, MD\(^11\), Chirag K Bhagat, PharmD\(^12\), Qiuping Yao, PhD\(^13\), Najla Al Ali, M.Sc\(^14\)*, Eric Padron, MD\(^15\), Roger Tell, MD, PhD\(^16\)*, Jeffrey E. Lancet, MD\(^1\), Pierre Fenaux, MD, PhD\(^17\)*, Alan F. List, MD\(^1\) and Rami S. Komrokji, MD\(^1\)

\(^1\)Malignant Hematology Department, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
\(^2\)Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
\(^3\)Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
\(^4\)Département de Hématologie Clinique, Centre Hospitalier Universitaire de Nice, Nice, France
\(^5\)Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
\(^6\)Department of Leukemia, MD Anderson Cancer Center, Houston, TX
\(^7\)Weill Cornell Medical College, New York, NY
\(^8\)Genoptix, Inc, Carlsbad, CA
\(^9\)Cancer Informatics Core, H. Lee Moffitt Cancer Center & Research Institute, Tampa
\(^10\)Leukemia Program, Cleveland Clinic, Cleveland, OH
\(^11\)Leukemia & Myeloid Disorders Program, Cleveland Clinic, Cleveland, OH

3095 Evaluating the Evidence for Long-Term Benefit from Specialty Centers Versus Real World for MDS Patients Treated with HMA

Program: Oral and Poster Abstracts
Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster II
Hematology Disease Topics & Pathways:
Diseases, Therapies, Non-Biological, MDS, chemotherapy, Clinically relevant, Myeloid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Sudipto Mukherjee, MD, PhD, MPH\(^1\),2, Tomas Radivoyevitch, PhD\(^3\),4*, Brian P. Hobbs, PhD\(^5\)*, Xuefei Jia, MS\(^6\), Rami S. Komrokji, MD\(^6\), David P. Steensma, MD\(^7\), Amy E. DeZern, MD\(^8\), Gail J. Roboz, MD\(^9\), Guillermo Garcia-Manero, MD\(^10\), Jaroslav P. Maciejewski\(^11\), Aziz Nazha, MD\(^1\) and Mikkael A. Sekeres, MD, MS\(^11,12\)

\(^1\)Cleveland Clinic, Cleveland, OH
\(^2\)Leukemia Program, Cleveland Clinic, Cleveland, OH
\(^3\)Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
\(^4\)Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
\(^5\)Cancer Biostatistics, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
\(^6\)Department of Malignant Hematology, H Lee Moffitt Cancer Center, Tampa, FL
\(^7\)Dana-Farber Cancer Institute, Boston, MA
\(^8\)Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
\(^9\)Weill Cornell Medicine and The Weill Medical College of Cornell University, New York, NY
\(^10\)Department of Leukemia, MD Anderson Cancer Center, Houston, TX
\(^11\)Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

3096 Does Trial Participation Improve Outcomes for Higher-Risk Myelodysplastic Syndromes (MDS) Patients Treated at Specialty Centers?

Program: Oral and Poster Abstracts
Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster II
Hematology Disease Topics & Pathways:
Diseases, MDS, Clinically relevant, Myeloid Malignancies

ASH 2018 Annual Meeting 59
3098 What Is the Optimal Time to Initiate Hypomethylating Agents (HMA) in Higher Risk Myelodysplastic Syndromes (MDS)?

Program: Oral and Poster Abstracts
Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster II
Hematology Disease Topics & Pathways:
Diseases, Therapies, Non-Biological, Bone Marrow Failure, MDS, chemotherapy, Clinically relevant, Myeloid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Rami S. Komrokij, MD1, Najla Al Ali, MSc2, David A Sallman, MD3, Eric Padron, MD4, Aziz Nazha, MD5, David P. Steensma, MD6, Amy E. DeZern, MD7, Gail J. Roboz, MD8, Guillermo Garcia-Manero, MD9, Mikkael A. Sekeres, MD, MS1, Jeffrey E. Lancet, MD1 and Alan F. List, MD9

1Malignant Hematology Department, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
2Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL
3Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL
4Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
5Dana-Farber Cancer Institute, Boston, MA
6Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
7Division of Hematology and Oncology, Weill Cornell Medical College of Cornell University, New York
8Department of Leukemia, MD Anderson Cancer Center, Houston, TX
9H. Lee Moffitt Cancer Center, Tampa, FL

3103 Therapy-Related MDS Can Be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS

Program: Oral and Poster Abstracts
Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster II
Hematology Disease Topics & Pathways:
Diseases, Adult, MDS, Study Population, Clinically relevant, Myeloid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Andrea Kuendgen, MD1, Meritxell Nomdedeu2, Heinz Tuechler3, Guillermo Garcia-Manero, MD4, Rami S. Komrokij, MD5, Mikkael A. Sekeres, MD, MS5, Matteo Giovanni Della Porta6, Alan F. List, MD7, Mario Cazzola8, Amy E. DeZern, MD9, Gail J. Roboz, MD10, David P. Steensma, MD11, Arjan A. Van de Loosdrecht, MD, PhD12, Hartmut Döhner, MD13, Xavier Calvo, MD14, Sabine Blum15, Arturo Pereira, MD, PhD16, Peter Valent17, Dolores Costa18, Aristoteles Giagounidis19, Luis Benlloch20, Uwe Platzbecker, MD21, Carme Pedro, MD22, Michael Lübbert23, Itziar Oiarzabal24, Javier Grau25, Maria Diez-Campelo26, Maria Teresa Cedena26, Sigrid Machnerdl-Spandl, MD27, Maria López-Pavía28, Claudia D. Baldus, MD29, Montserrat Martinez-de-Sola30, Reinhard Stauder, MD, MSc31, Brayan Merchán32, Christina Ganster33, Thomas Schroeder34, Barbara Hildebrandt35, Jordi Esteve, MD, PhD36, Benet Nomdedeu37, Francesc Cobo38, Francesc Sole, PhD39, Rainer Haas, MD40, Ulrich Gering, MD41, Peter L Greenberg, M.D.42, Detlef Haase, MD, PhD43 and Guillermo Sanz, MD, PhD44
3142 Venetoclax As Monotherapy or in Combination: Patterns of Use and Predictors of Outcomes in an International Multicenter Study of CLL Patients

Program: Oral and Poster Abstracts
Session: 642. CLL: Therapy, excluding Transplantation: Poster II

Hematology Disease Topics & Pathways:
Adult, antibodies, Biological, Leukemia, Diseases, Therapies, CLL, Study Population, Clinically relevant, Lymphoid Malignancies, TKI

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

**Anthony R. Mato, MD, MSCE**1, Lindsey E. Roeker, MD2, Toby A. Eyre3, Chadi Nabhan, MD3, Nicole Lamanna, MD4, Brian T. Hill, MD, PhD5,6, Danielle M. Brander, MD7, Paul Barr, MD8,9, Frederick Lansigan, MD10, Bruce Cheson, MD11, Arun K Singavi, MD12, Maryam Yazdy, MD13, Nirav N Shah, MD14, John N. Allan, MD15, Erica B Bhavsar, BS16, Joanna Rhodes, MD17, Kaitlin Kennard, RN, BSN18, Stephen J. Schuster, MD19, Annalynn M Williams, MS20, Alan P Skarbnik, MD21, Andre Goy, MD22, Catherine C. Coombs, MD23, Hande H. Tuncer, MD24, Chaitra S. Ujjani, MD25, Ryan Jacobs, MD26, Allison M. Winter,
3233 Natural History of Patients with Multiple Myeloma Refractory to CD38-Targeted Monoclonal Antibody-Based Treatment

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster II

Hematology Disease Topics & Pathways:

antibodies, Biological, multiple myeloma, Diseases, Non-Biological, Therapies, chemotherapy, Plasma Cell Disorders, Lymphoid Malignancies, Clinically relevant

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Ujjawal H Gandhi, PhD, MBBS1, Arjun Lakshman, MD, MRCP2, Zhubin Gahvari, MD3, Elizabeth McGehee, MD4, Megan Helena Jagosky, MD5, Ridihi Gupta, MBBS6, William Varnado, MD7, Saurabh Chhabra, MD8, Mark A. Fiala, BS9, Ehsan Malek, MD10, Joshua Mansour, MD11, Barry Paul, MD12, Alyssa Barnstead13, Saranya Kodali, MD14, Amarendra K. Neppalli, MD15, Michaela Liedtke, MD6, Kelly N. Godby, MD7, Yubin Kang, MD16, Ankik Kansagra, MD4, Emma C. Scott, MD17, Elvira Umyarova, MD14, Parameswaran Hari, MBBS, MD18, Ravi Vij, MBBS19, Saad Z. Usmani, MD20, Natalie Scott Callander, MD21, Robert Frank Cornell, MD22, Shaji K. Kumar, MD23 and Luciano J Costa, MD, PhD24

1Department of Medicine, Division of Hematology & Oncology, Vanderbilt University Medical Center, Nashville, TN
2Division of Hematology, Mayo Clinic, Rochester, MN
3University of Wisconsin, Madison, WI
4University of Texas Southwestern Medical Center, Dallas, TX
5Plasma Cell Disorders Section, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC, Levine Cancer Institute, Charlotte, NC
6Department of Medicine, Stanford, CA
7University of Alabama at Birmingham, Birmingham, AL
8Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI
9Washington University School of Medicine, Saint Louis, MO
**3239 Efficacy of Lenalidomide Based Three Drug Versus Two Drug Regimen for Relapsed Multiple Myeloma: A Systematic Review and Meta-Analysis of Randomized Trials**

Program: Oral and Poster Abstracts
Session: 653. Myeloma: Therapy, excluding Transplantation: Poster II
Hematology Disease Topics & Pathways:
multiple myeloma, Diseases, Therapies, Non-Biological, chemotherapy, Plasma Cell Disorders, Lymphoid Malignancies

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Muhammad Usman, MD1*, Warda Faridi, MD1*, Muhammad Asad Fraz, MD1*, Muhammad Junaid Tariq, MD1*, Saad Ullah Malik, MD1*, Fnu Sagar, MD1*, Awas Ijaz, MD1*, Abid Hussain, MD1*, Malik Qistas Ahmad, MD, MBBS1*, Muhammad Jahanzeb Khalil, MD1*, Amna Khalid, MD1*, Midhat Lakhani, MD1*, Ceren Durer, MD1*, Seren Durer, MD1* and Faiz Anwer, MD1,2

1Department of Medicine, Division of Hematology and Oncology, University of Arizona, Tucson, AZ
2Department of Hematology, Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

**3271 Pomalidomide + Low-Dose Dexamethasone + Daratumumab in Relapsed and/or Refractory Multiple Myeloma after Lenalidomide-Based Treatment Failure**

Program: Oral and Poster Abstracts
Session: 653. Myeloma: Therapy, excluding Transplantation: Poster II
Hematology Disease Topics & Pathways:
Diseases, multiple myeloma, Adult, Plasma Cell Disorders, Study Population, Lymphoid Malignancies, Clinically relevant

Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

David S Siegel, MD, PhD1, Gary J. Schiller, MD2, Christy J. Samaras, DO3, Michael Sebag, MD, PhD4, Jesus G. Berdeja, MD5, Siddhartha Ganguly, MD6, Jeffrey V Matous, MD7, Kevin Song, MD8, Christopher S. Seet, MD9, Giampaolo Talamo10*, Mirelis Acosta-Rivera11*, Michael Bar12*, Donald P. Quick, MD13, Bertrand Anz, MD14*, Gustavo Fonseca15*, Donna Reece16*, Amit Agarwal, MD, PhD17*, Weiyouan Chung17*, Faiza Zafar, MPAS17* and Nizar Bahlis, MD18

1John Theurer Cancer Center, Myeloma and Lymphoma Divisions, Hackensack University Medical Center, Hackensack, NJ
2David Geffen School of Medicine at UCLA, Los Angeles, CA
3Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
4McGill University Health Centre, Montreal, QC, Canada
5Sarah Cannon Research Institute, Nashville, TN
6The University of Kansas Cancer Center, Fairway, KS
7Colorado Blood Cancer Institute, Denver, CO
8The Vancouver General Hospital, Vancouver, BC, CAN
9UCLA Medical Center, Los Angeles, CA
10Penn State Hershey Cancer Institute, Hershey, PA
11Fundacion de Investigacion, San Juan, Puerto Rico
12Stamford Hospital, Stamford, CT
13Joe Arrington Cancer Research Treatment Center, Lubbock, TX
14Tennessee Oncology, Chattanooga, TN
15Florida Cancer Specialists, St. Petersburg, FL
3292 Efficacy and Safety of Daratumumab Based Regimens for Multiple Myeloma: A Systematic Review and Meta-Analysis

Program: Oral and Poster Abstracts
Session: 653. Myeloma: Therapy, excluding Transplantation: Poster II
Hematology Disease Topics & Pathways:
multiple myeloma, Diseases, Therapies, Non-Biological, chemotherapy, Plasma Cell Disorders, Lymphoid Malignancies
Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Muhammad Abu Zar, MD1*, Ahmad Kamal, MD1*, Ali Younas Khan, MD1*, Saad Ullah Malik, MD1*, Mustafa Nadeem Malik, MD1*, Abdul Rafae, MD1*, Ceren Durer, MD1*, Seren Durer, MD1*, Insija Ilyas Selene, MBBS1*, Anum Qureshi1*, Jemin Aby Jose, MD1*, Hafiz Muhammad Fazeel, MD1*, Zunairah Shah, MBBS1*, Muhammad Adil Rehman, MBBS1* and Faiz Anwer, MD1,2

1Department of Medicine, Division of Hematology and Oncology, University of Arizona, Tucson, AZ
2Department of Hematology, Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

3303 Natural History of Patients with Multiple Myeloma Refractory to Elotuzumab and Outcomes of Subsequent Therapy with Anti-CD38 Monoclonal Antibodies

Program: Oral and Poster Abstracts
Session: 653. Myeloma: Therapy, excluding Transplantation: Poster II
Hematology Disease Topics & Pathways:
Adult, antibodies, Biological, multiple myeloma, Diseases, Therapies, Study Population, Plasma Cell Disorders, Clinically relevant, Lymphoid Malignancies
Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

William Varnado, MD1,2, Megan Helena Jagosky, MD3*, Zhubin Gahvari, MD4, Saurabh Chhabra, MD5, Ujjawal H Gandhi, PhD, MBBS6, Arjun Lakshman, MD, MRCP7*, Elizabeth McGehee, MD8*, Ridhi Gupta, MBBS9, Ehsan Malek, MD10, Mark A. Fiala, BS11*, Joshua Mansour, MD12, Barry Paul, MD13*, Alyssa Barnstead14*, Saranya Kodali, MD15, Neppalli Amarendra, MD16*, Michaela Liedtke, MD17, Kelly N. Godby, MD1*, Yubin Kang, MD18, Ankit Kansgra, MD19*, Emma C. Scott, MD20, Elvira Umyarova, MD21, Parameswaran Hari, MBBS, MD22, Ravi Vij23, Saad Z. Usmani, MD23, Robert Frank Cornell, MD24, Shaji K. Kumar, MD25, Natalie Scott Callander, MD26 and Luciano J Costa, MD, PhD27

1University of Alabama at Birmingham, Birmingham, AL
2University of Alabama in Birmingham, Birmingham
3Plasma Cell Disorders Section, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC, Levine Cancer Institute, Charlotte, NC
4Medical College of Wisconsin, Milwaukee, WI
5Department of Medicine, Division of Hematology & Oncology, Vanderbilt University Medical Center, Nashville, TN
6Division of Hematology, Mayo Clinic, Rochester, MN
7University of Texas Southwestern Medical Center, Dallas, TX
8Stanford Cancer Institute, Stanford, CA
9University of Cincinnati, Cincinnati, OH
10University of Vermont, College of Medicine, Burlington, VT
11University of Alabama at Birmingham, Birmingham, AL
12Medical University of South Carolina, Charleston, SC
13Department of Medicine, Duke University School of Medicine, Durham, NC
14Oregon Health & Science University, Portland, OR
15University of Vermont, College of Medicine, Burlington, VT
16Medical University of South Carolina, Charleston
17Stanford University Cancer Center, Stanford, CA
18Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC
19UT Southwestern Medical Center, Dallas, TX
20Knight Cancer Institute, Oregon Health & Science University, Portland, OR
21Department of Medicine, Medical College of Wisconsin, Menominee Falls, WI
22Washington University School of Medicine at St. Louis, St. Louis, MO
23Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Charlotte, NC
3309 Presentation Pattern, Diagnostic Markers, Management and Outcome of IgD Multiple Myeloma: A Systematic Review

Program: Oral and Poster Abstracts
Session: 653. Myeloma: Therapy, excluding Transplantation: Poster II
Hematology Disease Topics & Pathways: Non-Biological, Therapies, chemotherapy
Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

**Insiya Ilyas Selene, MBBS**, Jemin Aby Jose, MD, Muhammad Jahanzeb Khalil, MD, Muhammad Junaid Tariq, MD, Seren Durer, MD, Ceren Durer, MD, Madeeha Shafqat, MDS, Shehroz Aslam, MD, Zunairah Shah, MBBS, Anum Qureshi, Faiza Jamil, Mustafa Nadeem Malik, MD, Abdul Rafae, MD, Muhammad Masab, MD, and Faiz Anwer, MD

1Department of Medicine, Division of Hematology and Oncology, University of Arizona, Tucson, AZ
2West Virginia University, West Virginia
3Department of Internal Medicine, Division of Hematology/Oncology, University of Arizona, Tucson, AZ
4Department of Hematology, Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

3365 Comparative Effectiveness of Busulfan/Cyclophosphamide Versus Busulfan/Fludarabine Myeloablative Conditioning for Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia

Program: Oral and Poster Abstracts
Hematology Disease Topics & Pathways: AML, Adult, Diseases, Non-Biological, Therapies, chemotherapy, Technology and Procedures, Study Population, cytogenetics, Clinically relevant, Quality Improvement, Myeloid Malignancies, NGS
Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

**Sagar S. Patel, MD**, Lisa Rybicki, MS, Arden Emrick, RN, Victoria Winslow, RN, Jamie Starn, RN, Jamie Elberson, RN, Brittany Hodgeman, RN, Brad Pohlman, MD, Brian J. Bolwell, MD, Aaron T. Gerds, MD, MS, Betty K. Hamilton, MD, Rabi Hanna, MD, Matt Kalaycio, MD, Navneet S. Majhail, MD, MS and Ronald Sobeks, MD

1Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
3Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
4Pediatric Blood and Marrow Transplant Program, Pediatrics Institute and Children’s Hospital, Cleveland Clinic, Cleveland, OH

3379 Prospective, Multi-Center, Phase I Clinical Trial of PLX-R18 Placental Expanded Adherent Stromal Cells in Subjects with Incomplete Hematopoietic Recovery after Hematopoietic Cell Transplantation

Program: Oral and Poster Abstracts
Hematology Disease Topics & Pathways: Biological, Adult, Therapies, Bone Marrow Failure, Biological Processes, Technology and Procedures, cell expansion, Study Population, Clinically relevant, hematopoiesis, transplantation
Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

**Hillard M Lazarus, MD**, Leland Metheny, MD, Tsila Zuckerman, MD, Carolina Escobar, MD, Joseph P. McGuirk, DO, Yael Rosen, MD and Jacob M. Rowe, MD

1Case Western Reserve University School of Medicine, Cleveland, OH
2Case Western Reserve University, Cleveland, OH
3456 Reduced Intensity Conditioning (RIC) Regimens Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML): A Comparison of Fludarabine/Busulfan (FB) and Fludarabine/Melphalan (FM) Based Regimens from the CIBMTR Program: Oral and Poster Abstracts
Session: 732. Clinical Allogeneic Transplantation: Results: Poster II
Hematology Disease Topics & Pathways:
Diseases, AML, Biological, Therapies, Myeloid Malignancies, transplantation
Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)
Rajneesh Nath, MD1, Zheng Zhou, MD, PhD2, Jan Cerny, MD, PhD3, Hai-Lin Wang, MPH4*, Khalid Bo-Subait4*, Zartash Guth5*, Gulrayz Ahmed6*, Muhammad Wagas Khan7*, Gerhard Carl Hildebrandt, MD8, Hassan B. Alkhateeb, MD9*, Moussab Damlaž, MD11*, Mrinal M. Patnaik, MD, MBBS9, Brenda M. Sandmaier, MD11,12,13, Daniel J. Weisdorf, MD14, Marcos de Lima, MD15, Mark R. Litzow, MD9 and Wael Saber, MD, MS14
1Banner MD Anderson Cancer Center, Gilbert, AZ
2Lahey Hospital and Medical Center, Burlington, MA
3Division of Stem Cell Transplantation, UMass Memorial Medical Center, Worcester, MA
4CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
5University of Cincinnati, Cincinnati, OH
6Mount Auburn Hospital-Harvard Medical School, Boston, MA
7University of Kentucky, Lexington, KY
8Department of Internal Medicine, Division of Hematology/BMT, University of Kentucky, Lexington, KY
9Division of Hematology, Mayo Clinic, Rochester, MN
10McGill, Montreal, QC, Canada
11Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
12Division of Hematology, Department of Medicine, University of Washington, Seattle, WA
13Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN
14Case Western Reserve University, Cleveland, OH

3562 The Healthcare Burden of Emergency Department Utilization for Multiple Myeloma: A Five Years U.S Nationwide Study
Program: Oral and Poster Abstracts
Session: 902. Health Services Research—Malignant Diseases: Poster II
Hematology Disease Topics & Pathways:
Diseases, Clinically relevant, Quality Improvement
Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)
Mohamed Mokhtar Bakr, MD1*, Umar Zahid, MD, MPH1,2*, Pavan Tenneti, MD3*, Rehan Farooqi, MD4* and Faiz Anwer, MD5,6
1Jersey Shore University Medical Center, Neptune, NJ
2Johns Hopkins University, Baltimore, MD
3University of Arizona, Tucson, AZ
4Internal Medicine, MedStar Health, Baltimore, MD
5Division of Hematology, Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH
6Department of Internal Medicine, Division of Hematology/Oncology, University of Arizona, Tucson, AZ

3570 Deaths Due to Thrombotic Versus Bleeding Events within 90 Days of Cancer Associated Thrombosis
Program: Oral and Poster Abstracts
Session: 903. Outcomes Research—Non-Malignant Hematology: Poster II
Hematology Disease Topics & Pathways:
Clinically relevant
Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Mailey L Wilks, MSN, APRN, NP-C1, Shyam K. Poudel, MD2, Deborah Y. Park, BS3, Xuefei Jia, MS4, Vicki Pinkava, MSBS, PA-C5, Meghan O’Brien, MS, ANP-BC6, Barb Tripp, CNS7, Jung-Min Song, RN, CNS3, Keith R. McCrae, MD5, Alok A. Khorana6 and Dana E. Angelini, MD2
1Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
3Cleveland Clinic Lerner College of Medicine, Cleveland Heights, OH
4Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
5Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
6Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH

3600 Psychosocial Evaluation in Allogeneic Hematopoietic Cell Transplantation Recipients (Allo HCT): Psychosocial Assessment of Candidates for Transplant (PACT) As a Tool to Identify High-Risk Patients and Its Association with Transplant Outcomes
Program: Oral and Poster Abstracts
Session: 904. Outcomes Research—Malignant Conditions: Poster II
Hematology Disease Topics & Pathways:
Adult, Study Population, Clinically relevant
Sunday, December 2, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Sanghee Hong1, Lisa Rybicki, MS2, Jane Dabney, LISW-S3, Christine Lawrence, LISW-S4, Betty K. Hamilton, MD5, Matt Kalaycio, MD6, Linda McLellan, LISW6, Ronald Sobecks, MD6, Stephanie J. Lee, MD, MPH7 and Navneet S. Majhail, MD, MS6
1University of Washington, Seattle, WA
2Cleveland Clinic, Quantitative Health Sciences, Cleveland, OH
3Blood & Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
4Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
5Taussig Cancer Institute, Blood and Marrow Transplant Program, Cleveland Clinic Foundation, Cleveland, OH
6Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH
7Fred Hutchinson Cancer Research Center, Seattle, WA

3671 Heterogeneous Hypoxia-Mediated Neutrophil and Red Blood Cell Adhesion to E-Selectin in Microscale Flow
Program: Oral and Poster Abstracts
Session: 114. Hemoglobinopathies, Excluding Thalassemia—Clinical: Poster III
Hematology Disease Topics & Pathways:
sickle cell disease, Diseases, cellular interactions, Biological Processes, Hemoglobinopathies
Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Yuncheng Man1, Erdem Kucukal, MS1, Shichen Liu1, Deepa Manwani, MD2,3, Jane Little, MD4,5 and Umut A. Gurkan, PhD1
1Case Western Reserve University, Cleveland, OH
2Children’s Hospital at Montefiore, Bronx, NY
3Albert Einstein College of Medicine, Bronx
4Division of Hematology/Oncology, Case Western Reserve University/University Hospitals Seidman Cancer Center, Cleveland, OH

3672 Hypoxia Enhanced Red Cell Adhesion in Vitro May Identify Patients at Risk for Vasculopathy
Program: Oral and Poster Abstracts
Session: 114. Hemoglobinopathies, Excluding Thalassemia—Clinical: Poster III
Hematology Disease Topics & Pathways:
sickle cell disease, Diseases, Hemoglobinopathies
Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Charlotte Yuan, BA1, Erina Quinn1, Sargam Kapoor, MD2, Myeongseop Kim, MS3, Erdem Kucukal, MS1, Umut A. Gurkan, PhD1 and Jane Little, MD2
3798 The Rate of Venous Thromboembolism in Cancer Patients Varies By Khorana Risk Category

Program: Oral and Poster Abstracts
Session: 331. Pathophysiology of Thrombosis: Poster III
Hematology Disease Topics & Pathways:
Diseases, Bleeding and clotting, Thrombosis, Thromboembolism
Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Alok A. Khorana1, Nicole M. Kuderer2, Keith R. McCrae, MD3, Dejan Milentijevic, PhD4*, Guillaume Germain, MA5*, François Laliberté, MA5*, Nguyen Le, BSc6*, Patrick Lefebvre, MA7*, Gary H. Lyman8 and Michael B. Streiff9

1Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH
2University of Washington, Seattle, WA
3Cleveland Clinic, Cleveland, OH
4Janssen Scientific Affairs, LLC, Titusville, NJ
5Groupe d’analyse, Ltée, Montréal, QC, Canada
6Analysis Group, Inc., Boston
7Analysis Group, Inc, Montreal, QC, Canada
8Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

3799 Healthcare Costs in Patients with Cancer Increase with Increasing Risk of Venous Thromboembolism

Program: Oral and Poster Abstracts
Session: 331. Pathophysiology of Thrombosis: Poster III
Hematology Disease Topics & Pathways:
Diseases, Bleeding and clotting, Thrombosis, Thromboembolism
Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Michael B. Streiff1, Keith R. McCrae, MD2, Nicole M. Kuderer3, Dejan Milentijevic, PhD4*, Guillaume Germain, MA5*, François Laliberté, MA5*, Nguyen Le, BSc6*, Patrick Lefebvre, MA7*, Gary H. Lyman8 and Alok A. Khorana9

1Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
2Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
3University of Washington, Seattle, WA
4Janssen Scientific Affairs, LLC, Titusville, NJ
5Groupe d’analyse, Ltée, Montréal, QC, Canada
6Analysis Group, Inc., Boston
7Analysis Group, Inc, Montreal, QC, Canada
8Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, WA
9Division of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH

3800 Exosome Polyphosphate Mediates the Activation of FXII By Cancer Cell-Derived Exosomes

Program: Oral and Poster Abstracts
Session: 331. Pathophysiology of Thrombosis: Poster III
Hematology Disease Topics & Pathways:
Biological Processes, cellular interactions, inflammation, molecular interactions, pathogenesis
Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Dewen You, PhD1,2*, Suman Kundu, MBA3*, Alvin H. Schmaier, MD4, Alok A. Khorana5,6 and Keith R. McCrae, MD5,7

1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
2Department of Cellular and Molecular Medicine, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
3Department of Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, OH
4Case Western Reserve University, Cleveland, OH
5Taussig Cancer Institute/Cleveland Clinic, Cleveland, OH
6Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH
7Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
3840 Targeting NAD⁺ Modulating Enzymes to Improve HSC Function in Aging and Bone Marrow Failure
Program: Oral and Poster Abstracts
Session: 503. Clonal Hematopoiesis: Aging and Inflammation: Poster III
Hematology Disease Topics & Pathways:
Diseases, Adult, Biological, Animal models, Therapies, bone marrow, Bone Marrow Failure, chemical interactions, Biological Processes, Technology and Procedures, cell expansion, Xenograft models, Study Population, Clinically relevant, Quality Improvement, Myeloid Malignancies, pharmacology, hematopoiesis, transfusion, inflammation, stem cells, metabolomics
Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)
Phillip J Maciejewski1*, Yihong Guan2*, Metis Hasipek, PhD2*, Anand D. Tiwari, PhD.1,2*, Dale Grabowski, BS2*, James G Phillips, PhD2*, Yogenthiran Saunthararajah, MD4, Jaroslaw P. Maciejewski2,3 and Babal K. Jha1,4*
1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
3Leukemia Program, Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
4Department of Translational Hematology and Oncology Research, Cleveland Clinic Lerner College of Medicine, Cleveland

3866 Heterozygous CTC1 Variants in Acquired Bone Marrow Failure
Program: Oral and Poster Abstracts
Session: 508. Bone Marrow Failure: Poster III
Hematology Disease Topics & Pathways:
Diseases, Adult, Bone Marrow Failure, Biological Processes, Technology and Procedures, genomics, NGS
Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)
Wenyi Shen, MD1,2*, Cassandra M. Hirsch3*, Bartlomiej P. Przychodzen4*, Reda Z. Mahfouz, MD, PhD5*, Tomas Radiovoyevitch6*, Louis Williams, MD, MBA7, Mohammad Fahad B. Asad8 and Jaroslaw P. Maciejewski8
1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China
3Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
4Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
5Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
6Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
7NYU, New York, NY
8Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

3869 Impact of Eltrombopag on Clonal Evolution in Refractory Aplastic Anemia
Program: Oral and Poster Abstracts
Session: 508. Bone Marrow Failure: Poster III
Hematology Disease Topics & Pathways:
Diseases, Bone Marrow Failure
Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)
Bhumika J. Patel, MD1, Shimoli Vipul Barot, MD2, Bartlomiej P. Przychodzen3*, Teodora Kuzmanovic, BA3*, Michael Clemente, MS4*, Cassandra M. Hirsch5*, Valeria Visconte, PhD6, Roy Souaid, MD7*, Marissa Versalle8*, Sarah S Lee, MD9, Tomas Radiovoyevitch10*, Metis Hasipek8*, Swapna Thota, MD11, Aziz Nazha, MD12, Matt Kalaycio, MD13, Anjali S. Advani, MD14, Hetty E. Carraway, MD, MBA14,15, Mikkael A. Sekeres, MD, MS15 and Jaroslaw P. Maciejewski15
1Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2Internal Medicine, Cleveland Clinic, Cleveland, OH
3Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
4Fauci Cancer Institute, Cleveland Clinic, Department of Translational Hematology and Oncology Research, Cleveland
5Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
6Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
7Thor, Cleveland
8Cleveland Clinic, Cleveland
9Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

ASH 2018 Annual Meeting
3871 The Shwachman-Diamond Syndrome Registry: Hematologic Complications
Session: 508. Bone Marrow Failure: Poster III
Hematology Disease Topics & Pathways:
Diseases, Bone Marrow Failure, Clinically relevant
Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)
Kasiani C. Myers, MD1, Elissa M. Furutani, MD2, Sara Loveless, BSN3, Maggie Malsch, MSN, RN4, Ashley Galvin5, Ellie Fratt5, Jordan Larson5, Jacob Cotton5, Leah Cheng5, Kelly McIntosh5, Joan Moore, RN6, Leann Mount, RN6, Rabi Hanna, MD7, Winfred Wang, MD8, Alison A. Bertuch, MD, PhD9, Stella M. Davies, PhD, MBBS, MRCP10 and Akiko Shimamura, MD, PhD11
1Bone Marrow Transplantation & Immune Deficiency, Cincinnati Children’s Hospital, Cincinnati, OH
2Cancer and Blood Disorders Center, Boston Children’s Hospital, Boston, MA
3Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
4Boston Children’s Hospital, Boston
5Cancer and Blood Disorders Center, Dana-Farber/Boston Children’s, Boston
6Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children’s Hospital Medical Center, Cincinnati
7Department of Pediatric Hematology Oncology and Bone Marrow Transplant, Cleveland Clinic, Cleveland, OH
8St. Jude Children’s Research Hospital, Memphis, TN
9Texas Children’s Hospital, Houston, TX
10Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
11Dana-Farber/Boston Children’s Cancer & Blood Disorders Center, Boston, MA

3995 FLT3-ITD Mutations Are Prevalent and Significantly Impact Outcome after Intensive Therapy in Elderly Adults with Acute Myeloid Leukemia (AML): Analysis of the North American Intergroup E2906 Phase III Trial in Patients Age ≥60 Years
Program: Oral and Poster Abstracts
Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster III
Hematology Disease Topics & Pathways:
AML, Diseases, Elderly, Technology and Procedures, Study Population, Clinically relevant, genetic profiling, Myeloid Malignancies
Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)
James M. Foran, MD1, Zhuxiong Sun, PhD2, Elisabeth Paitetta, PhD3, Janis Racevskis, PhD3, David F. Claxton, MD4, Hillard M Lazarus, MD5, Daniel A. Arber, MD6, Jacob M. Rowe, MD7, John Godwin, MD8, Yanming Zhang, MD9, Martin S. Tallman, MD10, Mark R. Litzow, MD11, Keith W. Pratz, MD12 and Selina Luger, MD13
1Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic Florida, Jacksonville, FL
2ECOG-ACRIN statistical center, Boston
3Cancer Center, Montefiore Medical Center, Bronx, NY
4Penn State Cancer Institute, Penn State M.S. Hershey Medical Center, Hershey, PA
5Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH
6University of Chicago, Chicago, IL
7The Ruth and Bruce Rappaport Faculty of Medicine, Shaare Zedek Medical Center, Jerusalem, Israel
8Providence Portland Medical Center, Portland, OR
9Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
10Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
11Division of Hematology, Mayo Clinic, Rochester, MN
12John Hopkins University, Baltimore, MD
13Division of Hematology-Oncology/Department of Medicine, University of Pennsylvania, Philadelphia, PA

3999 Outcomes of Patients with Newly-Diagnosed Acute Myeloid Leukemia and Hyperleukocytosis Who Did Not Undergo Intensive Chemotherapy: Results from a Large International Database
Program: Oral and Poster Abstracts
Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster III
Hematology Disease Topics & Pathways:
Diseases, AML, Adult, Study Population, Clinically relevant, Myeloid Malignancies
Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Rory M Shallis, MD1, Maximilian Stahl, MD2, Wei Wei, MD, PhD3*, Pau Fernandez4*, Etienne Lengline, MD5*, Judith Neukirchen, MD6*, Vijaya R. Bhatt, MD7, Mikkael A. Sekeres, MD, MS8, Amir T. Fathi, MD9, Heiko König, MD, PhD10, Selina Luger, MD11, Irum Khan, MBBS12, Gail J. Roboz, MD13, Thomas Cluzeau, MD, PhD14, David Martinez-Cuadron, MD15*, Emmanuel Raffoux, MD16*, Ulrich Germing, MD17*, Jayadev Manikkam Umakanthan, MBBS18, Sudipto Mukherjee, MD, PhD, MPH19, Andrew M. Brunner, MD20, Adam M. Miller, BS, MD21*, Christine M. McMahon, MD22, Ellen K. Ritchie, MD23, Rebeca Rodríguez-Veiga, MD24*, Raphael Itzykson, MD, PhD21, Blanca Boluda, MD25, Florence Rabian, MD26, Mar Tormo, MD, PhD22, Evelyn Gloria Acuna Cruz, MD27, Nikolai Podoltsev, MD, PhD23,24, Steven D. Gore, MD22,24 and Amer M. Zeidan, MBBS, MHS23,24*

1Department of Internal Medicine, Section of Hematology, Yale School of Medicine, West Haven, CT
2Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT
3Department of Biostatistics, Yale School of Public Health, New Haven, CT
4Hospital Universitari i Politècnic La Fe, Valencia; CIBERONC, Instituto Carlos III, Madrid, Spain
5Hospital St. Louis, Paris, France
6Dept. of Hematology, Oncology and Clinical Immunology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
7Department of Internal Medicine, Division of Hematology & Oncology, University of Nebraska Medical Center, Omaha, NE
8Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
9Massachusetts General Hospital Cancer Center, Harvard Medical School, Cambridge, MA
10Indiana University Simon Cancer Center, Indianapolis, IN
11Division of Hematology-Oncology/Department of Medicine, University of Pennsylvania, Philadelphia, PA
12University of Illinois, Chicago, IL
13Weill Cornell Medicine and The Weill Medical College of Cornell University, New York, NY
14Département de Hématologie Clinique, Centre Hospitalier Universitaire de Nice, Nice, France
15Hospital Universitari i Politècnic La Fe, Valencia, Spain
16Hematology Department, Saint-Louis Hospital AP-HP Paris France, Paris, France
17Klinik für Hämatologie, Onkologie and Klinische Immunologie, Universitätsklinik Düsseldorf, Düsseldorf, Germany
18University of Nebraska Medical Center, Omaha, NE
19Cleveland Clinic, Cleveland, OH
20Dana-Farber Cancer Institute, Boston, MA
21Hematologie clinique, Hôpital Saint-Louis, Paris, France
22Hematology Department, Hospital Clínico Universitario, Instituto de investigación INCLIVA, Valencia, Valencia, Spain
23Yale Cancer Center, Yale University School of Medicine, New Haven, CT
24Yale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University School of Medicine, New Haven, CT

4031 Exploration of Potential Relationships between CD22 and Selected Safety Outcomes in the Inotuzumab Ozogamicin Phase 3 INO-VATE Study
Program: Oral and Poster Abstracts
Session: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Poster III
Hematology Disease Topics & Pathways:
Leukemia, Diseases, Biological, ALL, antibodies, Therapies, Lymphoid Malignancies
Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Partow Kebriraie, MD1, Daniel J. DeAngelo, MD2, Anjali S. Advani, MD2, Susan M. O’Brien, MD2, David Marks2, Hagop M. Kantarjian, MD3, Elias J. Jabbour, MD3, Tao Wang4, Erik Vandendries, MD, PhD5*, A. Douglas Laird, PhD5, Sonja Nick, MSc10* and Matthias Stelljes, MD11

1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
2Dana-Farber Cancer Inst., Boston, MA
3Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH
4University of California Irvine Medical Center, Orange, CA
5University Hospitals Bristol, Bristol, United Kingdom
6Department of Leukemia, MD Anderson Cancer Center, Houston, TX
7Pfizer Inc, Groton, CT
8Pfizer Inc, Cambridge, MA
9Pfizer Inc, San Diego, CA
4040 Characteristics, Treatment Patterns and Outcomes Among Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Who Present with Hyperleukocytosis: Findings from a Large International Patient Cohort

Program: Oral and Poster Abstracts
Session: 615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Poster III

Hematology Disease Topics & Pathways:
- Diseases, AML, Clinically relevant, Myeloid Malignancies

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Maximilian Stahl, MD1, Wei Wei, MD, PhD2*, Pau Fernandez3*, Etienne Lengline, MD4*, Rory M Shellis, MD5, Judith Neukirchen, MD3*, Vijaya R. Bhatt, MD6, Mikkael A. Sekeres, MD, MS7, Amir T. Fathi, MD8, Heiko Konig, MD, PhD9, Selina Luget, MD10, Irum Khan, MBBS11*, Gail J. Roboz, MD12, Thomas Cluzeau, MD, PhD13*, David Martinez-Cuadron, MD14*, Emmanuel Raffoux, MD15*, Ulrich Germing, MD9*, Jayadev Manikkam Umakanthan, MBBS9, Sudipto Mukherjee, MD, PhD, MPH16, Andrew M. Brunner, MD17, Adam M. Miller, BS, MD18, Christine M. McMahon, MD10, Ellen K. Ritchie, MD12, Rebeca Rodriguez-Veiga, MD19, Raphael Itzykson, MD, PhD18, Blanca Boluda, MD13*, Florence Rabian, MD14*, Mar Tormo, MD15*, Evelyn Gloria Acuna Cruz, MD16*, Emma Rabinovich, MD11*, Brendan Yoo10*, Nikolai A. Podoltsnev, MD, PhD15, Steven D. Gore, MD1 and Amer M. Zeidan, MBBS, MHS14*

1Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT
2Department of Biostatistics, Yale School of Public Health, New Haven, CT
3Hospital Universitari i Politécnic La Fe, Valencia, Spain
4Hematology Department, Saint-Louis Hospital AP-HP Paris France, Paris, France
5Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany
6University of Nebraska Medical Center, Omaha, NE
7Leukemia Program, Cleveland Clinic, Cleveland, OH
8Massachusetts General Hospital Cancer Center, Harvard Medical School, Cambridge, MA
9Indiana University Simon Cancer Center, Indianapolis, IN
10Division of Hematology-Oncology/Department of Medicine, University of Pennsylvania, Philadelphia, PA
11University of Illinois, Chicago, IL
12Weill Cornell Medicine and The Weill Medical College of Cornell University, New York, NY
13Département de Hématologie Clinique, Centre Hospitalier Universitaire de Nice, Nice, France
14Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
15University Clinical Hospital, INCLIVA, Valencia, Spain, Valencia, Spain

4067 Targeting Antagonists of Retinoic Acid Signaling in Acute Myeloid Leukemia

Program: Oral and Poster Abstracts
Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III

Hematology Disease Topics & Pathways:
- apoptosis, Diseases, AML, Therapies, Non-Biological, chemical interactions, cellular interactions, Biological Processes, Technology and Procedures, epigenetics, Clinically relevant, Quality Improvement , Myeloid Malignancies, hematopoiesis, flow cytometry, metabolomics, RNA sequencing, molecular interactions, signal transduction

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Metis Hasipek, PhD1*, Dale Grabowski, BS1*, Yihong Guan1*, James G Phillips, PhD1*, Jaroslav P. Maciejewski2, Hetty E. Carraway, MD, MBA2-3 and Babal K. Jha4*

1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
2Taussig Cancer Institute, Cleveland Clinic, Department of Hematology and Medical Oncology, Cleveland, OH
3Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH
4Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

4146 Outcomes of Follicular Lymphoma Patients Treated with Frontline Bendamustine and Rituximab: Impact of Histologic Grade and Early Progression on Overall Survival

ASH 2018 Annual Meeting
Program: Oral and Poster Abstracts
Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster III
Hematology Disease Topics & Pathways:
Adult, Follicular Lymphoma, Diseases, Non-Hodgkin Lymphoma, Study Population, Lymphoid Malignancies
Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

**Intensive Induction Regimens after Deferring Initial Therapy Are Not Associated with Improved Progression-Free or Overall Survival in Patients with Mantle Cell Lymphoma (MCL)**

Program: Oral and Poster Abstracts
Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster III
Hematology Disease Topics & Pathways:
Adult, Mantle Cell Lymphoma, Non-Hodgkin Lymphoma, Study Population, Clinically relevant, Lymphoid Malignancies
Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)
Mehdi Hamadani, MD26, Timothy S. Fenske, MD27, Mary Malacek, MD28*, Brad S. Kahl, MD29*, Christopher R Flowers, MD, MS30 and Jonathan B. Cohen, MD, MS24
1Department of Hematology and Medical Oncology, Emory University Hospital, Atlanta, GA
2Biostatistics and Bioinformatics, Winship Cancer Institute of Emory University, Atlanta, GA
3Winship Cancer Institute, Biostatistics and Bioinformatics, Emory University, Atlanta, GA
4Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory University, Atlanta, GA
5Winship Cancer Institute, Emory University, Atlanta, GA
6University of Minnesota, Minneapolis, MN
7Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN
8Fox Chase Cancer Center, Philadelphia, PA
9Oregon Health and Science University, Portland, OR
10Knight Cancer Institute, Oregon Health and Science University, Portland, OR
11Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
12UNC, Chapel Hill, NC
13Northwestern University, Chicago, IL
14Division of Hematology, Northwestern University, Chicago, IL
15Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH
16Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH
17Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
18Levine Cancer Institute, Charlotte, NC
19Levine Cancer Institute, Concord, NC
20Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH
21Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, OH
22Divisions of Hematology and Medical Oncology, The Ohio State University Cancer Center, Columbus, OH
23Division of Hematology and Oncology, Medical College of Wisconsin, Brookfield, WI
24Emory University, Atlanta, GA
25Division of Hematology, The Ohio State University, Columbus, OH
26Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
27Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI
28Siteman Cancer Center, Washington University, St. Louis, MO
29Siteman Cancer Center, Washington University, St Louis, MO
30Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA

4202 Risk of Post-Transplant Lymphoproliferative Disorders (PTLD) in Solid Organ Transplantation Patients with EBV Viremia
Program: Oral and Poster Abstracts
Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Poster III
Hematology Disease Topics & Pathways:
Diseases, Lymphoma (any), Non-Hodgkin Lymphoma, Clinically relevant, Lymphoid Malignancies
Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)
Yazeed Sawalha, MD1, John McMichael, PhD2*, Lisa Rybicki, MS3*, Tamara A. Sussman, MD1*, Alex V. Mejia Garcia, MD1, Robert M. Dean, MD1, Brad Pohlan, MD1, Brian T. Hill, MD, PhD*3,5 and Deepa Jagadeesh, MD, MPH1
1Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH
2Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland
3Cleveland Clinic, Quantitative Health Sciences, Cleveland, OH
4Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH
5Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

4274 Poisson Regression Modeling of Chronic Myeloid Leukemia Mortality Trends
Program: Oral and Poster Abstracts
Session: 632. Chronic Myeloid Leukemia: Therapy: Poster III
Hematology Disease Topics & Pathways:
Diseases, Biological, Adult, CML, Therapies, immunotherapy, Study Population, Myeloid Malignancies, TKI
Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)
Tomas Radivoyevitch1*, Brian P. Hobbs, PhD1* and Jaroslaw P. Maciejewski1
4282 Hepcidin Suppression By Momelotinib Is Associated with Increased Iron Availability and Erythropoiesis in Transfusion-Dependent Myelofibrosis Patients

Program: Oral and Poster Abstracts
Session: 634. Myeloproliferative Syndromes: Clinical: Poster III
Hematology Disease Topics & Pathways:
Diseases, Adult, Therapies, Non-Biological, Biological Processes, Study Population, Clinically relevant, erythropoiesis, Myeloid Malignancies, inflammation, iron metabolism, signal transduction

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Stephen T Oh, MD, PhD1, Moshe Talpaz, MD2, Aaron T. Gerds, MD, MS3, Vikas Gupta, MD, FRCP, FRCPath4, Srdan Verstovsek, MD, PhD5, Ruben A. Mesa, MD, FACP6, Carole Brennan Miller, MD7, Candido E. Rivera, MD8, Angela Fleischman, MD, PhD9, Swati Goe10, Mark L Heaney, MD, PhD11, Casey O’Connell, MD12, Murat Arcasoy, MD13, Yafeng Zhang, PhD, MD14, Jun Kawashima, MD15, Tomas Ganz, MD, PhD16 and Carrie Baker Brachmann17

1Washington University School of Medicine, Saint Louis, MO
2Rogel Cancer Center, The University of Michigan - Michigan Medicine, Ann Arbor, MI
3Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
4Princess Margaret Cancer Centre, Toronto, ON, Canada
5Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX
6Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX
7Cancer Center, Ascension/St Agnes, Baltimore, MD
8Hematology, Mayo Clinic - Jacksonville, Jacksonville, FL
9University of California, Irvine, Irvine, CA
10Montefiore Medical Center Albert Einstein College of Medicine, Bronx, NY
11Columbia University Medical Center, New York, NY
12Jane Anne Nohl Division of Hematology, Keck School of Medicine of USC, Los Angeles, CA
13Duke Cancer Institute, Duke University School of Medicine, Durham, NC
14Biostatistics, Gilead Sciences, Inc., Foster City, CA
15Gilead Sciences, Inc., Foster City, CA
16Medicine, University of California, Los Angeles, Los Angeles, CA
17Gilead Science, Inc., Foster City, CA

4288 Survival Advantage to Allogeneic Transplant in Patients with Myelofibrosis with Intermediate-1 or Higher DIPSS Score

Program: Oral and Poster Abstracts
Session: 634. Myeloproliferative Syndromes: Clinical: Poster III
Hematology Disease Topics & Pathways:
Diseases, Biological, Therapies, Bone Marrow Failure, transplantation, TKI

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Kristina L. Gowin, DO1, Karen K. Ballen, MD2, Kwang Woo Ahn, PhD3,4, Zhen-Huan Hu, MPH5,6, Ying Liu, PhD7,5, Lucia Masarova, MD6, Srdan Verstovsek, MD, PhD7, Maria Coakley8, Tania Jain, MBBS9, Andrew Kuykendall, MD10, Rami Komrokji, MD11, Martha Wadleigh, MD12, Sarah Patches12, Murat Arcasoy, MD13, Michael Green13, Malathi Kandarpa, PhD14, Moshe Talpaz, MD15, Haris Ali, MD16, Vikas Gupta, MD, FRCP, FRCPath17, Rebecca Devlin18, Laura C. Michaelis, MD19, Gabriela S. Hobbs, MD20, Brady Lee Stein, MD21, Ashley Pariser, MD22, Aaron T. Gerds, MD, MS23, Kierstin Kuber24, Raajit Rampal25, Edwin P. Alyea III, MD26, Uday Popat, MD27, Ronald Sobecks, MD28, Bart L Scott, MD29, Ruben Mesa, MD30 and Wael Saber, MD, MS31

1Department of Hematology, University of Arizona, Tucson, WA
2Division of hematology/oncology, University of Virginia Health System, Charlottesville, VA
3CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
4Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee
5Division of Biostatistics, Institution for Health and Society, Medical College of Wisconsin, Milwaukee
6Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX
7Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX

ASH 2018 Annual Meeting
**4345 Lessons from Nature: A Novel Class of TET Inhibitors for TET2 Mutant Associated Diseases**

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster III

Hematology Disease Topics & Pathways:

Diseases, Therapies, Non-Biological, Bone Marrow Failure, chemotherapy, Biological Processes, epigenetics

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Yihong Guan1,*, Anand D. Tiwari, PhD.1,*, Metis Hasipek, PhD2,*, Dale Grabowski, BS2,*, Yvonne Parker2,*, Cassandra M. Hirsch2,*, Amy C Graham, BS, MS3,*, Yasunobu Nagata2,*, Bartlomiej P. Przychodzen1,*, Aziz Nazha, MD3, Daniel Lindner, MD, PhD3, Tomas Radiyovvietch, PhD2,3,*, James G Phillips, PhD2,*, Jaroslaw P. Maciejewski2 and Babal K. Jha1

1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
3Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

**4346 Modulation of TET2 Activity By Ascorbic Acid and Factors Affecting Lysine Acetylation**

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster III

Hematology Disease Topics & Pathways:

Diseases, Therapies, Non-Biological, Bone Marrow Failure, chemical interactions

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Yihong Guan1,*, Edward F Greenberg, MD1, Metis Hasipek, PhD1,*, Cassandra M. Hirsch1,*, Amy C Graham, BS, MS1,*, Tomas Radiyovvietch, PhD1,2,*, Shi Chen1,*, Xiaochen Liu1,*, Valeria Visconte, PhD3, Dewen You, PhD3, Eiju Negoro, MD, PhD1,*, Bartlomiej P. Przychodzen1,*, Hideki Makishima, MD, PhD1,2, Aziz Nazha, MD1, Daniel Gackowski, PhD1,*, Ewelina Zaradowska1,*, Mridul Mukherji, D.Phil.8, Mikkael A. Sekeres, MD, MS1, Mingjiang Xu, MD, PhD3, Ryszard Olninski, Professor7,*, Jaroslaw P. Maciejewski1 and Babal K. Jha1

1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
2Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
3Department of Biochemistry and Molecular Biology & Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL
4Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
5Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan
6Department of Clinical Biochemistry, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
7Department of Pharmacy, University of Missouri - Kansas City, Kansas City, MO
4350 SKI Controls MDS-Associated Chronic TGFβ Signaling, Aberrant Splicing, and Stem Cell Fitness
Program: Oral and Poster Abstracts
Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster III
Hematology Disease Topics & Pathways:
Diseases, Adult, Animal models, MDS, Biological Processes, Technology and Procedures, Study
Population, Myeloid Malignancies, genomics, hematoipoiesis, flow cytometry, molecular testing, NGS,
RNA sequencing, pathogenesis
Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)
David Muench, BS1, Kyle Ferchen, BS2*, Chinavenmeni S. Velu, PhD3,4*, Kith Pradhan, PhD5*, Kashish Chetel, MS6*, Clemencia Colmenares, PhD7*, Amit Verma, MD8, Nathan Salomonis, PhD6* and H. Leighton Grimes, PhD9
1Molecular and Developmental Biology Graduate Program, Cincinnati Children’s Hospital Medical Center, Fort Wright, KY
2Department of Cancer Biology, University of Cincinnati, Cincinnati
3Cincinnati Children’s Hosp. Med. Ctr., Cincinnati, OH
4Cincinnati Children’s Hosp. Med. Ctr., Cincinnati
5Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY
6Division of Biomedical Informatics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
7Lerner Research Institute, Cleveland Clinic, Cleveland, OH
8Albert Einstein College of Medicine-Montefiore Medical Center, Bronx, NY
9Division of Immunobiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

4351 Opposing Pathogenesis of Germline SAMD9/SAMD9L Variants in Adult Myelodysplastic Syndrome (MDS)
Program: Oral and Poster Abstracts
Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster III
Hematology Disease Topics & Pathways:
Diseases, MDS, Biological Processes, genomics, Myeloid Malignancies
Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)
Yasunobu Nagata1*, Satoshi Narumi, MD, PhD2*, Yihong Guan1*, Bartlomiej P. Przychodzen1*, Cassandra M. Hirsch1*, Hideki Makishima, MD, PhD3, Hirohito Shima2**, Victor Pastor Loyola, MSc4*, Teodora Kuzmanovic, BA4*, Tomas Radivoyevitch, PhD5**, Vera Adema, PhD4**, Hassan Awada, MD1, Kenichi Yoshida, MD, PhD2**, Francesc Sole, PhD6*, Babal K. Jha1*, Rabi Hanna, MD7, Thomas Leframboise, PhD8*, Seishi Ogawa, MD, PhD9, Mikael A. Sekeres, MD, MS10, Marcin W. Wlodarski, MD, PhD8,11, Jorg Cammenga, MD12* and Jaroslav P. Maciejewski1
1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan
3Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
4Division of Pediatric Hematology and Oncology, University of Freiburg, Freiburg, Germany
5Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
6MDS Research Group, Institut de Recerca Contra la Leucèmia Josep Carreras, Institut Català d’Oncologia-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
7Department of Pediatric Hematology Oncology and Bone Marrow Transplant, Cleveland Clinic, Cleveland, OH
8Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH
9Department of Pathology and Tumor Biology, Kyoto University, Sakyoku, Japan
10Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
11Hematology, St. Jude Children’s Research Hospital, Memphis, TN
12Linköping University, Department of Hematology, Linköping, SWE

4352 BRCA1 & BRCA2 Germline Variants Are Enriched in MDS/AML and Portend Higher Average Mutational Burden
Program: Oral and Poster Abstracts
Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster III
Hematology Disease Topics & Pathways:
Adult, Diseases, AML, MDS, Biological Processes, Technology and Procedures, DNA repair, Study
Population, cytogenetics, Clinically relevant, Myeloid Malignancies, genomics, NGS, pathogenesis

ASH 2018 Annual Meeting 77
4353 Distinct Implications of TP53 Hits for Patients with Treatment-Related MDS and AML

Program: Oral and Poster Abstracts
Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster III

Hematology Disease Topics & Pathways:
AML, Diseases, CMML, MDS, Myeloid Malignancies

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Teodora Kuzmanovic1†, Bhumika J. Patel, MD2, Yasunobu Nagata3†, Hassan Awada, MD4, Cassandra M. Hirsch3†, Bartlomiej P. Przychodzen1*, Srinivasa Reddy Sanikommu, MD5, Louis Williams, MD, MBA6, Sudipto Mukherjee, MD, PhD, MPH2, Anjali S. Advani, MD2, Aziz Nazha, MD2, Aaron T. Gerds, MD, MS5, Tomas Radirovoyitch, PhD3*, Hetty E. Carraway, MD, MBA7,10, Mikkael A. Sekeres, MD, MS11 and Jaroslaw P. Maciejewski3

1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
3Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
4Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
5Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC
6NYU, New York, NY
7Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH
8Cleveland Clinic, Cleveland, OH
9Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
10Taussig Cancer Institute, Cleveland Clinic, Department of Hematology and Medical Oncology, Cleveland, OH
11Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

4362 Planned Interim Analysis of a Phase 2 Study Evaluating the Combination of Pracinostat, a Histone Deacetylase Inhibitor (HDACi), and Azacitidine in Patients with High/Very High-Risk Myelodysplastic Syndrome (MDS)

Program: Oral and Poster Abstracts
Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster III

Hematology Disease Topics & Pathways:
Adult, Diseases, Non-Biological, Therapies, Biological Processes, chemotherapy, MDS, Study Population, epigenetics, Clinically relevant, Myeloid Malignancies

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Michael K Keng, MD1, Samer K. Khaled, MD2, Brenda Cooper, MD3, Erica D. Warlick, MD4, David Ramies, MD5, Silvia Mappa, MD6 and Ehab L. Atallah, MD7

1Division of Hematology/Oncology, University of Virginia Cancer Center, Charlottesville, VA
2Department of Hematology/HCT, City of Hope, Duarte, CA
3Hematologic Malignancies Program, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH
4Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN
5MEI Pharma, Inc., San Diego, CA
6Clinical Research and Development, Helsinn Healthcare, Lugano, Switzerland
7Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

4370 Diagnosis of Myelodysplastic Syndromes and Related Conditions: Rates of Discordance between Local and Central Review in the NHLBI MDS Natural History Study

ASH 2018 Annual Meeting 78
4374 Disparities in Participation in Interventional Clinical Trials for Myelodysplastic Syndromes

Program: Oral and Poster Abstracts
Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster III
Hematology Disease Topics & Pathways:
Diseases, Adult, MDS, Study Population, Clinically relevant, Myeloid Malignancies
Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

David P. Steensma, MD1, Rami S. Komrokji, MD2, Amy E. DeZern, MD3, Gail J. Roboz, MD4, Andrew M. Brunner, MD5, Richard M. Stone, MD6, John Barnard, PhD7 and Mikkael A. Sekeres, MD, MS8

1Dana-Farber Cancer Institute, Boston, MA
2Department of Malignant Hematology, H Lee Moffitt Cancer Center, Tampa, FL
3Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
4Weill Cornell Medicine and The Weill Medical College of Cornell University, New York, NY
5Massachusetts General Hospital, Boston, MA
6Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland
7Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

4389 Molecular Spectrum of CSF3R variants Correlate with Specific Myeloid Malignancies and Secondary Mutations

Program: Oral and Poster Abstracts
Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster III
Hematology Disease Topics & Pathways:
Diseases, Adult, AML, CML, MDS, Technology and Procedures, Study Population, Clinically relevant, Myeloid Malignancies, NGS
Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Vera Adema, PhD1*, Cassandra M. Hirsch1*, Bartlomiej Przychodzen1*, Yasunobu Nagata1*, Tomas Radivojevitch2,3*, Thomas Laframboise, PhD4*, Amy C Graham, BS, MS1*, Louis Williams, MD, MBA1, Hassan Awada, MD2, Aziz Nazha, MD3, Hetty E. Carraway, MD, MBA4,6, Valeria Santini7, Hrishikesh M
Mehta, PhD1,8,9*, Francesc Sole, PhD10, Mikkael A. Sekeres, MD, MS5, Valeria Visconte, PhD1, Rabi Hanna, MD9, Seth J. Corey, MD1,9,11 and Jaroslaw P. Maciejewski12
1 Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2 Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
3 Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
4 Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH
5 Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
6 Taussig Cancer Institute, Cleveland Clinic Program, Department of Hematology and Medical Oncology, Cleveland Clinic, OH
7 MDS Unit, AOI Careggi, University of Florence, Florence, Italy
8 Division of Hematology-Oncology, Department of Pediatrics, Virginia Commonwealth University, Richmond
9 Department of Pediatric Hematology Oncology and Bone Marrow Transplant, Cleveland Clinic, Cleveland, OH
10 MDS Research Group, Institut de Recerca Contra la Leucèmia Josep Carreras, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
11 Departments of Pediatrics, Microbiology/Immunology, Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA
12 Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

4410 Adverse Events, Patterns of Tumor Lysis Syndrome Prophylaxis and Management, and Dosing Patterns in a Large Cohort of Venetoclax Treated CLL Patients in Community and Academic Settings
Program: Oral and Poster Abstracts
Session: 641. CLL: Biology and Pathophysiology, excluding Therapy: Poster III
Hematology Disease Topics & Pathways:
Adapted, Biological, Leukemia, Diseases, Therapies, CLL, Study Population, Clinically relevant, Lymphoid Malignancies, Quality Improvement, TKI
Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)
Lindsey E. Roeker, MD1, Christopher P. Fox, MD, PhD2*, Toby A. Eyre3*, John N. Allan, MD4, Stephen J. Schuster, MD5, Chadi Nabhan, MD6, Brian T. Hill, MD, PhD7,8, Nirav N Shah, MD9, Frederick Lansigan, MD10, Maryam Yazdi, MD11, Nicole Lamanna, MD12, Bruce Cheson, MD13, Arun K Singavi, MD9, Catherine C. Coombs, MD14, Paul Barr, MD15, Alan P Skarbnik, MD16, Mazyar Shadman, MD, MPH17, Hande H. Tuncer, MD18, Chaitra S. Ujjani, MD17, Allison M. Winter, MD19, Joanna Rhodes, MD5, Colleen Dorsey, BSN, RN1*, Hannah Morse, BSN20*, John M. Pagel, MD, PhD21, Annalynn M Williams, MS22, Ryan Jacobs, MD23, Andre Goy, MD24, Sivraj Murakrishnan, MD10, Laurie Pearson, MD18*, Andrea Sitlinger, MD25, Neil Bailey, MS21*, Anna Schuh, MD26, Danielle M. Brander, MD27, Amy A Kirkwood, MS28* and Anthony R Mato, MD20
1 CLL Program, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY
2 Department of Clinical Haematology, Nottingham University Hospitals NHS Foundation Trust, Nottingham, United Kingdom
3 Oxford University Hospitals NHS Foundation Trust, Old Road, United Kingdom
4 Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY
5 Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
6 Cardinal Health Specialty Solutions, Deerfield, IL
7 Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH
8 Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
9 Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI
10 Dartmouth-Hitchcock Medical Center, Lebanon, NH
11 Department of hematology and oncology, Georgetown University Hospital Lombardi Comprehensive Cancer Center, Washington, DC
12 Hematology/Oncology Division, Columbia University Medical Center, New York, NY
13 Georgetown University Hospital Lombardi Comprehensive Cancer Center, Washington, DC
14 Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
15 University of Rochester, Rochester, NY
16 John Theurer Cancer Center, Myeloma and Lymphoma Divisions, Hackensack University Medical Center, Claster, NJ
17 Fred Hutchinson Cancer Research Center, Seattle, WA
18 Tufts Medical Center, Boston, MA
19 Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH
20 CLL Program, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY
21 Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA
22 University of Rochester Medical Center, Rochester, NY
23 Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC
24 John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, NJ
25 Department of Medicine, Duke University Medical Center, Durham, NC
26 Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
27 Duke Cancer Institute, Duke University Health System, Durham, NC
28 Cancer Research UK and University College London Cancer Trials Centre, London, United Kingdom

ASH 2018 Annual Meeting
4414 Factors That Influence Treatment Decision-Making: Perspectives of 1147 Chronic Lymphocytic Leukemia (CLL) Patients in the United States

Program: Oral and Poster Abstracts
Session: 641. CLL: Biology and Pathophysiology, excluding Therapy: Poster III

Hematology Disease Topics & Pathways:
Leukemia, Diseases, CLL, Clinically relevant, Lymphoid Malignancies, Quality Improvement

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Brian Koffman, MD, DCFP, DABFM, MS Ed1, Betsy Dennison, MS, RN2, Kaitlin Kennard, RN, BSN3, John C. Byrd, MD4, Richard R. Furman, MD5, John M. Pagel, MD, PhD6, Matthew S Davids7, Chadi Nabhan, MD8, Neil E. Kay, MD9, Tanya Siddiqi, MD10, Danielle M. Brander, MD11, William G. Wierda, MD, PhD12, Deborah M. Stephens13, Brian T. Hill, MD, PhD14,15, Javier Pinilla Ibarz, MD16, Bruce Cheson, MD17, Steven T Rosen18, Farrukh T. Awan, MD19,20, Michael Y. Choi, MD21, Thomas E Henry, MBA, RPh, CPh16, Lindsey E. Roeker, MD22 and Anthony R. Mato, MD MSCE22

1CLL Society, Claremont, CA
2Clarity Communications, Pompton Lakes, NJ
3Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
4Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH
5Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY
6Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA
7Department of Medical Oncology, Division of Hematologic Neoplasia, Dana-Farber Cancer Institute, Boston, MA
8Cardinal Health Specialty Solutions, Dublin, OH
9Division of Hematology, Mayo Clinic, Rochester, MN
10City of Hope National Medical Center, Duarte, CA
11Duke Cancer Institute, Duke University Health System, Durham, NC
12Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
13University of Utah Huntsman Cancer Institute, Salt Lake City, UT
14Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH
15Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
16H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
17Georgetown University Hospital Lombardi Comprehensive Cancer Center, Washington, DC
18Beckman Research Institute, Toni Stephenson Lymphoma Center, City of Hope, Duarte, CA
19The Ohio State University, Dallas, TX
20Harold C. Simmons Comprehensive Cancer Center, UT Southwestern, Dallas, TX
21Moore Cancer Center, University of California San Diego, La Jolla, CA
22CLL Program, Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY

4603 Risk Factors for Early Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia

Program: Oral and Poster Abstracts
Session: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Poster III

Hematology Disease Topics & Pathways:
Adult, Diseases, AML, Therapies, Non-Biological, chemotherapy, Biological Processes, Technology and Procedures, Study Population, cytogenetics, Clinically relevant, Myeloid Malignancies, immune mechanism, NGS

Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Sagar S. Patel, MD1, Betty K. Hamilton, MD1, Lisa Rybicki, MS2, Dawn Thomas3, Arden Emrick1, Aziz Nazha, MD4, Sudipto Mukherjee, MD, PhD, MPH5, Anjali S. Advani, MD6, Hetty E. Carraway, MD, MBA4,5, Brad Pohlman, MD6, Brian J. Bolwell, MD7, Robert M. Dean, MD,1, Aaron T. Gerds, MD, MS1, Rabi Hanna, MD8, Matt Kalaycio, MD9, Aiwen Zhang, PhD8, Mikkael A. Sekeres, MD, MS10, Jaroslav P. Maciejewski11, Navneet S. Majhail, MD, MS12, Medhat Askar, MD, PhD10 and Ronald Sobecks, MD1

1Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
3Allogene Laboratories, Cleveland Clinic, Cleveland, OH
4Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

ASH 2018 Annual Meeting 81
4627 Diversity and Richness Analysis of the Oral and Gastrointestinal Microbiome during Autologous Transplantation for Multiple Myeloma: Results of a Prospective Pilot Study and Correlation with Transplant Outcomes

Program: Oral and Poster Abstracts
Session: 731. Clinical Autologous Transplantation: Results: Poster III
Hematology Disease Topics & Pathways:
Diseases, multiple myeloma, Biological Processes, Plasma Cell Disorders, Lymphoid Malignancies
Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)
Najla H El Jurdi, MD1, Ali Filali, PhD2*, Iman Salem, MD2*, Mauricio Retuerto, MS2*, Nina Dambrosio, CNP3*, Hillard M Lazarus, MD4, Paolo F Caimi, MD5, Richard Creger, PharmD3*, Brenda Cooper, MD6, Ben Tomlinson, MD7, Leland Metheny, MD7, Ehsan Malek, MD8, Folashade Otegbeye, MBBChir, MPH9, Rafick-Pierre Sekaly, PhD2*, Mahmoud Ghannoun, PhD2* and Marcos de Lima, MD2

4695 National Trends in Leukemia Related Emergency Department Visits, Health Care Burden and Disposition Rate in the United States, 2010-2014

Program: Oral and Poster Abstracts
Session: 901. Health Services Research—Non-Malignant Conditions: Poster III
Hematology Disease Topics & Pathways:
Clinically relevant, Quality Improvement
Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)
Mohamed Mokhtar Bakr, MD1*, Umar Zahid, MD, MPH2,3*, Pavan Tenneti, MD4*, Alsadiq Waleed Al-Hillan, MD5 and Faiz Anwer, MD6,7

4709 Incidence of Neutropenic Fever at a Safety Net Hospital in Cancer Chemotherapy Patients Receiving Prophylactic Pegfilgrastim Manual Injection Compared to the on-Body Auto-Injector

Program: Oral and Poster Abstracts
Session: 901. Health Services Research—Non-Malignant Conditions: Poster III
Hematology Disease Topics & Pathways:
Quality Improvement
Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)
Atin Jindal, MD1*, Jan Kover, BPharm2*, Vanja Raduka, PharmD3, R.Ph3* and Timothy E. O’Brien, MD4

ASH 2018 Annual Meeting
4718 Identifying Neutropenic Fever Earlier: An Application of a Skin Patch for Continuous Temperature Monitoring

Program: Oral and Poster Abstracts
Session: 901. Health Services Research—Non-Malignant Conditions: Poster III
Hematology Disease Topics & Pathways:
Clinically relevant, Quality Improvement
Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Nina Dambrosio, CNP1*, Molly Porter, CNP2*, Erica Bauer, RN2*, Nathan Levitan, MD3*, Deborah Liedtke, RN2*, Marcos de Lima, MD4 and Ehsan Malek, MD5

1Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH
2Seidman Cancer Center, Adult Stem Cell Transplant, Cleveland, OH
3University Hospitals Seidman Cancer Center, Cleveland, OH
4Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH
5Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Shaker Hts, OH

4731 Factors Associated with Early Therapy Initiation in Patients (pts) with Myelodysplastic Syndromes (MDS) in the Connect® MDS/AML Disease Registry

Program: Oral and Poster Abstracts
Session: 902. Health Services Research—Malignant Diseases: Poster III
Hematology Disease Topics & Pathways:
Biological, Diseases, Therapies, Non-Biological, chemotherapy, MDS, Myeloid Malignancies
Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Christopher R. Cogle, MD1, Guillermo Garcia-Manero, MD2, David L. Grinblatt3, Rami S. Komrokji, MD4, Michael R. Savona, MD5, Bart L. Scott, MD6, Mikkael A. Sekeres, MD, MS7, Chrystal U. Louis8*, E. Dawn Flick9*, Melissa Nifenecker8*, Arlene S. Swern8* and David P. Steensma10

1University of Florida, Gainesville, FL
2MD Anderson Cancer Center, Houston, TX
3NorthShore University HealthSystem, Evanston, IL
4Department of Malignant Hematology, H Lee Moffitt Cancer Center, Tampa, FL
5Vanderbilt-Ingram Cancer Center, Nashville, TN
6Fred Hutchinson Cancer Research Center, Seattle, WA
7Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
8Celgene Corporation, Summit, NJ
9Celgene Corporation, San Francisco, CA
10Dana-Farber Cancer Institute, Boston, MA

4736 Healthcare Resource Utilization (HCRU) in Patients (pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated in the Connect® MDS/AML Disease Registry

Program: Oral and Poster Abstracts
Session: 902. Health Services Research—Malignant Diseases: Poster III
Hematology Disease Topics & Pathways:
Biological, AML, Diseases, Therapies, Myeloid Malignancies, transfusion
Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Sudipto Mukherjee, MD, PhD, MHP1, Mehrdad Abedi, MD2, Harry P. Erba, MD, PhD3, Daniel A Pollyea, MD4, Gail J. Roboz, MD5, Michael A. Thompson, MD, PhD, FASCO6, Chrystal U. Louis7*, E. Dawn Flick8*, Melissa Nifenecker9*, Pavel Kiselev9*, Arlene S. Swern7* and Christopher R. Cogle, MD9

1Cleveland Clinic, Cleveland, OH
2University of California Davis Comprehensive Cancer Center, Sacramento, CA
3University of Alabama at Birmingham, Birmingham, AL
4University of Colorado, Denver, CO
5Weill Cornell Medical College, New York, NY
6Aurora Research Institute, Advocate Aurora Health, Milwaukee, WI
7Celgene Corporation, Summit, NJ
4755 Early Infectious Complications after Autologous Hematopoietic Cell Transplantation (AHCT) for Lymphoma

Program: Oral and Poster Abstracts
Session: 902. Health Services Research—Malignant Diseases: Poster III
Hematology Disease Topics & Pathways:
Diseases, Adult, Lymphoma (any), Study Population, Lymphoid Malignancies, Clinically relevant
Monday, December 3, 2018, 6:00 PM–8:00 PM; Hall GH (San Diego Convention Center)
Shofia Rahman, MD1, Lisa Rybicki, MS2, Eric Cober, MD3, Robert M. Dean, MD4, Betty K. Hamilton, MD5, Deepa Jagadeesh, MD, MPH5, Brian T. Hill, MD, PhD6,7, Brad Pohlman, MD8, Ronald Sobecks, MD9, Matt Kalaycio, MD10, Sherif Mossad, MD11 and Navneet S. Majhail, MD, MS3

1Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH
2Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
3Division of Infectious Disease, Medicine Institute, Cleveland Clinic, Cleveland, OH
4Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
5Taussig Cancer Institute, Blood and Marrow Transplant Program, Cleveland Clinic Foundation, Cleveland, OH
6Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
7Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
8Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
9Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

4759 Treatment Patterns and Outcomes of Patients with CLL Treated with Chemoimmuno– and Novel Agent–Based Therapy: A Multicenter Study

Program: Oral and Poster Abstracts
Session: 902. Health Services Research—Malignant Diseases: Poster III
Hematology Disease Topics & Pathways:
Diseases, Leukemia, Therapies, Non-Biological, CLL, chemotherapy, Clinically relevant, Lymphoid Malignancies, pharmacology
Monday, December 3, 2018, 6:00 PM–8:00 PM; Hall GH (San Diego Convention Center)
Anthony R Mato, MD1, Maryam Sarraf Yazdy, MD2, Brian T. Hill, MD, PhD3,4, Mazyar Shadman5, Hande Tuncer, MD6, Allison M. Winter, MD7, Kaitlin Kennard, RN, BSN8, John N. Allan, MD9, Chaitra S. Ujjiani, MD10, Danielle M. Brander, MD11, Chadi Nabhan, MD12, Paul Barr, MD13, Jennifer R. Brown, MD, PhD14, Christopher P. Fox, MD, PhD15, Joanna Rhodes, MD16, Anna Schuh, MD17, Toby A. Eyre, MD18, Nicole Lamanna, MD19, Nitin Jain, MD20, William G. Wierda, MD, PhD21, Alan P Skarbnik, MD22, Lindsey E. Roeker, MD23, Rajat Bannerji, MD, PhD24, Andrew M. Evans, MD25, Frederick Lansig, MD26, Jennifer C. Samp, MS, PharmD27, Jacqueline Nielsen, PhD28, James M. Pauff29, Thomas J. Kipps, MD, PhD29, Stephen J. Schuster, MD30, George A Follows, MD, PhD31, Bruce Cheson, MD32 and Barbara Eichhorst33

1CLL Program, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY
2Division of Hematology, Medstar Georgetown University Hospital, Washington, DC
3Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH
4Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
5Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
6Tufts Medical Center, Boston, MA
7Cleveland Clinic, Cleveland, OH
8Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
9Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY
10Fred Hutchinson Cancer Research Center, Seattle, WA
11Duke Cancer Institute, Duke University Health System, Durham, NC
12Cardinal Health Specialty Solutions, Deerfield, IL
13University of Rochester, Rochester, NY
14Dana-Farber Cancer Institute, Boston, MA
15Department of Clinical Haematology, Nottingham University Hospitals NHS Foundation Trust, Nottingham, United Kingdom
16Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA
17Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
18Churchill Hospital, Oxford University, Oxford, United Kingdom
4768 Adolescent and Young Adult (AYA) Hematopoietic Cell Transplantation (HCT) Recipients Have Similar Quality of Life (QoL) Compared to Older Adults in the First Year Post-Transplantation

Program: Oral and Poster Abstracts
Session: 902. Health Services Research—Malignant Diseases: Poster III
Hematology Disease Topics & Pathways:
Young Adult, Study Population
Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Reema R Mathanda, MD1, Betty K. Hamilton, MD2, Lisa Rybicki, MS3, Anjali S. Advani, MD4, Brian J. Bolwell, MD5, Amy Colver, LISH-S4, Jane Dabney, LISH-S5, Christina Ferraro, CNP4*, Aron Flagg, MD5*, Rabi Hanna, MD5, Matt Kalaycio, MD4, Christine Lawrence, LISH-S4*, Linda McLellan, LISH4*, Ronald Sobecks, MD4 and Navneet S. Majhail, MD, MS4

1Department of Pediatric Hematology Oncology and Bone Marrow Transplant, Cleveland Clinic Foundation, Cleveland, OH
2Taussig Cancer Institute, Blood and Marrow Transplant Program, Cleveland Clinic Foundation, Cleveland, OH
3Cleveland Clinic, Quantitative Health Sciences, Cleveland, OH
4Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH
5Department of Pediatric Hematology Oncology and Bone Marrow Transplant, Cleveland Clinic, Cleveland, OH

4788 The Impact of Marital Status on Hematopoietic Stem Cell Transplant (HCT) Recipient Outcomes: A Surrogate for Consistent Caregiver. a CIBMTR Registry Study

Program: Oral and Poster Abstracts
Session: 902. Health Services Research—Malignant Diseases: Poster III
Hematology Disease Topics & Pathways:
Adult, Study Population, Clinically relevant, Quality Improvement
Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Jason Tay, MD1, Ruta Brazauskas, PhD2,3*, Naya He3*, Sara Beattie4*, Christopher Bredeson, MD, FRPC, MSC5, Jignesh Dalal, MD6, Shahrulk H. Hashmi, MD, MPH7,8, Theresa E. Hahn, PhD9, Nandita Khera, MD10, William A. Wood, MD, MPH11 and Wael Saber, MD, MS12

1Univ. of Ottawa/Ottawa Hosp., Calgary, AB, Canada
2Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI
3CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
4Department of Psychosocial Oncology and Rehabilitation, Tom Baker Cancer Centre, Calgary, AB, Canada
5Ottawa General Hospital, Ottawa, ON, CAN
6Rainbow Babies & Children's Hospital, Cleveland, OH
7Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
8Department of Internal Medicine, Mayo Clinic, Rochester, MN
9Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY
10Department of Hematology/Oncology, Mayo Clinic, Rochester, MN
11Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC
12Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC

4802 Cost and Value Analysis of Standard Versus Rapid Daratumumab Infusion in Multiple Myeloma

Program: Oral and Poster Abstracts
Session: 902. Health Services Research—Malignant Diseases: Poster III
4804 Results from the ITP World IMPACT Survey (I-WiSh): Patients with Immune Thrombocytopenia (ITP) Experience Impaired Quality of Life (QoL) Regarding Daily Activities, Social Interactions, Emotional Well-Being and Working Lives

Program: Oral and Poster Abstracts
Session: 903. Outcomes Research—Non-Malignant Hematology: Poster III
Hematology Disease Topics & Pathways:
autoimmune disorders, Diseases, Bleeding and clotting, ITP, Immune Disorders
Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Nichola Cooper, MRCP1, Alexandra Kruse2*, Caroline Kruse2*, Shirley Watson3*, Mervyn Morgan3*, James B. Bussel, MD4, Waleed Ghanima5, Donald M. Arnold, MD, MSc, FRCP6, Cristina Santoro7*, Ming Hou, MD8, Yoshiaki Tomiyama, MD9, Serge Laborde10*, Barbara Lovrencic11*, John Waller, PhD, BSc11*, Tom Bailey12*, Gavin Taylor-Stokes12*, Miona Stankovic13* and Andrew Provan14*

1Hammersmith Hospital, Imperial College London, London, United Kingdom
2Platelet Disorder Support Association, Cleveland
3ITP Support Association, Bolnhurst, United Kingdom
4Division of Hematology/Oncology, Weill Cornell Medical College, New York
5Department of Medicine, Ostfold Hospital Trust, Kalnes, Norway
6Department of Medicine, McMaster University, Hamilton, Canada
7Department of Cellular Biotechnologies & Haematology, 'Sapienza' University of Rome, Rome, Italy
8Department of Hematology, Shandong University, Jinan, China
9Osaka University Hospital, Osaka, Japan
10O’Cyto, Saint Loubes, France
11Italian Association Immune Thrombocytopenic Purpura, Caprino Veronese, Italy
12Bespoke Team, Adelphi Real World, Macclesfield, United Kingdom
13Novartis Pharma AG, Basel, Switzerland
14Barts and The London School of Medicine and Dentistry, London, United Kingdom

4805 Risk of Venous Thromboembolism in Acute Leukemias: A Meta-Analysis

Program: Oral and Poster Abstracts
Session: 903. Outcomes Research—Non-Malignant Hematology: Poster III
Hematology Disease Topics & Pathways:
Quality Improvement
Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Madeline Waldron, PharmD1*, Caitlin Siebenaller, PharmD2*, Brian P. Hobbs, PhD3*, Marc Earl, PharmD2*, Mary Schleicher4*, Hetty E. Carraway, MD, MBA5,6, Anjali S. Advani, MD7, Aziz Nazha, MD8, Aaron T. Gerds, MD, MS9, Betty K. Hamilton, MD5, Ronald Sobecks, MD9, Matt Kalaycio, MD9, Mikaela A. Sekeres, MD, MS10 and Sudipto Mukherjee, MD, PhD, MPH10

1Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2Department of Pharmacy, Cleveland Clinic, Cleveland, OH
3Cancer Biostatistics, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
4Medical Library Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH
5Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
6Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH
7Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH
8Cleveland Clinic, Cleveland, OH
9Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH
10Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

ASH 2018 Annual Meeting 86
4806 Impact of Venous Thromboembolism during High Intensity Chemotherapy for Acute Leukemia Patients on Duration of Hospital Stay

Program: Oral and Poster Abstracts
Session: 903. Outcomes Research—Non-Malignant Hematology: Poster III
Hematology Disease Topics & Pathways: Quality Improvement
Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Madeline Waldron, PharmD1*, Caitlin Siebenaller, PharmD2*, Marc Earl, PharmD2*, Xuefei Jia, MS3*, Hetty E. Carraway, MD, MBA4,5, Anjali S. Advani, MD6, Aziz Nazha, MD6, Aaron T. Gerds, MD, MS6, Betty K. Hamilton, MD6, Ronald Sobecks, MD3, Matt Kalaycio, MD3, Barb Tripp, CNS7,0, Brian P. Hobbs, PhD3*, Mikkael A. Sekeres, MD, MS11 and Sudipto Mukherjee, MD, PhD, MPH11

1Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2Department of Pharmacy, Cleveland Clinic, Cleveland, OH
3Cancer Biostatistics, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
4Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
5Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH
6Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH
7Cleveland Clinic, Cleveland, OH
8Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
9Leukemia Program, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH
10Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
11Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

4809 Clinical Outcomes of Isolated Distal Deep Vein Thrombosis Associated with Cancer: The Cleveland Clinic Experience

Program: Oral and Poster Abstracts
Session: 903. Outcomes Research—Non-Malignant Hematology: Poster III
Hematology Disease Topics & Pathways: Diseases, Bleeding and clotting, Clinically relevant, VTE
Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Shyam K. Poudel, MD1*, Xuefei Jia, MS2*, Deborah Y. Park, BS3*, Mailey Lynn Wilks, CNP, MSN, APRN1*, Vicki Pinkava, MSBS, PA-C1*, Meghan O'Brien, MS, ANP-BC1*, Barbara Tripp, CNS, AOCN1*, Jung-Min Song, RN, CNS1*, Keith R. McCrae, MD4, Alok A. Khorana1 and Dana E. Angelini, MD1

1Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
2Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH
3Cleveland Clinic Lerner College of Medicine, Cleveland Heights, OH
4Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

4832 Patient-Reported Outcomes in Systemic Light-Chain Amyloidosis

Program: Oral and Poster Abstracts
Session: 904. Outcomes Research—Malignant Conditions: Poster III
Hematology Disease Topics & Pathways: Diseases, Adult, Plasma Cell Disorders, Study Population, Lymphoid Malignancies, Clinically relevant
Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Rajshekhar Chakraborty, MBBS1, Lisa Rybicki, MS2*, Christy J. Samaras, DO2, Beth M. Faiman, PhD, CNP3, Jason Valenta, MD1 and Navneet S. Majhail, MD, MS4

1Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2Cleveland Clinic Foundation, Cleveland, OH
3Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
4Leukemia Program, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH

4834 Factors Influencing Incidence of Supraventricular Arrhythmias during and after Autologous Stem Cell Transplant in Multiple Myeloma
Program: Oral and Poster Abstracts
Session: 904. Outcomes Research—Malignant Conditions: Poster III
Hematology Disease Topics & Pathways:
Clinically relevant, Quality Improvement
Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Megan Sturdy, MD\textsuperscript{1*}, Rebecca Ye, BA\textsuperscript{2}, Trevor L Jenkins, MD\textsuperscript{3*}, James Driscoll, MD, PhD\textsuperscript{4}, Paolo Caimi, MD\textsuperscript{5}, Leland Metheny, MD\textsuperscript{6}, Rachel Zebrowski, RN\textsuperscript{7*}, Nicole Ferrari\textsuperscript{8*}, Merle Kolk\textsuperscript{9*}, Marcos de Lima, MD\textsuperscript{10} and Ehsan Malek, MD\textsuperscript{10}

\textsuperscript{1}University Hospitals Richmond Medical Center, Cleveland, OH
\textsuperscript{2}New York University, Cleveland, OH
\textsuperscript{3}Harrington Heart & Vascular Institute, University Hospital Cleveland Medical Center, Cleveland, OH
\textsuperscript{4}Division of Hematology & Oncology, University of Cincinnati, Cincinnati, OH
\textsuperscript{5}University Hospitals of Cleveland, Cleveland, OH
\textsuperscript{6}Stem Cell Transplant Program, University Hospitals Cleveland Medical Center, Cleveland, OH
\textsuperscript{7}University Hospitals Seidman Cancer Center, Cleveland, OH
\textsuperscript{8}University Hospital Cleveland Medical Center, Cleveland, OH
\textsuperscript{9}Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Cleveland Medical Center, Cleveland, OH
\textsuperscript{10}Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH

\textbf{4835 Venous Thromboembolism with Contemporary Lenalidomide-Based Regimens and Adequate Thromboprophylaxis in Newly Diagnosed Multiple Myeloma: A Systemic Review and Meta-Analysis}

Program: Oral and Poster Abstracts
Session: 904. Outcomes Research—Malignant Conditions: Poster III
Hematology Disease Topics & Pathways:
Diseases, Adult, multiple myeloma, Plasma Cell Disorders, Study Population, Lymphoid Malignancies, Clinically relevant
Monday, December 3, 2018, 6:00 PM-8:00 PM; Hall GH (San Diego Convention Center)

Rajeshkhar Chakraborty, MBBS\textsuperscript{1}, Saad Ullah Malik\textsuperscript{2*}, Naimisha Marneni\textsuperscript{3*}, Alex V. Mejia Garcia, MD\textsuperscript{3}, Faiz Anwer, MD\textsuperscript{4,5}, Alok A. Khorana\textsuperscript{6} and Navneet S. Majhail, MD, MS\textsuperscript{7}

\textsuperscript{1}Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
\textsuperscript{2}University of Arizona, Tucson
\textsuperscript{3}Cleveland Clinic, Cleveland
\textsuperscript{4}Taussig Cancer Institute, Cleveland Clinic, Cleveland
\textsuperscript{5}University of Arizona, Tucson, AZ
\textsuperscript{6}Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH
\textsuperscript{7}Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH